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ABSTRACT
The work presented within this thesis expands upon the theme within 
this laboratory, of utilising epitope-labelled recombinant proteins for the 
construction of multivalent subunit vaccines. Mammalian-cell expression- 
vectors were constructed which encoded a 14 amino acid epitope-tag, termed Pk- 
tag. The genes encoding the haemagglutinin (HN) and fusion (F) glycoproteins 
(model type H and type I proteins respectively) from the paramyxovirus simian 
virus 5 (SV5), were inserted into the above vectors such that the sequence 
encoding the Pk-tag was present at the amino (N) or carboxy (C) terminus of 
SV5 HN, and the C-terminus of SV5 F. The genes were expressed in 
mammalian cells by utilising the vaccinia virus/T7 transient-expression 
system. Encouraging results were obtained which demonstrated that the 
addition of the Pk-tag to the N or C termini of SV5 HN, or to the C-terminus of 
SV5 F, did not prevent the production of; full length, N-linked glycosylated, 
oligomeric, natively folded and cell-surface localised Pk-tagged protein.
An attempt was made to produce secretable forms of Pk-tagged SV5 HN 
and F. For this purpose, a vector was constructed which encoded a truncated 
version of the SV5 F protein in which the C-terminal transmembrane anchor & 
cytoplasmic tail were deleted, but which still possessed the sequence encoding 
the C-terminal Pk-tag at the C-terminus of the ectodomain. Expression of this 
gene in mammalian cells resulted in the production of a protein which had 
undergone N-linked glycosylation and partial oligomerisation. No secretion of 
the truncated Pk-tagged protein into the external milieu was detected.
Furthermore, production of potentially secretable forms of N & C- 
terminally Pk-tagged SV5 HN was achieved by the construction of plasmid 
vectors in which the non-cleavable native HN signal sequence was replaced by a 
putative cleavable signal sequence from the Epstein Barr virus gp220/360 
glycoprotein. Expression of the modified Pk-tagged HN genes in mammalian 
cells produced proteins of a lower mwt. than expected and which, apart from a 
small proportion of the N-terminally Pk-tagged molecules, did not possess N- 
linked oligosaccharides and were not recognised by conformationally sensitive 
mAbs. No secretion of the modified Pk-tagged HN into the external milieu was
detected.
Following the first initial characterisation of the Pk-tagged HN & F, in 
which very encouraging results were obtained, an attempt was made to isolate 
cell-lines which constitutively or inducibly expressed Pk-tagged HN. Production 
of Pk-tagged HN could not be detected from constructs in which expression was 
driven from constitutive promoters. However, production of N-terminally Pk- 
tagged HN (but not C-terminally tagged HN) was detected when expression was 
driven by the tTa inducible expression system. As a further development to the 
tTa system, a 293 cell-line was isolated which expressed high-levels of functional 
tTa. The tTa-producing cell-line was subsequently utilised in an attempt to 
isolate cell-lines which inducibly produce N-terminally Pk-tagged HN. These 
cells are currently undergoing selection for drug resistance.
Further experiments were performed to try and develop a system 
whereby the low copy number of episomally-maintained EBV-based vectors 
present in a stable cell-line could be amplified to high copy number, whereby a 
subsequent increase in protein production would be envisaged. For this
purpose, SV40 ori-containing, EBV-based vectors were constructed in which the 
expression of the non-toxic SV5 P protein was under the control of the hCMV IE 
promoter/enhancer. Cell-lines were isolated which produced the SV5 P in 
various amounts. Transient amplification of the episomal copy number was 
attempted via a transient expression of the SV40 LTAg, using plasmid DNA 
transfection. No subsequent increase in protein production was observed by way 
of a Western blot analysis.
INTRODUCTION
The long term aim of one of the projects within this laboratory has been concerned 
with the development of multivalent subunit vaccines, via what has been termed solid 
matrix-antibody-antigen or SMAA complexes. The work presented in this thesis, although 
continuing with the above theme, has been directed towards the production and analysis of 
epitope-labelled simian virus 5 (SV5) glycoproteins in mammalian cells. Subsequently this 
project has involved extensive recombinant DNA technology, recombinant protein 
production, and analysis of protein processing through the mammalian-cell exocytotic 
pathway. Therefore, the following introduction primarily concentrates upon the 
heterologous expression of proteins, particularly in mammalian cells, and upon the 
processing of glycoproteins derived from the paramyxovirus SV5.
Chapter 1 of the introduction briefly outlines present and possible future methods 
for the production of vaccines against viral disease and introduces the concept of producing 
multivalent subunit vaccines as SMAA complexes. Chapter 2 focuses on the paramyxo­
viruses, with emphasis being directed towards the paramyxovirus simian virus 5 (SV5) and 
its envelope glycoproteins: haemagglutinin-neuraminidase (HN) and fusion (F) proteins. 
One of the most important areas in recombinant protein production is choosing and 
developing a suitable expression system for the protein(s) of choice, chapter 3 outlines 
heterologous gene expression technology with particular emphasis being placed on vectors 
used for recombinant protein production from mammalian cells. Furthermore, a thorough 
understanding of the post-translational modifications which may occur to expressed 
proteins and how targeting of proteins can be manipulated within mammalian cells, is 
important to the development of some recombinant vaccines, and chapter 4 briefly presents 
some of the knowledge gained in the field of mammalian-cell protein exocytosis. Finally, in 
the last section of the introduction, the aims of the work undertaken in this thesis are stated.
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CHAPTER 1
VACCINES AGAINST VIRAL DISEASE
1 / Adaptive immune responses to viral vaccines.
Protection from viral disease in vertebrates is due to the application of two defence 
mechanisms: non-adaptive & adaptive immune responses. Non-adaptive immune responses 
involves barriers to the primary infection, such as the external skin and mucous linings of 
the respiratory and gastrointestinal tract, and also circulatory phagocytic cells which may 
engulf and neutralise foreign bodies. Adaptive immune responses are composed of 
humoral and cell-mediated immune responses, primarily involving antibodies and cytotoxic 
T lymphocytes (CTLs) respectively.
1.1 / Humoral immune responses.
Humoral immune responses primarily defend a host organism against infection of its 
cells by invading viral pathogens (viral neutralisation). However, the humoral response may 
also target virus-infected cells for lysis by either the complement pathway or through a 
process termed antibody-dependent-cellular-cytotoxicity, or ADCC. The above responses 
are mediated through glycoprotein effector molecules termed immunoglobulins (Igs or 
antibodies, of which there are nine classes in man; IgAi, IgA2, IgD, IgE, IgGi, IgG2a< IgG2b/ 
IgG3, IgG4 & IgM), which are either membrane-bound or secreted from plasma cells 
(derived from activated B cells) and circulate throughout the body via the blood and lymph.
Antibodies, or to be more exact the antigen-binding site, or paratope, of the antibody, 
recognise small antigenic determinants termed epitopes which are present in the structure of
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a foreign molecule (antigen). Such molecules tend to be proteins or modified proteins and, 
to a lesser extent, polysaccharides and smaller chemicals. Epitopes can either be continuous 
or discontinuous (Barlow et al., 1986), whereby continuous epitopes consist of a linear 
sequence of amino acids (derived from the primary amino acid sequence), usually consisting 
of 5 to 10 amino acids in length (reviewed in Randall & Souberbielle, 1990). In contrast, 
discontinuous epitopes are derived from the juxtaposition of amino acids, distinct from each 
other in the primary amino acid sequence, mediated by the folding of the protein into its 
tertiary and quaternary structures. Discontinuous epitopes are therefore conformationally 
sensitive. The extent to which the humoral immune response protects against viral disease 
depends primarily upon the nature of the infecting viral agent.
1.2 / Cell-mediated immunity.
Due to the host-cell dependent nature of a virus replication cycle, viruses are, during 
their replication/assembly phase, concealed from the neutralising effects brought about by 
the humoral immune system. Therefore, a further defence against the spread of virus from 
infected cells, is through the specific targeting of such infected cells by T-cells. T-cells 
recognise infected cells through receptors (T-cell receptors, TCRs) present on their cell- 
surface, which interact with virus-derived oligopeptide fragments that are displayed on the 
surface of infected cells. This surface expression is mediated through an association of the 
viral-derived oligopeptides with cellular molecules termed major histocompatibility 
complexes, of which there are two types: MHC I & MHC II.
There are distinct subsets of T cells which are distinguished by the cluster 
differentiation marker (CD) they possess on their cell-surface. CD4" CD8+ T-cells interact 
with oligopeptides presented in association with MHC I molecules, whereas CD4+ CD8" T- 
cells interact with oligopeptides associated with MHC II molecules. Other surface molecules 
are also involved in the interaction of T-cells with their target cells which are reviewed in 
Hanke & Randall, 1994.
Primarily CD8+ cells are involved in the lysis of infected cells and are thus termed 
cytotoxic T-lymphocytes (CTLs), whereas CD4+ cells are primarily involved in immune
3
modulation through the release of soluble effector molecules termed cytokines, which
regulate processes such as the activation of CTLs and the proliferation, of B-cells into 
antibody-secreting plasma cells, although these functions are not mutually exclusive 
(reviewed in Hanke & Randall, 1994).
2 / Viral vaccines
Although the spread of many viral diseases has been successfully controlled by 
improvements in public health facilities, active immunisation, through the administration of 
vaccines, has also played a major role in curtailing the dissemination of viral disease, a 
classic example of which is the elimination of variola virus from the general population, and 
recently the elimination of poliovirus from North America. A further need for effective viral 
vaccines is the poor chemotherapy which is currently available for viral diseases.
A vaccine is "material originating from a micro-organism that induces an 
immunologically mediated resistance to disease" and not necessarily to infection (Mims, 
1988). Examples of vaccine types currently in use, and also of current experimental vaccines 
are depicted in figure 1. An ideal vaccine should possess the following characteristics: 
induce resistance to disease, be capable of oral administration, induce a life-long immunity 
to disease after only one dose, be safe, highly stable, cheap to produce and give combined 
protection against multiple diseases. However, there exists, at present, no such ideal vaccine 
and current vaccines possess only a combination of the above features.
2.1 / \fflcole virus vaccines
Conventional methods for viral vaccine preparation has involved the use of whole 
virus particles. As depicted in figure 1, vaccines derived from whole virus particles can be 
divided into two categories: inactivated particles or infectious particles. Inactivated virus 
vaccines are usually prepared by treatment of wildtype virus with protein cross-linking 
agents such as formalin and B-propiolactone. Infectious virus vaccines can be separated into
3 categories; attenuated virus, non-pathogenic related virus, and wild type pathogen 
administered by a route which doesn't result in disease (examples of inactivated and
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Inactivated virus - Poliovirus (Salk)
- Influenza virus
- Rabies virus
- Hepatitis A virus
Infectious virus -> Attenuated - Measles virus
- Mumps virus
- Rubella virus
- Poliovirus (Sabin)
- Yellow fever virus
-> Virulent - Adenovirus type 5
-> Related - Vaccinia virus
- Calf Rotavirus
Amino acid-based
Administration
Whole proteins
Synthetic peptides - Experimental approach
- Hepatitis B virus surface 
antigen
Nucleic acid-based
Administration
(DNA or RNA)
Whole proteins/ 
Polyepitopes - Experimental approach
Recombinant
Viral Vectors
Whole proteins/ 
Polyepitopes
-Experimental. Vectors 
include; Vaccinia virus, 
Adenovirus, Herpes 
simplex virus, Retroviruses 
and Alphaviruses
Figure 1 - Commonly administered types of viral vaccine for human use, with 
examples of viral pathogens, and some recent novel approaches to future vaccine 
development. See text for details.
infectious viral vaccines in use to date are shown in figure 1). Attenuated viruses have 
traditionally been produced by serial passage of wild type virus in a non-host-related cell­
line, with subsequent screening for potential attenuated variants. However, molecular 
biology techniques now allow the possibility of selective mutagenesis for certain viruses. 
The above vaccine preparation approaches have obviously meet with great success but they 
both have their advantages and disadvantages, as compared below.
Inactivated vaccines - produced from virulent particles.
- generally multiple doses required.
- large number of particles required.
- generally induce a poor CTL immune response (see above).
- possibility of incomplete inactivation.
- generally can be administered to immunosuppressed persons.
- preparations are usually very stable.
- spread to unvaccinated persons has not been demonstrated.
- possibility of enhancement of disease upon natural infection.
- the inactivation process can lead to destruction of neutralising epitopes.
Infectious viral vaccines - possibility of reversion to virulent phenotype.
- possibility of spread to unvaccinated persons.
- risk of developing persistent or latent infections with some vaccines.
- generally can not be administered to immunosuppressed people.
- possibility of contamination of cell-lines by virulent microbes.
- tend to be less stable than inactivated vaccines.
- usually stimulates both humoral & CTL responses (see above).
- small number of particles required.
- generally fewer doses are required for adequate protection.
- possibility of enhancement of disease upon natural infection.
2.2 I SuUunit t ivuu vaccinns
Subunit vaccines, depicted in figure 1, are a relatively new approach to vaccine 
development and can be administered either as; peptides/purified proteins, by a novel 
nucleic acid-based approach termed genetic immunisation, or by infectious recombinant
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virus vectors. Successful use of subunit vaccine technology has been demonstrated with the 
current hepatitis B virus vaccine which is produced from recombinantly produced surface 
antigen expressed in yeast (Valenzuela et al., 1982).
2.2.1/ Purified proteins / synthetic peptides.
Advantages of using purified proteins/synthetic peptides for immunisation include 
that only preselected immunogens are administered and that the vaccine is non-infectious. 
In the latter case, this is an important safety consideration if vaccines are being developed 
against agents such as retroviruses. However, there are numerous disadvantages which 
include; (1) it can be expensive and technologically challenging to produce large amounts of 
purified proteins, (2) it may be difficult to determine which proteins/peptides are inducing 
protective immune responses, (3) MHC polymorphism within the human population has to 
be taken into account in the design of peptide-based vaccines and finally (4) the 
administration of proteins/peptides on their own is generally only weakly-immunogenic. 
However, there are numerous methods for presenting proteins/peptides to the immune 
system and for enhancing their immunogenicity (a process termed adjuvanticity), which 
have been experimentally demonstrated to induce good humoral and importantly, in some 
approaches, CTL responses. These include; aluminium gels (the only adjuvant currently 
licensed for human use), quil A, muramyl dipeptide (derived from M. tububerculosis'), solid- 
matrix-antibody-antigen complexes (Randall & Young 1991, and discussed below) and 
liposomes (reviewed in Gupta et al., 1993).
2.2.2/ Recombinant viral vectors.
Included in the category of subunit virus vaccines are recombinant viruses which 
have been altered using recombinant DNA techniques to express proteins, or portions 
thereof, from unrelated viruses and are thus acting as infectious carriers for the 
administration of subunit vaccines. The advantages of such a system include; (1) due to 
infection by the virus vector, genes are expressed within the host cell and the proteins are 
therefore properly processed (e.g folding and glycosylation) and will therefore tend to
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induce appropriate humoral and CTL immune responses, and (2) vectors such as 
adenovirus type 5 and vaccinia virus are, or have been, routinely used for mass 
immunisation programmes and their safety, although not absolute, is relatively good. 
However, there are additional problems to those already described above for 
peptide/protein-administered subunit virus vaccines, which include; (1) the size of the viral 
genome can restrict the size of the insert genes, and (2) protective immune responses will 
probably be mounted to the virus vector as well as to the subunit protein, thus rendering 
repeated administrations unlikely (reviewed in Randall & Souberbielle, 1990). [More detail 
on the construction of recombinant viruses and their use in heterologous protein expression 
is given in chapter 3, section 2.1.1].
2.2.3/ Genetic immunisation.
One of the most recent, novel and exciting approaches to vaccine advancement has 
been the development of technology for direct-gene-transfer into living tissue, primarily as 
part of a DNA plasmid molecule. Therefore, this section will be more expansive in detailing 
some of the current knowledge in this field. This approach of direct-gene-transfer has been 
referred to as genetic immunisation or nucleic acid immunisation. The advantages of such 
an approach include;
1) Since viral proteins are produced within the host cell, the proteins will acquire host-cell 
post-translational modifications and will therefore adopt the native conformation.
2) Intracellular production of the desired proteins will also therefore result in the elicitation 
of CTL responses as well as humoral responses. Indeed, humoral and/or CTL responses 
have clearly been demonstrated against the rabies virus G protein (Xiang et al. 1995), 
influenza virus HA & NP proteins (Ulmer et al., 1993 and Fynan et al., 1993), HIV-1 gpl20 
(Fuller & Haynes, 1995) and the hepatitis B surface antigen (Davis et al., 1995 and Mancini et 
al., 1996).
3) It is very cheap, safe and straight-forward to produce large amounts of plasmid DNA to 
very high purity.
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4) DNA can be stored lyophilised at room temperature and is stable for at least one year in 
this condition, thereby allowing easy storage and transport.
5) Plasmid DNA is relatively easy to manipulate and therefore desirable characteristics can 
be added to gene products or, conversely, deleterious features removed.
6) Immunisation can be multivalent simply by producing a mixture of plasmids encoding 
different immunogens, or by the production of poly-CTL-epitope proteins which can be 
constructed from known CTL-epitopes of various viruses or tumour antigens (Thomson et 
(d, 1996).
However, as with the vaccination strategies mentioned above, there are foreseeable 
problems which could arise from using plasmid DNA as a means of genetic immunisation. 
Such problems include;
1) The introduction of DNA into the cell nucleus may result in the insertion of the plasmid, 
or portions thereof, into the host cell genome thereby possibly eliciting insertional mutations 
in essential genes, or upregulating potential oncogenes. However, integration of DNA into 
genomes generally requires the active replication of the genome which does not commonly 
occur in post-mitotic cells such as muscle cells, a common site for injection of DNA. Indeed, 
it has been demonstrated that plasmid DNA injected into mouse muscle cells remains in an 
extrachromosomal form (sensitive PCR and Southern blotting techniques could not detect 
any integrated plasmid DNA sequence), and has not undergone replication as elucidated by 
the presence of the bacterial methylation pattern (reviewed in Danko & Wolff, 1994).
2) Anti-DNA immune responses may be generated to transfected plasmid molecules 
resulting in auto-immune diseases such as systemic lupus erythematosus (SLE). However, it 
is apparently very difficult to illicit a humoral immune response against intact DNA and one 
study involving DNA immunisation could not detect the presence of any anti-DNA 
antibodies (reviewed in Robertson, 1994 and Xiang et al. 1995).
3) Depending upon the tissue which takes-up and expresses the foreign gene, expression 
may not be prolonged enough to develop a protective immune response. Indeed it has been 
demonstrated that direct injection of plasmid DNA into exposed brain, liver, spleen, uterus, 
stomach, lung or kidney did not result in any detectable gene expression, but then direct
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injection of such tissues is not a practicable situation for human vaccination. However, in a 
perhaps more relevant scenario it has been demonstrated that muscle cells which have 
taken-up circular plasmid DNA, via direct injection, can express the gene product (in this 
case luciferase) for at least 2 years, or for at least for 4 months if the plasmid was linearised 
prior to injection (Wolff et al. 1990 and reviewed in Danko & Wolff, 1994).
4) However, theoretical problems may arise due to prolonged expression such as; the 
induction of tolerance, auto-immunity, anaphylaxis, hyperimmunity or autoaggression 
(reviewed in Robertson, 1994). Circumstances where such phenomenon may occur due to 
prolonged expression of the antigen may be over come by selective targeting of the DNA to 
tissues which rapidly degrade the DNA or perhaps by incorporating genes encoding slow- 
acting toxic proteins into the plasmid vectors thereby eliminating transfected cells after a 
short period of expression. Another possible approach to achieving either short-term or 
prolonged gene expression is by controlling such expression via the use of inducible 
promoters. Perhaps, to date, the most likely candidate for such an inducible promoter is the 
tetracycline-responsive promoter developed by Gossen et al. (1995) whereby gene expression 
is induced by the addition of tetracycline derivatives (more detail on this system is given in 
chapter 3, section 2.2.2.1).
5) Uptake of naked DNA into tissue is an inefficient process and in the case of direct 
injection into muscle cells, necrotizing agents such as snake toxins or local anaesthetics (such 
as bupivacaine) have been administered to facilitate the uptake of DNA. However, a non­
invasive approach using DNA-coated gold particles fired onto the epidermis of the skin via 
a "gene gun" has shown promising results (Fynan et al., 1993).
3 / SMAA complexes as multivalent subunit vaccines.
Solid-matrix-antibody-antigen (SMAA) complexes have been suggested to be a 
potential carrier system for the presentation of single or multiple microbial subunits to the 
immune system (Randall, 1989). The basis of the design, which is depicted in figure 2, 
consists of a solid matrix to which are bound appropriate monoclonal antibodies (mAbs) to 
the antigen of choice. The solid matrix, to date, has consisted of a killed & fixed suspension
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of the Cowan A strain of Staphylococcus aureus (Randall & Young, 1988), or the adjuvant 
alum (Randall et al., 1993b). In the case of S. aureus the mAbs interact with the solid matrix 
via binding of the Ig Fc region to protein A present on the surface of the S.aureus. Purified 
antigen can then be incorporated into the complex via an interaction with the specific 
monoclonal antibodies, thereby also facilitating another purification step upon the antigens 
of choice.
SMAA complexes have been demonstrated to induce both vigorous humoral and 
class I-restricted CTL immune responses (Randall & Young, 1988), where immunisation of 
mice with SMAA complexes containing internal & envelope proteins from the 
paramyxovirus simian virus 5 (SV5) protected mice from subsequent infection by SV5 
(Randall et al., 1988). Furthermore, clearance of a persistent SV5 infection in mice was 
achieved through the action of CD8+ effector T-cells, induced by the administration of 
SMAA complexes containing internal proteins and envelope glycoproteins from SV5 
(Randall & Young, 1991).
In a recent development to the above SMAA complex technology, Hanke et al. (1992, 
1994a, 1994b and 1995) have demonstrated that a single mAb, which recognises a 14 amino 
acid oligopeptide epitope (derived from the P/V proteins of SV5 (Southern et al., 1991)), can 
be used in the construction of SMAA complexes containing multiple epitope-labelled- 
antigens (figure 2, panel C). The mAb has been referred to as anti-Pk and the epitope to 
which it interacts has been labelled Pk-tag. The advantages of such a system include; (1) 
antigens for which there are no monoclonal antibodies available can be Pk-tagged and 
incorporated into SMAA complexes, and (2) large scale production of only one monoclonal 
antibody is required..
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Figure 2: Schematic of possible SMAA complexes which could be utilised as 
multivalent vaccines.
A - Different mAbs are attached to individual solid matrices prior to the binding of the respective 
antigens. The resulting SMAA complexes may be pooled together before being employed as 
potential immunogens. ® - The solid matrix is saturated with a mixture of mAbs prior to the 
addition of the respective antigens. C - A single tag-specific mAb and tag-linked antigens are 
utilised for the construction of SMAA complexes. D & IB - The same as C, except that Fab or single 
chain Fv fragments of antibodies, respectively, are employed. Furthermore, additional mAbs to 
host cell antigens, and/or immunostimulating protein such as cholera toxin B subunit, may be 
included to enhance particular types of immune response (not shown). Modified fromHanke 
(1993).
CHAPTER 2
THE PARAMYXQVIRIDAE: THE VIRUSES AND THEIR
STRUCTURE .
1 / The Viruses.
The viruses contained within the family Paramyxoviridae possess a cell-derived 
envelope and contain a linear negative strand RNA genome. Virus members within the 
family Paramyxoviridae therefore belong to the same group of viruses comprising the 
families; Rhabdoviridae, Arenaviridae, Bunyaviridae and Orthomyxoviridae. The 
Paramyxoviridae and the Rhabdoviridae differ from the other 3 families in that their 
genome is non-segmented.
In 1993 the family Paramyxoviridae was divided by the International Committee on 
the Taxonomy of Viruses into two subfamilies (figure 1): namely the Paramyxovirinae and 
the Pneumovirinae. The subfamily Paramyxovirinae contains three genera, the 
Parainfluenzavirus, Rubulavirus and the Morbillivirus, whilst the subfamily Pneumovirinae 
possesses one genera, the Pneumovirus. This new classification was based upon several 
criteria; genome organisation, biological activities of the encoded proteins, sequence 
relationship of the encoded proteins and morphological characteristics.
2 / Paramyxovirus structure and encoded proteins.
2.1 / Virion Structure (figuceO.
Paramyxoviridae are pleiomorphic viruses which, although generally observed to be 
spherical in nature, can form filamentous particles. The viruses contain a host-cell-derived
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lipid membrane into which are inserted membrane-bound virus-encoded glycoproteins 
which extend approximately 8 to 12 nm from the envelope surface (Lamb & Kolakofsky, 
1996). The envelope surrounds a "scaffold" comprised of a virus-encoded Matrix (M) 
protein, inside of which is located the helical ribonucleoprotein (RNP) core.
THE FAMILY PARAMYXOVIRIDAE
THE SUBFAMILY PARAMYXOVIRINAE
GENUS Parainfluenzavirus - Sendai Virus (SeV).
- Human parainfluenza virus type 1 & 3 (hPTVl/3).
- Bo-vine parainfluenza virus type 3 (bPIV3).
GENUS Rubulavirus - Simian virus 5 (SV5).
- Mumps virus (MuV).
- Newcastle disease virus (NDV).
- Human parainfluenza virus types; 2,4a & 4b. 
(hPIV2/4a/4b).
GENUS Morbillivirus - Measles virus (MeV).
- Dolphin morbillivirus (DMV).
- Canine distemper virus (CDV).
- Phocine distemper virus (PDV).
- Rinderpest virus (RiV.
THE SUBFAMILY PNEUMO VIRINAE
GENUS Pneumovirus - Human respiratory syncytial virus (hReSV).
- Bovine respiratory syncytial virus (bReSV).
- Pneumonia virus of mice (PVM).
- Turkey rhinotracheitis virus (TRV).
Figure 3- Organisation of the family Paramyxoviridae, showing subfamilies, genera and 
representative examples of viruses, abbreviations shown as used throughout this thesis. 
Adapted from Lamb & Kolakofsky 1996.
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Figure 4: Diagrammatic representation of the structure of the simian virus 5 
(SV5) virion (adapted from Young, 1991).
SV5 consists of a single strand RNA genome of negative polarity to which are associated the
nucleocapsid proteins (NP). Also associated with the NPs are the phospho (P) proteins and the 
large (L) proteins which form the viral polymerase complex. The V protein has been shown to be 
associated with the nucleocapsid but definitive evidence for this association has not been 
published. Surrounding this nucleocapsid is a matrix produced from the homologous association 
of the matrix (M) protein which interacts with the host-cell-derived lipid bilayer and to the 
bilayer-inserted virally encoded glycoproteins - Haemagglutinin-Neuraminidase (HN) and 
Fusion (F). Not shown is the membrane-bound small hydrophobic (SH) protein, whose function 
is unknown.
Nucleocapsid:
[Nucleoprotein (NP-e), associated with Large (L- ®), 
(V-o) and Phospho-(P-O) proteins, complexed with 
negative sense RNA genome]
Fusion (F) 
protein
ipid bilayer
Matrix (M) 
protein Haemagglutinin- 
neuraminidase (HN)
protein
The ribonucleoprotein core (sometimes referred to as the nucleocapsid core) consists of the 
single-stranded RNA genome of negative polarity (approximately 15Kbp), which is tightly 
associated with the nucleoprotein (NP) to which is adhered the phosphoprotein (P) and 
Large (L) proteins. This RNP core, rather than the free genomic RNA, is the template for all 
RNA synthesis (Hamaguchi et al., 1983) performed by the polymerase complex which is 
comprised of, at least, the P and L proteins.
2.2 / Paramyxovirus genome (figure 5).
The negative sense linear genomic RNA of the Paramyxoviridae has to serve two 
functions within the replicative cycle of the viruses: first to act as a template for synthesis of 
the positive stranded antigenome, which is an intermediate in the replicative cycle, and 
second to act as a template for the synthesis of messenger RNAs (mRNAs). As previously 
mentioned, the genome of the Paramyxoviruses is a nonsegmented single-stranded RNA of 
negative polarity and approximately 15Kbp in length. The genome codes for between 6 and 
10 polypeptides which are transcribed, by a virally encoded polymerase, with decreasing 
frequency as the distance from the 3' leader sequence increases. The complete sequence of 
the RNA is known for many members of the Paramyxoviridae, including; Sendai virus, 
Human parainfluenza virus 3, Simian virus 5, Mumps virus, Measles virus, Canine 
distemper virus and Respiratory syncytial virus (Gallinski et al., 1991). Using this sequence 
information, sequences which may comprise coding and non-coding regions of the genome 
can be predicted and possible functions assigned. The genome has been shown to possess 3' 
(leader sequence) and 5' (trailer or negative leader sequence) extra-cistronic regions of 
approximately 50 nucleotides, which appear to be control regions for regulating 
transcription and translation. Further potential control elements have been located at the 
start and end of individual Paramyxovirus genes which are semi-conserved between 
different viruses (Gallinski, 1991). Moreover, regions putatively involved in 
transcription/replication control are the non-transcribed intercistronic regions (ICR), which 
again are semi-conserved between the Paramyxoviridae and in the case of Measles virus,
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Figure 5: Genome organisation of representative members from each genus of 
the family Paramxyoviridae.
For Sendai virus, regions putatively involved in transcription/replication control are indicated in 
bold lettering, with genomic sense and mRNA species illustrated. Gene size is approximately
drawn to scale (adapted from Lamb & Kolakofsky 1996).
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Sendai virus and PIV3 consists of a trinucleotide sequence. The ICR of the other
Paramyxoviruses vary from between 1-52 nucleotides.
2.3 / Paramyxovirus encoded proteins.
2.3.1 /The nucleocapsid Protein (NP).
The nucleocapsid proteins of the Paramyxoviridae are acidic in nature, range in 
molecular weight between 53 and 58Kda (Lamb & Kolakofsky, 1996) and are the most 
abundant proteins to be found within the RNP (Lamb et al., 1976). NP has several functions 
in virus replication including; genome encapsidation (thus rendering the genome RNAse- 
resistance), an association with the P-L polymerase complex during transcription/ 
replication, and a possible interaction with the matrix protein during virion assembly 
(Markwell and Fox, 1980). During viral replication, it is hypothesised that the polymerase 
complex recruits NP and that along with the elongating genome, is incorporated into a 
growing RNP. There does not appear to be a unique interaction with genomic RNA as NP 
expressed on it's own in cell-lines appears to form nucleocapsid-like structures, utilising 
cellular RNA, of equal density to viral nucleocapsids (Blumberg et ah, 1983, Buchholz et al., 
1993). The N-terminal three quarters of Sendai virus NP appears to be all that is necessary 
for RNP assembly (Buchholz et ah, 1993) and indeed is well conserved among related 
viruses. This region is composed of 2 separate domains, the N-terminal domain is positively 
charged and presumably interacts with the genomic RNA, with the other region tending to 
be hydrophobic in nature, and thus may be involved in the NP:NP interactions (Morgan 
E.M et al., 1984). The C-terminal region of NP has been found to be vital in the replication of 
an encapsidated cDNA-encoded Sendai virus genome where nucleocapsids prepared from 
C-terminally deleted NP could not act as templates for new rounds of genome replication 
(Curran et ah, 1993).
2.3.2 / The Phosphoprotein (P).
As the name suggests, the P proteins are highly phosphorylated. The P gene of the 
Pneumovirinae and hPIVl encode a single polypeptide, whilst in the case of some members
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of the Paramyxovirinae multiple polypeptides are produced. This is due to overlapping 
reading frames from internal start codons (C proteins produced) and RNA editing where 
pseudo-templated addition of nucleotides can occur, which result in frame-shifting during 
translation and a separate species of mRNA produced (which encodes V proteins, reviewed 
in Lamb & Kolakofsky, 1996).
The length of the P proteins vary considerable within the Paramyxoviridae, ranging 
from 241 amino acids in the Pneumoviruses to 603 amino acids in the Parainfluenzaviruses and 
Morbilliviruses. The P protein is a regulatory protein which has a key role in transcription 
and replication. In unison with the viral L protein it forms the viral polymerase complex (P­
L). Moreover, in association with soluble NP, the complex P-NP is formed which 
presumably maintains the NP in a soluble state until the interaction with the nascent RNA 
(Horikami et al., 1992 and Parks, 1994, Precious etal., 1995). Furthermore, P may play a major 
role in the interaction of the L protein with the template RNA by binding to the 
nucleocapsid NP whilst also maintaining an association with the L protein (Ryan and 
Portner, 1990).
The exact function of the aforementioned C and V proteins is in dispute but they 
may play a role in the fine tuning of the transcription / replication modes of at least some 
members of the Paramyxoviridae (Curran et al., 1992 & 1994 and Precious et al., 1995).
2.3.3 I The Laaze(L) proOein.
Many L genes from the Paramyxoviridae family have been sequenced and shown to 
express a large polypeptide of approximately 2200 amino acids. The large size and low 
abundance (approximately 50 copies per virion) of the L protein in the virion suggested it's 
role as the RNA-dependant RNA polymerase (RDRP) (reviewed in Lamb & Kolakofsky, 
1996). Overall there appears to be very little sequence homology except in five short regions 
of high homology, which is also conserved between other RDRPs, for example of Vesticular 
stomatitis virus (Poch et al., 1990). To date, no structure-function studies have been carried 
out for paramyxovirus L proteins.
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2.3.4 / The Matrix (M) protein.
The M protein is the most abundant protein in the virion and appears to play a major 
role in the budding of newly produced viral particles. The molecular weights range from 
between 38Kda to 42Kda for the different members of the family, with the protein 
possessing a basic and slightly hydrophobic nature, albeit lacking any known membrane- 
spanning domain (reviewed in Lamb & Kolakofsky, 1996). Fractionation studies and 
electron micrographs indicate that the M protein is located underlying the lipid membrane 
as a peripheral membrane protein, and can self-associate to form paracrystalline sheets and 
tubes in vitro . An association with the RNP has also been postulated (the basic nature of M 
may thus be important in the interaction with the acidic NPs of the RNP, reviewed in Lamb 
& Kolakofsky, 1996). Furthermore, it appears that the M protein may interact with the 
cytoplasmic tails of the virally-encoded integral membrane glycoproteins (Sanderson et al., 
1993) and evidence of an interaction with actin has been found (Bohn et al., 1986). For Sendai 
virus, recently synthesised M appears to be highly phosphorylated, yet M protein located 
within matured virions is unphosphorylated. A clear role for this phosphorylation 
phenomenon has not yet been established (Lamb & Choppin, 1977).
2.3.5 / The integral membrane proteins.
The pneumoviruses and some members of the rubulaviruses (SV5 and MuV) encode 
three polypeptides which are located within the envelope of virions and infected cells; the 
attachment protein, fusion protein and small hydrophobic protein. Other members of the 
Paramyxoviridae family only encode the attachment and fusion proteins. As their names 
imply, these envelope proteins are involved in the adsorption, penetration and intracellular 
spread of the viruses. For the most part in this thesis, greater detail will be given for the 
envelope proteins derived from SV5.
2.3.5.1 / The attachment proteins.
The attachment proteins of the Paramyxoviridae are primarily involved in the 
adsorption of virions to target cells. For the Parainfluenzaviruses and Rubulaviruses, the
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attachment protein (designated Haemagglutinin-Neuraminidase, HN) has both haemagglu- 
tinating activity, for the binding of virions to sialic acid containing receptors, and 
neuraminidase activity (which cleaves sialic acid and possesses an acidic pH optima of 
between pH 4.8 & 5.5), presumably for the release of progeny virions from infected cells, by 
prevention of self-aggregation (reviewed in Lamb & Kolakosky, 1996). In contrast, the 
Morbilliviruses have an attachment protein (designated Haemagglutinin, H) which possesses 
only haemagglutinating capabilities, but in contrast to HN, is not believed to bind to sialic- 
acid-containing receptors due to the viruses restricted host range, and the lack of a 
neuraminidase activity. Indeed, the specific cellular receptor for measles virus has recently 
been elucidated as being CD46 (Naniche et al, 1993). The Pnuemovirus RS virus attachment 
protein (designated, G) has neither haemagglutinating or neuraminidase activities 
(Matthews, 1982; Gruber and Levine, 1983) and the cellular receptor has not yet been 
defined. A further function of some Paramyxoviridae attachment proteins is to aid in the 
membrane fusion and penetration stage of virion entry into cells. These functional 
differences observed between members of the Paramyxoviridae are reflected in the overall 
poor amino acid sequence homology between the proteins.
3D Structure - In contrast to the influenza virus HA and NA glycoproteins (Wilson d 
al., 1981 and Varghese et al, 1983), none of the Paramyxoviridae envelope glycoproteins 
have been, to date, successfully crystallised and X-ray analysed, although soluble forms of 
some of the HN glycoproteins have been produced which may well turn out to be more 
easily crystallised (Parks & Lamb 1990). However, the attachment proteins have been 
extensively analysed using biochemical and immunological methods. Indeed, tryptic digest 
analysis and 2D electron-microscopy has shown that the HN molecule is composed of a 
trypsin sensitive stalk region and a trypsin resistant head region which is composed of four 
subunits, and is analogous to the structure defined for the influenza virus NA. Sequence 
alignments between Influenza NA and the Paramyxovirus attachment proteins also reveal 
that amino acids involved in the neuraminidase activity of NA are conserved within the HN 
proteins (Colman et al., 1993). The majority of these amino acids are located in 4 conserved
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regions, 3 of which are absent from the MuV H protein, thereby supporting the role of these 
regions in the neuraminidase activity of HN.
Current evidence seems to suggest that the tetrameric structure for the attachment 
protein of some members of the Paramyxoviridae, (including; SV5, SeV, MuV and NDV) is 
composed of a mixture of covalently and non-covalently linked dimers ( Markwell & Fox, 
1980 and Ng et al., 1989). The proportion of the dimers which covalently form tetramers or 
merely non-covalently associate to form tetramers may, in part, be due to expression level 
and hence the concentration of the dimers found within the ER. Low concentration of HN, 
as found early in infection produced predominantly non-covalently associated tetramers 
and conversely, high concentration, as found late in infection produced predominantly 
covalently bound tetramers (Morrison et al., 1990). Stable formation of these tetramers is 
apparently dependant upon a functional trans-membrane domain, cytoplasmic region, and 
a correctly folded ectodomain of the HN monomer (Ng et al., 1990; Parks & Lamb, 1990 and 
Parks & Lamb, 1991).
Monomeric subunit - In SV5, the HN monomer is produced as a polypeptide of 565 
amino acids and has an unmodified predicted mwt. of - 62Kda (Hiebert et al., 1985). The 
protein is generally divided into three regions (figure 6) comprised of the; 17 amino acid 
cytoplasmic tail, 19 amino acid trans-membrane domain (which co-functions as a signal 
sequence) and the 529 amino acid ectodomain. Furthermore, for the majority of the 
Paramyxoviridae, including; SV5, NDV, MeV, SeV, ReSV and hPIV3, the molecule has been 
shown to be orientated within the virion/cellular membrane in a type II topology (reviewed 
by Morrison, 1988 and illustrated in figure 7), analogous to the Influenza virus NA.
The attachment molecules are glycosylated by the addition of N-linked 
oligosaccharides (figure 6) and also by O-linked oligosaccharides in the case of the 
Pneumovirus G protein (Gruber & Levine, 1985 and Wertz et al., 1985). In SV5 and MeV, 
oligosaccharides are added to all of the 4 potential N-linked glycosylation sites (Ng et al., 
1990 and Hu et al., 1994) which gives the protein an apparent molecular weight of 
approximately 68-75Kda, depending on the cell-type in which expression is occurring
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Figure 6: Diagrammatic representation of simian virus 5 (SV5) HN & F glycopro­
teins (adapted from Lamb & Kolakofsky, 1996).
Panel A) Schematic of the Haemagglutinin-Neuraminidase (HN) glycoprotein from SV5.
SV5 HN possesses an N-terminal cytoplasmic tail of 17 amino acids followed by a 19 amino acid 
hydrophobic signal/stop-transfer sequence which targets and anchors the protein into the ER 
membrane, m a type II topology (see also figure 7). The ectodomain of the protein contains four 
potential sequons for the addition of N-linked oligosaccharides, all of which are utilised.
Panel B) Schematic of the Fusion (F) glycoprotein from SV5.
SV5 F possesses a 19 amino acid N-terminal signal sequence and membrane anchor which directs, and 
initially anchors, the nascent polypeptide to the ER. At the C-terminal region of the molecule are 
depicted the 19 amino acid cytoplasmic tail and the 38 amino acid membrane-anchor. Cleavage of the 
signal sequence occurs resulting in a type I membrane topology (see also figure 7). The ectodomain 
contains six potential sequons for the addition of N-linked oligosaccharides, all of which are utilised. 
Also depicted are the heptad repeat regions and the cleavage activation region along with 
representative examples of the fusion peptide amino acid sequence of other Paramyxovirinae, 
depicting the close homology of the peptide between the different members.
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Figure 7: Schematic depicting the membrane insertion of type I & II
glycoproteins (adapted from Shaw et ah, 1988).
Panel A) Type 1 glycoprotein.
A type I glycoprotein possesses an N-terminal signal sequence of approximately 10-20 amino acids, 
which directs the ribosomes to the ER. A membrane-spanning stop-transfer sequence component of 
the signal sequence, anchors the polypeptide into the ER membrane followed by the continual 
translocation of the growing polypeptide chain into the ER lumen. A stop-transfer sequence present 
at the C-terminus halts further translocation of the polypeptide into the ER lumen, and translation 
typically terminates after the addition of a short C-terminus cytoplasmic tail. Cleavage after the first 
stop-transfer sequence, by signal peptidase, releases the N-terminus into the ER lumen.
Panel B) Type II glycoprotein.
A type II glycoprotein possesses a short N-terminus cytoplasmic tail which is followed by a single 
hydrophobic region which serves as both a signal sequence, to direct the ribosomes to the ER, and as 
a membrane anchor. No cleavage after the membrane anchor occurs, and translocation of the nascent 
polypeptide chain into the ER lumen continues until translation is terminated.
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(Paterson et al., 1985). The ReSV G protein is 298 amino acids long with an unglycosylated 
mwt. of -SSKda and a glycosylated mwt. of ~84Kda to 90Kda, half of which is attributable 
to O-linked glycosylation (Collins, 1991). For the HN and H proteins of SeV and MuV it has 
been shown that glycosylation is required for incorporation into the virions (Nakamura et 
al., 1982 and Herrler & Compans, 1983). However, for NDV, glycosylation apparently wasn't 
required for virion incorporation, but was required for infectivity (Morrison et al., 1981). 
Site-directed mutagenesis of the N-linked glycosylated sites in the SV5 protein showed 
varying effects on protein folding, transport and oligomerisation depending on the site of 
the mutation and the number of mutations introduced into the one molecule. Removal of all 
the glycosylation sites, or the expression of WT protein in the presence of the N-linked 
glycosylation inhibitor, tunicamycin, resulted in the production of a protein which; was not 
recognised by conformationally-sensitive mAbs, did not oligomerise to form the native 
structure, was not transported to the cell-surface, and which accumulated in the ER due to a 
stable association with the resident ER protein GRP78-BiP. The removal of the third (g3) 
glycosylation site at amino acid 267 had the most deleterious effect on protein folding. This 
appears to be in contrast to a similar study carried out by Hu et al. (1994) in which it was 
observed that mutations of the individual N-linked sites in the MeV H protein had little 
effect on folding and oligomerisation. However, in both cases, it was still apparent that 
native folding was due to a synergistic effect from the individual carbohydrate chains.
Glycine residues (important in forming bends and a-helices) and cysteine residues 
(important in intra-and-intermolecular bonding) within the attachment proteins have also 
been implicated as being important in the folding and oligomerisation process of protein 
maturation, and are well conserved within the Paramyxoviridae (Morrison & Portner, 1991 
and Hu & Norrby, 1994). Furthermore, it has been demonstrated that the HN protein of SV5 
undergoes fatty acid acylation via the addition of myristic and palmitic acid residues, 
possibly to the cysteine residue within the cytoplasmic tail (Veit et al., 1989). The exact 
function of these modifications is unclear, but they may possibly contribute to the stability of 
the protein within the membrane (Morrison & Portner, 1991).
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Intracellular Processing (greater detail on protein trafficking can be found in chapter 
3) - Using p-^ilse^;i^l^<^;Ll^i^in5 and studies Ng et al. (1989) have
demonstrated that SV5 HN monomers oligomerise, in the ER, with a half-life (T1/ 2) of 25-30
mins., prior to transport to the golgi network. This is significantly slower than the 
oligomerisation rates determined for Influenza virus HA & VSV G which have T1/2 of 7-10 
mins. and 6-8 mins. respectively (Gething et al., 1986 and Doms et al., 1987). The transport 
rate of the HN to the medial golgi network was demonstrated using EndoH analysis in 
which EndoH resistant forms of HN were detected after approximately lhr, but an accurate 
determination could not be made due to the presence of multiple species of HN after EndoH 
treatment (Ng et al., 1989). Using pulse-labelling experiments and immunofluoresence 
analysis it has been shown, for the SV5 HN, that the protein is turned over within the cell 
with a Ti/2 of -2hrs, and is lost from the cell surface with a Ti/2 of - 50 mins (Ng et al, 
1990) which is similar to that found for SeV and MuV (Roux ef al., 1985 and Waxham & 
Wolinsky, 1986). This turn-over appears not to be dependent on the presence of other SV5 
proteins, as HN expressed in CV1 cells infected by an SV40-recombinant also showed 
internalisation of HN (data not shown-Ng et ah, 1989). Furthermore, this internalisation was 
antibody independent. However, this loss from the cell-surface is not observed for hPlV3 
HN which apparently is stabily expressed at the cell-surface (Leser et al., 1996).
Using gold-labelling electronmicroscopy immunocytochemistry experiments, Leser 
et al have further shown that SV5 HN is internalised via clathrin-coated pits and that the 
internalisation appears to be of the non-recycling type, thereby resulting in the degradation 
of HN (included in this category are the Tumour Necrosis Factor, Interleukin 2 and 
Epidermal Growth Factor receptors, Leser et al., 1996 and references therein). Furthermore, 
Leser et al. (1996) demonstrated that the SV5 HN protein was found to co-localise with 
transferrin (a marker for early endosomes), and bovine serum albumin (a marker for late 
endosomes). Prior to this study, Ng et al. (1989) showed that HN also co-localised with 
ovalbumin, a marker for lysosomes, thereby demonstrating the most likely degradative 
pathway for internalised SV5 HN. As the cytoplasmic tail of SV5 HN does not possess a 
tyrosine residue which has been implicated as being the critical residue for internalisation,
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as present in the cytoplasmic tails of many proteins, the exact signal for internalisation of 
HN still remains to be elucidated, although a study by Ector et al (1992) demonstrated that 
the trans-membrane domain and the first six amino acids C-terminal to the trans-membrane 
domain were critical for internalisation. A possible role for the involvement of other SV5 
proteins, as stated above can be ruled out, but an involvement with cellular proteins in 
directly inducing internalisation can not be eliminated.
Using co-precipitation studies of radio-labelled cells, Ng et al. (1989) showed that 
monomeric SV5 HN possessed a specific and transient (T1/2 of 20-25 mins.) association with
the resident ER chaperone protein GRP78-BiP. However, malfolded monomers were found 
to be stabily associated with GRP78-BiP (T1/2 of >6hrs), thereby preventing the passage of 
malfolded proteins to the golgi network.
Role in the Fusion process - An initial demonstration of the possible role of the 
Paramyxoviridae attachment protein in the fusion process was illustrated by Portner et al. 
(1987) where mAbs to the SeV HN were produced which inhibited virion fusion but did not 
affect the haemagglutinating or neuraminidase activities of the HN protein. Apart from SV5, 
all the other members of the Paramyxoviridae require the presence of the attachment protein 
for viral fusion (reviewed in Lamb & Kolakofsky, 1996 and references therein). From 
chimaera studies, Deng et al. (1994) have shown that for hPIV2 & NDV HN proteins, the 
trans-membrane domain and the first 82 residues of the ectodomain are important for 
binding to F and aiding the fusion process. Furthermore, experiments carried out by Bousse 
et al. (1994) have demonstrated that a single point-mutation (asn->lys) in the proposed 
globular head region of hPIVl HN was the source of the difference between a high and low 
fusogenic strain of hPIVl. No differences in the primary amino acid sequence of the F 
proteins were demonstrated.
2.3.S.2 I ITih FfsSooi Prottins.
The fusion (F) proteins are the major proteins of the Paramyxoviridae involved in 
cell-cell and virus-cell fusion, which occurs in a pH-independent manner (Choppin &
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Compans, 1975). This is in contrast to the pH-dependant (pH5.0-5.5) fusion carried out by 
the Influenza virus HA (White et al., 1983). With the exception of SV5, all members of the 
Paramyxoviridae require the co-expression of the homotypic HN/H protein for efficient 
fusion to take place (reviewed in Lamb & Kolakofsky, 1996). The requirement for co­
expression of homotypic HN/H with the F protein may be due to the binding of the HN/H 
protein to its receptor molecule, where-upon a conformational change in the associated F 
protein occurs, resulting in a subsequent exposure of the fusion peptide. For SV5, contact of 
F with the cellular membrane or an unknown receptor may be the triggering factor.
Analysis of cloned mRNAs reveal that the F monomer ranges in length from between 
529-580 amino acids (reviewed in Lamb & Kolakofsky, 1996). There is some degree of 
homology in the primary amino acid sequence throughout the family, especially for glycine, 
proline and cysteine residues, which is translated to an observed conservation of structural 
features (Morrison, 1988 and Morrison & Portner, 1991). The monomer possesses an N- 
terminal cleavable signal-sequence, and a C-terminal trans-membrane domain, which thus 
confers a type 1 membrane topology to the full length molecule (figures 6 & 7). The F- 
protein possesses between 3 and 6 potential N-linked glycosylation sites, with all six sites 
being occupied in the case of the SV5 F protein (Bagai & Lamb, 1995). Mutation of individual 
sites in the F 2 region of SV5 F resulted in a negligible change in surface expression, however, 
mutation of sites in the FI region resulted in minor to major changes in intracellular 
transport and protein stability (Bagai & Lamb, 1995). Furthermore, Collins & Mottet, (1991) 
have demonstrated that unglycosylated ReSV F undergoes inefficient cleavage. There is no 
evidence for O-linked glycosylation being involved, however, at least for NDV F, fatty acid 
acylation may be involved in the post-translational modification of the F-protein, but a 
function for this has not been elucidated. However, mutation of the cysteine residue in the 
cytoplasmic domain of the influenza virus HA protein (also a type I glycoprotein), which 
prevents palmitylation of the protein, did not prevent surface expression, virion assembly or 
infectivity although, except for one mutant, all the viruses were attenuated in a mouse 
model (Jin et al., 1996).
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The F-protein is synthesised as an inactive precursor (Fo) which is activated by
proteolytic cleavage and trimming. This activation process is carried out by host-cell 
proteases in the trans-golgi network to form the disulphide linked subunits Fi & F2 (Scheid 
& Choppin, 1974). From cross-linking experiments, these monomers then go on to form non- 
covalently linked oligomers, possibly homotrimers (Russell et al., 1994). From the nature of 
the cleavage site (shown in figure 6) and the site of cleavage within the cell, furin, a 
subtilisin-like protease, has been implicated as the enzyme responsible for the initial 
cleavage event (with the exception of Sendai virus). This initial cleavage is then followed by 
a trimming of the F2 subunit by a carboxypeptidase (reviewed in Lamb & Kolakofsky, 
1996).
The cleavage-activation process is a prerequisite for biological activity of the F- 
protein. Anderson et al. (1992) have shown that for the ReSV F, a mutant which does not 
undergo cleavage; was glycosylated (but not to complex forms), did not form oligomers, had 
a long association with the ER resident protein GRP78-BiP, was not recognised by 
conformation-specific mAbs, and had very little surface expression. Cleavage of Fo into Fi & 
F2 exposes a hydrophobic domain, termed the fusion peptide (or fusion related ectodomain- 
FRED), which is 20 amino acids in length and is located at the N-terminus of the Fi subunit. 
The fusion peptides from members of the Paramyxovirinae share between 70 and 90% 
amino acid homology (Paterson & Lamb, 1987 and depicted in figure 6). Evidence for this 
region being able to insert into membranes has been demonstrated using hydrophobic 
photo-affinity labelling probes (Novick & Hoekstra, 1988), and by the ability of the SV5 
fusion peptide to act as a membrane anchor (Paterson & Lamb, 1987; Paterson & Lamb, 1990 
and Parks & Lamb, 1990). Intriguingly, Horvath & Lamb (1992) have demonstrated that the 
invariant nature of the amino acids within the fusion peptide may have been selected so as 
to reach a compromise between fusion activity and viral replication, since mutation of 
glycines 3,7 & 12 to alanines dramatically increased syncytial formation.
Also located on the monomers are 2 regions of a-helix motifs, termed hep tad repeats 
(figure 6), located immediately adjacent to the fusion peptide and the transmembrane 
anchor domain. A study by Sergel-Germano et al. (1994) demonstrated that these two
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regions may be important in protecting the fusion peptide from the aqueous environment, 
and have perhaps a more direct role in the fusion process.
As has been examined for the HN/H proteins, the integrity of the cytoplasmic tail in 
the intracellular transport and biological activity of F has been analysed. A study by Sergei 
& Morrison (1995) using deletion mutants of the NDV F demonstrated that removal of the 
C-terminal tail produced a protein which underwent minimal proteolytic cleavage and 
resulted in a lack of syncytial formation. Deletion of the C-terminal half of the tail, resulted 
in a protein which was proteolytically cleaved but which did not result in syncytial 
formation. Removal of the C-terminal quarter, brought back 30% of syncytial forming 
activity, with WT characteristics been observed by a mutant deleted of the C-terminal 
eighth.
As has been previously mentioned, all members of the Paramyxoviridae, with the 
exception of SV5, require co-expression of homotypic HN/H & F to produce efficient fusion 
activity. An examination of the regions on MeV F which are involved with the interaction 
with its homotypic HN/H has been carried out by Wild et al. (1994). Using chimaere studies 
between CDV F and MeV F they observed that a region of 45 amino acids (Cys 337 -> Arg 
381) located within the cysteine-rich region (figure 6) was critical for the interaction. 
Interestingly, SeV F disulphide links have been recently elucidated by Iwata et al. (1994) 
where 2 loops are produced. If this can be shown to extrapolate to MeV F then these loop 
regions are to be found within this critical region of binding to H, and therefore perhaps the 
loops interlock with similar "pocket" regions on the homotypic attachment protein.
2.3.5.31 The Small Hydrophobic Protein (SH).
The Rubulaviruses, MuV & SV5, and members of the Pneumoviruses encode a third 
integral membrane protein, called the SH protein (or 1A in the case of ReSV), figure 5 
(reviewed in Lamb & Kolakofsky, 1996). Detectable expression of an SH protein has been 
demonstrated for all the above viruses except in the case of MuV. The predicted amino acid 
sequence of SV5 SH indicates a protein of 44 amino acids in length, comprised of three 
domains: an N-terminal hydrophilic sequence, an intermediate hydrophobic sequence
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which is of sufficient length to span a membrane, and a short (5 amino acids) hydrophilic C- 
terminal region. This arrangement would confer a type II topology on the SH protein 
(Hiebert et al., 1988). Pneumovirus SH (or lA) contains 64 amino acids and possesses similar 
domains and topology to the above SV5 SH. In contrast, ReSV SH is apparently modified by 
the addition of N-linked glycosylation on the C-terminal ectodomain, which adds a further 
7-23Kda in mwt compared with the unglycosylated protein (reviewed in Lamb & 
Kolakofsky, 1996). A function for SH has not yet been elucidated, but it is found to co­
localise with HN in SV5 infected cells, but is excluded from the virion (Hiebert et al, 1988).
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CHAPTER 3
HETEROLOGOUS GENE EXPRESSION
1 / Introduction.
The realisation that individual gene products could be produced within a 
heterologous host occurred with the advent of recombinant DNA technology in the early 
1970s. At that early time point, the idea that genes could be inserted into plasmids, 
mobilised into bacteria with protein subsequently being produced was indeed 
revolutionary, with much of modern-day biotechnology and molecular biology being in its 
debt. However, since those early pioneering years, many different expression systems have 
been created for the heterologous expression, or over-expression, of introduced genes. 
Examples of such expression systems and some of their advantages & disadvantages are 
shown in table 1.
An important stage in any project where heterologous expression of a protein is 
required is the choice of host cell. Moreover, the choice of host cell is largely dependant on 
several factors, including; the nature of the protein, the purpose of protein production, the 
cost involved and the facilities & expertise available. The former two factors are considered 
to be the most important. The nature, or property, of the protein involved in the study can 
generally be grouped into 2 areas (table 2); nature of the polypeptide, and modifications/3D 
structure of the polypeptide as found in the native host cell. Generally, natively-unmodified 
polypeptides 80 to 500 amino acids in length which contain few cysteine residues and are not 
highly hydrophobic in nature should be well expressed in a bacterial system, especially if 
expressed as a fusion protein and/or are secreted into the external milieu (Goeddel, 1990).
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However, large, highly modified, hydrophobic, mammalian cell-surface glycoproteins are 
unlikely to be expressed well in bacteria and an alternative system, such as insect cells or 
mammalian cells, would probably be more appropriate. However, the reason for protein 
production, as discussed below, will also influence the choice of host cell for expression.
Host Cell Example Advantages Disadvantages
Bacterial E. coli
B. sshtilis
Rapid growth, cheap, genetics 
well known, good for secretion, 
large amounts of protein made. 
Quick to set-up the system.
Few post-translational
modifications. Poor codon
useage for mammalian genes. 
Proteolytic degradation. Prot­
ein may possess N-terminal
methionine/formyl methionine
Yeast S. cerevisiae
P. pastoris
As for bacterial, plus some
post-translational modificat- 
ions.Useful for protein-proteir
interaction studies.
Only a basic post-translational 
modification system present.
Fungi Aspergillus Rapid growth, cheap, some 
post-translational modifica­
tions.
As for yeast.
Insect Sf9 Cheaper than mammalian cells
Mammalian-like post-transla­
tional modifications. Generally
more protein produced than
mammalian cells.
More expensive than yeast or
bacterial systems. Genetics less
well known. More time consu­
ming than yeast or bacterial
systems.
Protozoan Leishmania Rapid growth, cheap, some 
post-translational modification. 
Large amounts of protein prod­
uced.
Genetics less well known.
Only basic post-translational
modifications occur.
Mammalian Hela, Cos-7,
293, CHO,
BalbC, BHK.
Many post-translational modif­
ications. Can observe pheno­
typic changes & protein-protein
interactions.
Expensive. Time consuming to
produce stable cell-lines. Slow
growth rate. Generally poor
yields of protein.
TABLE 1 - Examples of host cells available for the heterologous expression of recombinant 
proteins, listing some of their potential advantages and disadvantages.
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NATURE OF POLYPEPTIDE MODIFICATIONS/3D STRUCTURE
Small peptides, < 80 amino acids in 
length.
Phosphorylation.
Secreted polypeptides, 80-500 amino 
acids in length.
Glycosylation.
Secreted & surface polypeptides,
> 500 amino acids in length.
Fatty acid acylation.
non-secreted polypeptides, > 80 
amino acids in length.
Disulphide bond formation.
hydrophobicity/hydrophilicity of 
the polypeptide.
Oligomerisation.
Specific proteolytic cleavage.
TABLE 2 - Factors related to polypeptide structure and post-translational modification 
which influence the choice of heterologous expression system for protein production. Note - 
not all of the possible post-translational modifications are listed.
Most applications of recombinant proteins fall into three broad categories
i) Structural studies.
ii) Functional studies.
iii) Biotechnological development, e.g vaccines, hormones & pharmaceuticals.
Again the choice of host-cell depends on the nature of the protein. Not all structural 
studies on natively expressed mammalian proteins have to be produced from proteins 
expressed from a mammalian-cell system. Many natively unmodified intracellular 
mammalian proteins, or parts thereof, have been expressed in bacteria in large amounts and 
successfully crystallised and X-ray analysed (Ghosh et al., 1995). However, most mammalian 
and viral surface glycoproteins are extensively post-translationally modified. Where these 
modifications confer, in part, the 3D structure of the molecule, an expression system will 
have to be chosen which carries out these natively-found modifications. The above statement
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is also true for proteins which are being produced for functional studies, in that higher 
eukaryote proteins which are not extensively modified can be functionally produced in 
bacteria. Likewise, highly complex, integral membrane oligomeric enzymes found in 
mammalian cells, may only be successfully expressed, in a functionally active form, in 
mammalian cells or other higher eukaryotes.
Biotechnological use of expression systems for the production of recombinant 
proteins depends upon the proteins' use. For example, for some purposes antibodies can be 
readily produced against highly complex mammalian proteins which are produced in a 
malfolded form from a bacterial expression system, either as a full length polypeptide, or 
portions thereof. However, antibodies which are produced, for example, to neutralise viral 
infectivity, may have to be raised against a natively folded protein which must, therefore, be 
expressed in a suitable expression system.
In summary, the choice of host-cell depends upon the nature of the protein and the 
intended use of the protein. For a number of applications for recombinant proteins, the 
generalisation " make host-like proteins in host-like systems" can be applied.
The rest of this chapter will detail current knowledge in the field of mammalian-cell 
expression. A general review on some of the other expression systems currently available, as 
detailed in table 1 is given in Goeddel, (1990) (bacteria, and yeast), Zhang et al., (1995) 
(Leishmania), Gellissen et al.,( 1992) & Gregg et al., (1993) (Pichia pastoris expression system), 
and Summers & Smith, (1987) & O'Reilly, (1992) (Insect cells).
2 / Mammalian-cell expression systems.
Due to the aforementioned problems, considerable effort has been made in 
constructing systems for the heterologous expression of proteins in mammalian cells. The 
diversity of mammalian-cell expression technology has dramatically increased over the past 
10-15 years such that now, for many purposes, expression in mammalian-cells is routine and 
a first choice system rather than been viewed as a tedious last-choice option.
There are numerous reasons for expressing cloned eukaryotic genes in mammalian- 
cells, these include (Sambrook et al., 1989);
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1) To verify the identity of a cloned gene by using immunological or functional assays to 
detect the encoded protein.
2) To generate large amounts of proteins that are normally only available in insufficient 
quantities from natural sources, e.g hormones, antibodies.
3) To examine the synthesis and intracellular transport of proteins when expressed in various 
cell-types.
4) To express genes which code for proteins that require higher eukaryotic post-translational 
modifications e.g, cell surface receptors.
5) To express intron-containing genomic sequences which cannot be transcribed correctly 
into mRNA in bacteria or lower eukaryotes.
6) To investigate structure-function relationships by analysing the properties of wild type 
and mutant proteins.
7) To identify DNA sequence elements involved in the control of eukaryotic gene expression.
The choice of which mammalian expression system to utilise depends, in part, upon 
the following five parameters;
1) The species and type of mammalian cell available.
2) The size of the gene which is to be expressed.
3) Whether the experiment requires the transient or stable expression of the protein.
4) The method of transfer of the foreign gene.
5) The presence of controlling elements in the DNA.
Not all mammalian cells can be transfected or infected efficiently with foreign DNA 
and cell-lines from different species will not necessarily process the protein as found in the 
native cell. For example, Chinese hamster ovary (CHO) cells which are routinely used for 
bulk protein production, tend to add more terminal sialic acid residues to secretory and 
transmembrane glycoproteins than do human, monkey or mouse cells (Sambrook et al., 1989). 
This is an important consideration when the expressed protein is intended for human use.
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The size of the gene to be expressed within a particular cell-line is important due to 
the strict packaging size some mammalian viral vectors possess. Therefore, direct DNA
transfection may be the only option.
The isolation of stable cell-lines which express the desired protein can be a laborious 
task, but is generally necessary if more than a few micrograms of protein is required. 
However, for a number of experiments such as the determination of protein localisation by 
immunofluoresence, transient expression of the protein is probably all that is required.
The presence of controlling elements for the gene/cDNA is critical to successful 
expression in that cDNAs can only be expressed if they are placed within a vector which 
possesses expression elements such as; promoter, enhancer, splice acceptor and/or donor 
sequences, and polyadenylation signals (see figure 10). Sequences from genomic DNA may 
possess these required sequences, but there is no guarantee that they will work in the chosen 
cell-lines available , especially if the DNA sequences are from genes which are expressed in a 
tissue specific manner, and that the protein is produced at an appropriate level.
2.1 / Current vectors for gene transfer into mammalian cells.
Generally, vectors for introduction of foreign DNA into mammalian cells can be 
broadly categorised into 2 types: those based on virus infection and those which are based 
on direct DNA transfer (although sometimes the two systems merge together, as detailed in 
the text to follow).
2.1.1 / Viral Vector Systems
Many viruses which infect mammalian cells have evolved mechanisms to specifically 
increase the production of viral proteins by "hijacking" the cellular transcription/translation 
machinery. With the increase in the understanding of the molecular biology of many 
mammalian viruses, has come the ability to genetically engineer viral genomes by the 
introduction of desired coding regions for foreign genes. Such introduced genes, under the 
control of viral expression elements, has made it possible to produce infectious recombinant 
virus particles which, upon infection, produce high levels of foreign gene expression.
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Furthermore, viral-mediated gene transfer provides a convenient and efficient means to 
introduce foreign DNA into the majority of the recipient cells, whereby nearly 100% of the 
recipient cells may express the foreign gene product. In addition, for many viruses, viral 
replication can yield multiple copies of the template DNA/RNA which can then serve to 
amplify the transcription of the foreign gene. Furthermore, because some viruses possess a 
wide host-range, viral-mediated gene transfer may allow the convenient introduction of 
foreign genes into a variety of different cell-types from different species. Individual examples 
of selected viral vector systems are described below.
2.1.1.11 Papovavirus exprrssion system.
Papovaviruses (derived from Papilloma, polyoma and vacuolating viruses) are non- 
enveloped viruses which possess a small DS circular DNA genome of approximately 5Kbp. 
Of all the members of the Papovaviruses, Simian virus 40 (SV40) and polyoma viruses are the 
best studied. SV40 virus DNA replicates to a high copy number (>100,000 copies per cell, and 
has thus been more widely employed for expression studies than the lower copy number 
polyoma virus) in primate cells whilst polyoma virus replicates in murine cells.
The SV40 viral genome (figure 6) can be divided into two regions, the early region 
which codes for the transforming antigens (large T and small t) and the late region which 
codes for the structural proteins (VP1, VP2 and VP3). After infection by SV40, the early genes 
are expressed first, with DNA replication, which is primarily mediated through the Large T 
antigen, being initiated 12 hours post-infection. Thirty six to forty eight hours post-infection 
the capsid proteins are expressed, with virion release and cell-death occurring 72-96 hrs post­
infection.
Recombinant SV40 viruses can be constructed by the insertion of foreign DNA into 
the early or late regions of the viral genome (figure 8). Recombinant viral stocks can be 
produced by providing either a helper virus or a helper cell-line which complements the 
missing function ,e.g. Cos cells (Gluzman, 1981). Much success has occurred through the use 
of late replacement recombinants where the cDNA is incorporated in place of the genes 
encoding the; VP1, VP2 and VP3 proteins.
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Figure 8: Schematic depicting the genome organisation of SV40 and its use as a 
heterologous expression system.
Panel A) A schematic of the SV40 genome illustrated in a linear form.
The early gene products, small & large T antigens (and a possible third T antigen: X) are shown in 
red, and the late gene products (virion proteins (VP) 1,2 & 3) are illustrated in blue. Also shown 
are the regions substituted for foreign DNA in the construction of early or late replacement 
vectors.
Panel B) Construction of recombinant SV40.
Appropriate plasmids are constructed in which the early or late genes of SV40 are replaced by the 
DNA of choice. Early replacement vectors are transfected into large T antigen expressing cell-lines, 
such as Cos cells, whereas late replacement vectors are co-transfected with DNA which encodes 
the virion proteins, or by helper virus. Approximately 72 hrs post-transfection, virus is isolated 
and screened for foreign protein expression and large titre stocks prepared.
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The advantages of the SV40 virus system are the high levels of expression which can 
be obtained: 1-10 (igs/10^ cells, and that potentially toxic proteins can be expressed. The 
small size of the viral genome also contributes to ease of inserting foreign DNA sequences. 
The high level of expression observed with the SV40 system is primarily due to high plasmid 
copy number and the near 100% infection rate. However, there are many disadvantages 
which have restricted their use, including;
1) Primarily only monkey cells can be infected, although infection can occur in 
human cells, albeit poorly.
2) Recombinant SV40 viruses can only be used for transient studies or batch harvest 
procedures due to cell death 3-4 days post-infection.
3) Packaging size restricts the size of the insert to <2.5Kbp.
4) DNA rearrangements frequently occur during the replication of these recombinant 
viruses.
2.1.1.21 Vaccinia virus expression system..
Vaccinia virus is a member of the orthopoxvirus genus of the family Poxviridae, and 
replicates in the cytoplasm of avian or mammalian cells. Vaccinia virus possesses a large 
(185Kbp) linear ds DNA genome and encodes its own transcription and RNA processing 
system. The virus encodes approximately 200 genes: 100 early genes which are expressed 
soon after infection, and 100 late genes which are expressed after DNA replication at 6 hrs 
post-infection. Virions are formed about 6 hrs after infection and continue for approximately 
48 hrs.
After the eradication of smallpox, vaccinia virus research changed direction and the 
possibility of inserting exogenous DNA into the virus was investigated, primarily as a means 
of delivering foreign antigens for immunisation purposes (Panicali & Paoleiti, 1982 and 
Mackett et al1982), although it was observed that vaccinia virus would also be a useful 
candidate for heterologous protein production.
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Recombinant vaccinia viruses are constructed by homologous recombination of 
plasmid DNA with the viral genomic DNA. This recombination event is usually targeted to 
viral thymidine kinase gene (other possible sites of integration are listed in Miner & Hruby, 
1990), where recombinants are enriched for by the TK" phenotype, or by a colour indicator if 
the B-galactosidase gene was included on the plasmid (Chakrabarti, 1985). Dominant 
selectable markers such as neomycin phosphotransferase and E. coli xanthine-guanine 
phosphoribosyl transferase-gpf, have recently been utilised (reviewed in Miner & Hruby, 
1990).
Early studies with recombinant viruses had the foreign gene being transcribed from
the early/late or late viral promoters, 7.5K (Mackett et al., 1984) & 11K (BertRolet et al., 1985)
respectively. However, a higher expressing system has been developed, initially by Fuerst et
D S
al, (1986) where the specific T7^JNA-dependant RNA polymerase (T7-JEDRP) is used to direct 
transcription of foreign genes which are placed downstream of the T7010 promoter, in place 
of the above viral promoters, and upstream of the To termination sequence. Expression of the 
foreign gene can be achieved in two ways (figure 9);
1) By infection of the cell-line with a recombinant vaccinia virus (vTF7-3) which 
expresses the T7-RDRP, followed by a subsequent transfection with the T7 promoter 
plasmid (figure 7), or
2) By constructing a second recombinant virus which contains the foreign gene 
downstream of the T7 promoter, and co-infecting the two viruses into the cell-line.
With this approach, nearly 100% of the recipient cells can express the foreign gene.Using the 
latter system of expression, very high levels of specific mRNA for the foreign gene is 
produced (24-48 hrs post-infection), often up to 30% of the total cell RNA (Feurst et al., 1987). 
However, it appears that only 5-10% of this mRNA is properly capped and thus a significant 
proportion of message is poorly translated, if at all. To try and alleviate this inherent 
drawback, a leader sequence from a picornavirus - EMCV virus (encephalomyocarditis virus) 
- which possesses an internal ribosomal entry site has been added immediately upstream of 
the AUG initiation codon of the foreign gene, and downstream from the T7 promoter. This
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Figure 9: Heterologous protein expression using vaccinia virus (adapted from
Miner and Hruby 1990).
Panel A) Production of recombiant vaccinia virus vectors.
DNA of choice is cloned into the appropriate plasmid downstream of a vaccinia virus promoter or 
T7 promoter. Also present on the plasmid are flanking regions for insertion into the vaccinia 
genome and elements for the selection of recombinant viruses. The plasmid is transfected into 
vaccinia virus infected cells and virus is isolated upto 48hrs post-transfection. The isolated virus is 
selected then screened for recombinant protein production, plaque purified and high titre stocks 
produced which are used for heterologous protein production.
Panel B) Quick plasmid expression.
Transient expression can also be achieved by plasmid transfection after infection of the cells with 
wild type vaccinia virus or a T7 RNA polymerase expressing recombinant vaccinia virus. This 
alleviates the time-consuming construction of recombinant viruses if only a few experiments are 
to are to be perfomed
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addition was shown to increase a reporter gene expression by 4-7 fold, and a further 2 fold if 
the cells were incubated in hypertonic medium (Elroy-stein et aU, 1989).
There are numerous advantages of the vaccinia virus system including;
1) Vaccinia is a relative safe virus to work with, especially the attenuated strains.
2) Vaccinia has a very wide host range, c.f. SV40 virus.
3) Large size of the genome means large genes, or multiple genes can be inserted, up to 
approximately 25Kbp (Smith & Moss, 1983), c.f. SV40 virus.
4) Very high levels of recombinant gene expression can be obtained, even of toxic proteins, 
especially if the T7 system is utilised.
However, there are of course some disadvantages of using the vaccinia system, 
including;
1) Expression requires an ongoing infection, which ultimately kills the cell, (a highly 
attenuated avian host-restricted vaccinia virus recombinant has recently been developed by 
Wyatt et ah, (1995) which encodes the T7 RDRP. This avian virus induces a drastically 
reduced cytopathology when infected into mammalian cells, but still retains the very high 
levels of recombinant gene expression as observed for the replication-competent vaccinia 
viruses).
2) Vaccinia virus can only be used for transient expressions and batch harvest procedures.
3) There is still a small risk of infection and pathological complications, even from the 
attenuated strains of virus.
4) Time consuming to initially produce the recombinant viruses.
2.1.1.3 / .Ade^r^c^o^irr^u expression system
Human adenovirus, of which there are nearly 50 serotypes known, is a member of the 
mastadenovirus genus of the family Adenoviridae and can cause acute respiratory and 
ocular disease in humans. The molecular biology of adenovirus has been well investigated 
(reviewed in Shenk, 1996) and has contributed to the development of adenoviruses as a 
vehicle for the heterologous expression of recombinant proteins in mammalian cells.
35
Although adenovirus can be used for the above purpose, most research has been carried out 
to investigate the use of adenovirus as a delivery system for performing gene therapy and 
vaccination studies (reviewed in Imler, 1995).
Adenovirus virions are non-enveloped and icosahedral in structure, containing a 
double-stranded linear DNA genome of approximately 35Kbp which is replicated in the 
nucleus of primate cells, without the need for host-cell replication/division (Imler, 1995 and 
figure 10). The genome can be divided into an early (E) and a late (L) region. The early region 
consists of the; El, E2, E3 & E4 regions which are essential for transcription & replication of 
the viral genome, shutting off host-cell protein synthesis and modulating the immune 
response to the viral infection. The early regions are expressed soon after infection. The late 
region consists of the; LI, L2, L3, L4 & L5 regions which encode most of the structural 
proteins of the virion, and are expressed after the onset of DNA replication, 6-8 hours post­
infection.
Heterologous protein expression using adenoviruses can be achieved in two ways. By 
the construction of recombinant viruses (figure 10), or by the virions acting as chaperones to 
facilitate the uptake of plasmid DNA into cells in a process termed receptor-mediated gene 
delivery (RMGD).
Adenovirus serotype 5 (Ad5), or its derivatives, is extensively used for the 
construction of recombinant viruses due to the low pathogenicity and non-oncogenic nature 
of the virus. Recombinant adenoviruses are constructed, in the majority of cases, by the 
replacement of viral sequences, primarily the sequences from the early regions: El and/or 
E3. Vectors deleted in El are replication-defective and can only replicate in a helper cell-line 
(293 cells), but expression of foreign genes can still occur in cell culture and in vivo . Vectors 
deleted in the El region can accommodate 5.0 - 5.2Kbp of insert DNA. The E3 region is non- 
essential for virus replication in cell-culture, and deletion of this region can result in the 
insertion of 4.5 - 4.7Kbp of foreign DNA.
El-deleted viruses are primarily used for safety reasons and for expression purposes, 
where DNA inserted into the El region has been found to be highly expressed from 
associated promoters (especially the hCMV IE enhancer/promoter, Xu et al1995) and
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Figure 10: Schematic depicting the genome organisation of adenovirus 5 and its use
as a heterologous expression system (adapted from Imler 1996).
Panel A) A schematic of the Ad 5 genome.
Illustrated are the major transcription/translation products. Early gene products (E1-E4) are shown in 
red, late gene products (L1-L5) are shown in blue. Also shown are the positions of the major late 
promoter (MLP), the encapsidation signal (ES), and regions which are routinely deleted in the 
construction of recombinant viruses.
Panel B) A schematic depicting the construction ofa recombiant adenovirus expression vector.
Typically the foreign DNA is inserted into an E. coli plasmid shuttle-vector which contains homologous 
DNA (including an encapsidation signal) to the adenovirus genome flanking the foreign DNA insert. 
This plasmid is then co-transfected into cells (usually 293 cells, if the El region has been deleted) with an 
ad 5 replacement vector which does not contain an encapsidation signal and is deleted for one of the 
non-essential ad genes, e.g E3 or El. Intracellular homologous recombination occurs between the two 
plasmids, resulting in the production of infectious recombinant virus which is screeened for foreign 
protein production, plaque purified and high titre stocks produced.
ElAi
IX
ElB
0 10
I I
Tripartite leader 
i
1 2
4 4
4 4
4 4
4 4
4 4
MLP
t 20
VAI li 
VAI2i
30 40 50 60
l I L
E3iA—►
70 80
J I
90
I
lOOrnu
I
E4
{lOmu = ~3.6Kbp} — Regions ccmmonly deleted in replacement vectors.
Co-transfection into 293 cells & 
Intracellular homologous recombination
▼
rTRES+ AE3 UR
3
4
hor<?ign D\ \
up to SKbp
INFECTIOUS VIRAL VECTOR
independent of the insert orientation (although expression levels have been observed to be 
up to 7-fold higher if the transcription cassette is in the parallel orientation (Hitt et al., 1995). 
This is in contrast to inserts within the E3 region, where expression is highly orientation 
dependant, and associated-promoter independent (reviewed by Graham & Prevec, 1992). The 
choice of replication-competent or replication-deficient viruses for the construction of 
recombinant virus depends upon the intended application. For recombinant protein 
production and vaccination purposes, short-term high-level protein expression, as potentially 
produced by replication-competent viruses, may be the first choice (Hitt et al., 1995 and 
Imler, 1995).
Advantages of using adenovirus for recombinant protein production include;
1) Adenovirus will infect almost any type & species of mammalian cell.
2) The small genome size confers ease of introducing foreign sequences.
3) Defective viruses which are essentially non-pathogenic are available.
4) Very high titres of recombinant virus can be cultured.
5) Adenovirus will infect and replicate in non-dividing cells.
6) Up to 8.0Kbp can be inserted into El & E3 deleted viral genomes.
7) Generally, high levels of recombinant protein can be transiently expressed.
Disadvantages of using adenovirus for recombinant protein production include;
1) Currently, only up to 8.0IKbp of DNA can be inserted into El & E3 deleted viral genomes, 
although with the construction of appropriate helper cell-lines, a theoretical limit of 
approximately 30Kbp could be achieved (recently Caravokyri & Leppard (1995) have isolated 
a 293 cell-line which constitutively expresses the Ad pIX gene and can thus coimplement for 
viruses defective in this region. This subsequently increases the cloning capacity to -9.2 
Kbp).
2) There is still a small risk of infection and pathological complications.
3) Adenovirus can only be used for transient expressions / batch harvest procedures.
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4) Currently, even the replication-deficient viruses induce some degree of cytopathology in 
infected cells, although mutants in the penton base (a structural protein) have been 
demonstrated to induce a reduced cytopathology (Dr. Paul Freimuth, unpublished results).
5) 1t is time consuming to construct the recombinant viruses (although a recent technical 
improvement by Chartier et al. (1996), whereby homologous recombination between the two 
plasmids can occur within E. coli, will significantly increase the speed of recombinant virus 
production).
6) Recombination between the integrated El region in 293 cells and the viral genome can 
result in the rescue of replication-competent viruses which can contaminate recombinant 
virus preparations, although new El helper cells have been constructed which appear to 
alleviate this problem (Imler et al., 1995).
As stated earlier, adenovirus virions can be used to enhance DNA delivery into target 
cells. The natural route of Ad infection in cells requires the disruption of the endosomal 
membrane, in a pH-dependant manner, with the subsequent release of the Ad virions into 
the cytoplasm. Uptake of naked plasmid DNA into transfected cells results in a large 
proportion of the molecules not reaching the nucleus due to degradation within endosomes, 
therefore the endosomolytic activity of Ad viruses has been utilised to enhance entry of 
plasmid DNA into target cells.
Plasmid DNA can be attached to a ligand for a specific cellular receptor via a 
polylysine region present on the ligand. Mixing of high levels of Ad particles (3000 to 10,000 
virions per cell) with the plasmid-conjugate mixture has been shown to increase DNA 
expression by 350-fold with greater than 90% transient transfection efficiency, compared to 
plasmid-conjugate alone. This result is dependant on cell-lines and Ad strains employed. 
Moreover, if the plasmid-conjugate is physically linked to the Ad particles via a biotin- 
strepavidin linkage, expression can be further increased 3-20 fold, again dependant upon the 
criteria mentioned above (Gotten et al., 1993).
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2.1.1.4 / Adeno-aasooirrted virus ((AAV) exprrssSrn system.
AAV is a parvovirus and is a member of the genus Dependovirss belonging to the 
family Parvoviridae. Parvoviruses possess a linear ssDNA genome of approximately 5Kbp in 
length. AAV, being a member of the Dependovirsis genera is, in the majority of situations, 
replication defective and is thus dependant upon co-infection of the cell either by adenovirus 
or herpesvirus with subsequent replication of the AAV genome in the nucleus. Under 
conditions where helper viruses are not present, AAV can integrate, by non-homologous 
recombination via terminal repeats (tr) present on the AAV genome, specifically into human 
chromosome 19 where it remains silent until rescued by a helper virus. AAV can establish a 
stable latent state with a high frequency; 19-70% of exposed cells, even in non-dividing cells 
(reviewed in Berns, 1996). AAV carries two sets of functional genes and encodes 7 
polypeptides: 3 structural proteins (VPl-3) and 4 non-structural proteins (rep proteins) 
involved in replication of the genome and transactivation of the structural gene promoter.
AAV can be used as a vector for heterologous protein expression by production of 
recombinant virus particles, or by direct DNA transfection of plasmid DNA. Recombinant 
viruses are constructed by the replacement of the DNA encoding the structural proteins with 
the foreign DNA, thus retaining the rep genes and supplying the structural proteins, in trans, 
by transfection of an appropriate plasmid. This procedure allows approximately 2Kbp of 
foreign DNA to be inserted with the foreign DNA still being integrated at a specific site on 
chromosome 19. Another approach is to add AAV tr onto both ends of the foreign DNA 
allowing up to approximately 4.5Kbp of foreign DNA to be packaged into recombinant 
particles, when both the rep and capsid proteins are supplied in trans (Lebkowski et al., 
1988). Expression of the introduced gene has been successfully driven by the AAV promoter 
40 (p40, Tratschin et al., 1985) or by other viral promoters such as the CMV IE promoter and 
the 8V40 early promoter.
Advantages of AAV as a vector for heterologous protein expression include;
a) The small genome size allows ease of handling.
b) Isolation of stabily expressing cell-lines with a known site of integration can be produced 
(although integration sites outwith chromosome 19 frequently do occur).
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c) AAV can infect most mammalian cells.
d) AAV has not been associated with any known human disease.
e) No cytopathology is observed in cells infected with AAV.
Disadvantages of AAV as a vector for heterologous protein expression include;
a) Difficult to obtain high titre stocks of virus.
b) Production of virus stocks generally requires the presence of helper viruses.
c) Only approximately 4.5Kbp of foreign DNA can be packaged (although if the liposome- 
based transfection method is utilised, larger inserts will be possible).
2.1.1.5 / Alphavirus expression system.
Alpha viruses are a group of Togaviruses which infect many cell-types and species, 
ranging from mosquito to mammalian & avian cells. The genome consists of ssRNA of 
message sense which is approximately 12 Kbp in length, and encodes two sets of functional 
genes: the replicase & transcriptase genes (4 in total) and the structural genes (4 in total). All 
the replication and transcription functions are carried out by the viral replicase/transcriptase 
in the cytoplasm of the infected cell (Berglund et al1996 and figure 11).
Semliki Forest virus (SFV) and Sindbis virus (SV) are two of the alphaviruses which 
have been intensively investigated for their use as heterologous expression vectors, both for 
recombinant protein production and vaccination purposes (Berglund et al., 1996). SFV vectors 
have been utilised to express a variety of different proteins including; human transferrin 
receptor, chick lysozyme, E. coli B-galactosidase and the mouse dihydrofolate reductase 
(Liljesstrom & Garoff, 1991).
Alphavirus vectors are generally constructed in two forms, replicative recombinants 
or suicide recombinants. Replicative recombinants have the foreign DNA inserted in addition 
to the viral genes such that the RNA is infectious and virions are produced. However, these 
constructs have been shown to be frequently unstable during passage and, in most cases, the 
production of new virions is undesirable. Therefore, a preferred, and more commonly used 
approach, is to replace the structural genes with the foreign DNA.
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Figure 11: Schematic depicting the replication/transcription of alphaviruses, and 
their use in the heterologous expression of proteins (adapted from Berglund
1996).
Panel A) Replication/transcription ofa typical alphavirus.
Upon entry of the capped (grey circles) message sense ssRNA genome into the cytosol, translation of 
the rep genes produces the replication/transcription (Rep) proteins. The 5' and 3' ends of the genome 
and anti-genome contain the replication signals (sequences) required for Rep binding (black 
rectangles). The Rep proteins produce further genomes via a negative polarity ssRNA intermediate, 
and also transcribes the structural genes, via an internal promoter, which encode the virion proteins. 
Panel B) Heterologous protein expression using an alphavirus system.
Typically, foreign DNA is inserted into a plasmid whicli contains only the rep genes from an 
alphavirus downstream from an SP6 promoter. Following linearisation and in vitro transcription, the 
message sense RNA is transfected into appropriate cells and subsequent amplification of the RNA, 
via the Rep proteins, results in high level translation of the foreign gene. Alternatively, a helper 
plasmid which has deleted rep genes, but which encodes the structural proteins, can be 
co^t^^^^I^^<^II^i^c^cd/tI^arsfected resulting in the production of recombinant alphavirus particles which 
can be used for infection of cells resulting in the production of the protein of interest.
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DNA of interest is cloned into appropriate plasmid-based vectors which then, 
generally, serve as templates for the in vitro synthesis of recombinant mRNA. The mRNA is 
then transfected into the cell-line of choice and subsequent translation of the 
replicase/transcriptase genes leads to the amplification of the transfected RNA (up to 50% of 
total cellular mRNA) with subsequent large amounts of protein being produced for up to 80 
hrs post-transfection (~lmg of LacZ per 10? cells, i.e up to 25% of the total cellular protein),
& Garoff, 1991). Due to inherent differences between cell-types in the uptake of 
RNA, a packaging system has been developed whereby recombinant RNA is packaged into 
infectious virions via co-transfection with packaging-deficient helper RNA molecules which 
encode the structural proteins (figure 9).
A third approach for the expression from alphavirus-based vectors has recently been 
developed by Dubensky et al. (1996) involving a layered DNA-RNA vector system. This 
system, which is independent of helper vectors, involves the use of a eukaryotic promoter 
(e.g. CMV I.E. promoter) which drives the expression of the replicase/foreign gene after 
transfection of the plasmid DNA into cells. The replicase then takes-over the 
replication/transcription of the RNA in the cytoplasm.
Recently, it has been demonstrated that the addition of DNA, encoding the first 30 
amino acids of the capsid gene, to the 5' end of the foreign DNA sequence results in an 
increase in expression of the fusion protein of up to 10-fold (Liljestrom, 1994). Furthermore, 
incubation of the infected/transfected cells in medium containing elevated levels of K+ ions 
has been observed to result in a further increase in protein expression of up to 5-fold 
(Liljestrom, 1994).
In summary, the main advantages of the alphavirus expression vector system include;
a) Very high levels of protein production can be achieved.
b) Replicase/transcriptase complex caps the mRNA leading to efficient translation.
c) RNA is in the positive sense, i.e infectious.
d) High titres of recombinant viruses can be obtained without the need for time consuming 
recombination, screening and plaque purifying techniques.
e) Vectors can be RNA, DNA or viral particle based.
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f) Alphaviruses have a wide host-range.
g) Very little morphological change occurs for up to 48hrs post-infection/transfection.
h) SFV and SV have not frequently been associated with human disease.
i) For biosafety purposes, helper viruses and possibilities of recombination to produce WT 
virus can be avoided by using the DNA-based plasmid approach. Furthermore, attenuated 
strains are available which require the exogenous addition of protease to cleave the viral 
spike protein to induce infectivity.
Disadvantages of the alphavirus expression vector system include;
a) Currently can only be used for transient and batch harvest procedures.
b) Safety concerns for working with alphaviruses and the possibility of recombination events 
occurring between helper RNA and vector RNA (see above).
Two other viral vectors which are being increasingly investigated for use in gene 
therapy studies are members of the retroviruses and herpesviruses. These viruses are 
currently rarely used for heterologous protein production, but can be useful as a means of 
infecting cells which are impervious to infection by other viruses or by the various methods 
of naked DNA transfection. Reviews on herpesvirus vectors are given in Glorioso et al., 1995; 
Fink et al., 1996 and Leib& Olivo, 1993, and for retroviral vectors in Levinson, 1990.
2.1.2 / Direct DNA Transfer.
Viral-mediated-gene-transfer (VMGT) for heterologous protein production has, in a 
large number of situations, been extremely useful. However, due to the aforementioned 
problems associated with VMGT, direct DNA transfer is still widely used as a means for 
transient protein production and as the initial stage to the production of stabily expressing 
cell-lines.
In designing a plasmid-based vector for the expression of a foreign gene there are 
numerous factors which have to be considered, including;
a) Choice of promoter element to initiate transcription.
b) Choice of enhancer element to enhance transcription.
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c) Whether an intron is required for efficient transcription/RNA processing.
d) Choice of transcription termination and polyadenylation sequences.
e) Is an optimal translation initiation signal present?
f) Is the codon sequence optimal for mammalian cells?
g) Is the protein to be transiently produced, or are expressing-cell-lines necessary?
h) If cell-lines are to be produced, is the gene to be integrated into the cellular genome or 
would an episomal maintenance be beneficial?
i) If integration is required, is random integration sufficient or would site-directed integration
be advantageous?
j) If cell-lines are produced, is expression of the gene to be constitutive or regulated?
k) Choice of selectable marker if cell-lines are produced: amplifiable vs non-amplifiable?
A detailed account of promoter/enhancer elements and the factors which interact 
with them will not be given here but can be found in books such as Eukaryotic Gene 
Transcription (Goodburn, 1996).
2.1.2.1 I Choict of promoter and onhanscr.
A eukaryotic promoter is a cis-acting element of approximately lOObp in length which 
is present immediately upstream of a gene and possesses sequences required to assimilate 
RNA polymerase II (RNA pol II) and various transcription initiation factors for the initiation 
of gene transcription (figure 12). Enhancers are also cis-acting elements which, when bound 
by trans-acting factors can serve either to enhance or repress transcription from associated 
genes (figure 12). The key properties which make a DNA sequence an enhancer element 
include; (1) they tend to be relatively large elements and may contain repeated sequences 
which can function independently, (2) they can influence gene expression over considerable 
distances from the gene, (3) they may function in either orientation, (4) they may function in 
a position-independent manner being upstream or downstream from the gene, (5) they may 
function in a cell-type or tissue-specific manner, and (6) they appear to increase the 
probability but not the level of gene transcription (Walters et al., 1995).
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Figure 12; Diagrammatic representation of an RNA Polymerase II transcrip­
tion unit.
One of many possible arrangements of sequence elements in genes coding for eukaryotic mRNA
molecules is illustrated. Shown is the enhancer region from the human cytomegalovirus (hCMV)
major immediate-early promoter and some of the transcription factors which bind to consensus
sequences within the enhancer (see text for more detail).
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Promoters for driving heterologous gene expression can be divided into 2 categories: 
constitutive and inducible. The majority of promoter/enhancer elements used for the 
heterologous constitutive expression of proteins in mammalian cells are those derived from 
viruses. Examples include the; CMV major immediate early enhancer/promoter (CMV IE), 
SV40 early/late promoters, RSV long terminal repeat (RSV LTR), adenovirus major late 
promoter (Ad MLP) and the HSV thymidine kinase promoter (HSV TK). These elements are 
often used due to their activity in a wide variety of cell-types and the high level of gene 
expression they confer.
Generally it has been observed that the human CMV IE element confers the highest 
level of expression of genes transfected into primate cells followed by the RSV LTR then the 
SV40 promoters (Wilkinson & Akrigg, 1991; Kronman et al,, 1992; Harrison et al., 1995 and 
Rotondaro et al., 1996). However, of course this is not absolute and is largely dependant upon 
the chosen cell-line for expression of the gene. For example, Rotondaro et al, (1996) found that 
the murine CMV major IE element performed 2-fold better in murine cells compared with the 
human version of the promoter. The high level of gene expression observed with the CMV IE 
element is possibly reflecting the ubiquitous nature of the transcription factors which bind to 
the element such as; NF-kB, CREB and API, which is present in many cell types (Wilkinson 
& Akrigg, 1991 and figure 12). Moreover, expression from the CMV IE element can be further 
increased by employing cells which express the adenovirus El a gene product (which 
transactivates transcription from the CMV enhancer), such as 293 and CHO L761h cells.
Furthermore, various mammalian enhancer/promoter elements have also been 
utilised with some limited success, such as the; immunoglobulin enhancer/promoter, fi-actin 
promoter/enhancer, y-globulin and fi-globulin enhancer/promoters, elongation factor la 
promoter, and human muscle-specific promoters (Dahler et al., 1994; Kawamoto et al., 1988; 
Mizushima & Nagata, 1990 and Harrison et al., 1995). However, some of these elements 
appeared to be very tissue-specific which can be a major advantage or drawback depending 
upon the intended application.
With the aforementioned success of the vaccinia virus/T7 RDRP system, attempts 
have also been made to develop a non-viral T7 expression system which would thus not be
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dependant upon host-cell availability of transcription factors and RNA polymerase. Cell­
lines permanently expressing the T7 RDRP (located either in the nucleus or the cytoplasm) 
have been developed (reviewed in Lieber et al., 1993) which apparently expressed CAT and 
human growth hormone to levels similar to that achieved with the hCMV major IE promoter. 
However, this high expression was due to illegitimate activation of the T7 promoter by RNA 
pol II and although attempts to produce mutant promoters which were exclusive for the T7 
RDRP have been partially successful, expression levels have been no greater than those 
obtained with the RSV LTR or hCMV major IE promoter (reviewed in Lieber et al., 1993).
Inducible expression systems have been widely utilised in bacteria and yeast and 
have recently been developed for use in mammalian expression studies. Inducible promoters 
can be divided into two groups: (1) promoters which are responsive to endogenous cellular 
transactivators, and (2) promoters which are regulated by exogenous bacterial regulatory 
proteins. Examples of the former group include the; interferon 6-promoter, heat-shock 
promoter, metallothionein promoter and the mouse mammary tumour virus promoter, with 
induction from these promoters being in the range of 5-200 fold (reviewed in Levinson, 
1990). However, these promoters tend to produce high levels of basal expression and their 
induction may cause pleiotropic effects to the cells. Furthermore, as with the example of 
hormonal control, induction may require the presence of specific receptors on or within the 
cells.
Therefore, recent interest in the use of exogenous prokaryotic-based control elements 
has increased dramatically. Such mediation of expression can be achieved in two manners: 
the transrepression principle and the transactivation principle. Two inducible prokaryotic 
repressor/operator (R/O) elements which have been utilised to regulate gene expression in 
mammalian cells, via the repression principle, are the E.coli lactose (lac ) operon (where 
isopropyl-fi-D-thiogalactopyranoside, IPTG, is the inducer) and the (TnlO - derived) 
tetracycline (tet ) operon (where tetracycline is the inducer) (Gossen et al., 1994). The basis of 
the regulatory effect is the close proximity of the respective operator sequences to the 
eukaryotic promoter, such that binding of the repressor protein to the operator sequences 
inhibits the formation of an active RNA pol II transcription complex at the promoter.
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However, such Lac R/O-based systems have never proved satisfactory with induction been 
slow, incomplete and usually requires near cytotoxic concentrations of IPTG. The 
corresponding Tet R/O system has been developed in yeast and plant cells, but for reasons 
not fully understood, but perhaps due to low intracellular concentrations of the tet repressor, 
has not been adapted to mammalian cells (Gossen et al., 1994).
Therefore, the second approach - the transactivation principle - has been developed 
whereby transcriptional activation domains are fused (via recombinant DNA technology) to 
the repressor proteins of the above systems. Great success has recently been achieved using 
the tetracycline transactivator (tTa) protein which is a fusion protein between Tet R and the 
acidic domain of herpes simplex virus VP16 (Gossen & Bujard, 1992 and figure 13). This tTa 
protein stimulates transcription from a promoter sequence, usually the minimal hCMV major 
IE promoter, when combined with upstream tet operators. Transcription is repressed in the 
presence of tetracycline and activated in the absence of tetracycline and can be regulated over 
a 10'5-fold range (Gossen & Bujard, 1992). A recent development in the tTa system has been 
the isolation of a reverse TetR phenotype where the presence of tetracycline derivatives, 
especially doxycycline, are required for binding of the reverse tTa (rtTa) molecule to the 
operator sequences and thus for activation of transcription (Gossen et al., 1995 and figure 13). 
This system should have great implications for regulation of gene expression in transgenics 
and of control of expression of cytotoxic genes. The advantage of the tTa/rtTa system over 
similar Lac-based systems is the high affinity of tetracycline for TetR/rTetR (1000-fold 
greater than IPTG is for LacR) which results in lower intracellular concentrations required for 
regulated gene expression (Gossen & Bujard, 1992). Furthermore, many tetracycline 
derivatives are available and their pharmokinetics have been studied in great detail which 
will facilitate the application of these systems to transgenic animals, or appropriate cell-lines 
in vitro .
2.1.2.2 / Intron present or utsest, and choice of 3' untranslated region (UTR).
The presence of an intron has been found to be either essential or detrimental to the
expression of a gene depending upon factors such as; (1) promoter/enhancer element used to
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Figure 13: Diagrammatic representation of tetracycline-controlled transactiva - 
tor (tTa) systems (adapted from Didcock, 1996).
Panel A) Transcriptional repression in the presence of tetracyclines.
In the presence of tetracycline, the TetR domain of the tTa protein does not bind to the upstream 
tet operator sequences and thus transcription of the downstream DNA is minimal. In the absence 
of tetracycline, tTa can bind to the upstream tet operator sequences and, through the action of the 
acidic domain from the herpes simplex virus VP16 protein, recruit various transcription factors to 
upregulate the expression of downstream genes.
Panel B) Transcriptional activation in the presence of tetracyclines.
A mutated form of the tTa protein-rtTa- binds to the tet operator sequences in the presence of 
tetracyclines (especially doxycycHne) and thus transcription of downstream genes is activated. In 
the absence of doxycycline, rtTa cannot bind to the tet operator sequences and therefore 
transcription of downstream genes is minimal.
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drive transcription. (2) the gene which is being expressed, and (3) cell-line in which the gene 
is being expressed. It has been observed that for genes driven by the immunoglobulin 
enhancer/promoter an intron is required for efficient expression although the requirement 
was not restricted to a particular intron (Kriegler, 1990). An intron is not apparently required 
for efficient expression from the CMV IE element (Nueberger & Williams, 1988) although 
some workers have found evidence contradictory to this. Furthermore, it has been shown by 
Buchman & Berg (1988) that expression of the fi-globin gene from an SV40 early promoter 
required the presence of an intron in which case transcription was increased by over 400-fold. 
Moreover, experiments performed by Petitclerc et al. (1995) demonstrated that the SV40 late 
promoter was more efficient than the SV40 early intron, although the greatest gene 
expression was observed when a chimearic intron, composed of an adenovirus donor & 
immunoglobulin acceptor sites, was employed. Other genes such as the dihydrofolate 
reductase gene, which do not possess introns, showed a modest increase in expression of 10- 
20 fold if an intron was included in the construct. This intron-dependant gene expression was 
also noted for the HSV tk promoter. In contrast to expression in mammalian cells in vitro, 
there is a profound requirement for the presence of introns for expression of introduced 
genes in transgenic animals (Brinster et al., 1988).
The 3' untranslated region (figure 12) contains the signals for transcription 
termination and subsequent addition of poly A residues. The choice of polyA signal can have 
a significant effect on the expression of the chosen gene due to the role in mRNA stability 
provided by the polyA signal. For example ornithine decarboxylase mRNA has a half-life of 
only 1 /2hour compared to dihydrofolate reductase mRNA with a half-life of nearly 100 
hours (reviewed in Wolfe, 1993). Efficient signals for polyadenylation frequently used for 
heterologous expression are derived from the; SV40 late polyA signal, bovine growth 
hormone poly A signal, mouse/human fi-globin polyA and the CMV IE gene polyA due to 
the long half-life that they confer to the mRNAs produced. Furthermore, Wilkinson & Akrigg 
(1991) have demonstrated that using a polyA signal combined with the respective promoter, 
in this case the CMV IE promoter and polyA signal, can increase expression by 7-fold than 
when the same promoter was used in conjunction with the SV40 late polyA signal.
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2.1.2.31 Optrmat Crantlatron (ciStrc^trors requence.
The efficiency with which a scanning mammalian ribosome recognises an AUG codon 
has been shown to be highly dependent upon the context of the surrounding sequences and 
is not simply the first AUG that is encountered. From studies carried out by Kozak (1989) and 
Grunert & Jackson (1994) the optimal translation initiation codon is:
A A
gccgcc cc(AUG)G u
g c
where residues in bold capital letters exert the most positive influence. Those residues in 
underlined capital letters exert a modest positive influence, with the remaining lower case 
residues exerting a yet smaller but nevertheless positive influence. For heterologous protein 
expression in mammalian cells, initiator codons should conform to this optimal context if 
high levels of protein production is required.
Furthermore, some genes can contain upstream AUG codons in the 5' untranslated 
region which should ideally be removed when constructing the vector. Similarly, the 
presence of significant secondary structure near the initiator AUG can significantly affect 
translation and thus most vectors should be designed to contain 5' untranslated sequences 
derived from the particular promoter element used for the transcription initiation, or by 
incorporating leader sequences such as those derived from the fi-globin gene or adenovirus 
tripartite leader.
2.1.2.4 / Oprcmcenrcrs fre mnmmnlcns-enll erdit nengn.
tRNAs specifying a particular amino acid can recognise multiple codons present in
the coding sequence of DNA due to the degeneracy of the genetic code. The abundance of 
tRNAs which recognise particular codons vary considerably between organisms, and this can 
lead to a significant reduction in protein production if particular tRNAs are present in low 
abundance. Altering the codon useage for optimal recognition by mammalian tRNAs has 
been shown to significantly increase the amount of HIV gpl20 and green-fluorescent-protein 
by up to 45-fold (Haas et al. 1996 ; Levy et al., 1996 and Zolotukin et al., 1996).
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2.1.2.5 I Transient or stable expression of the protein.
For many purposes, transient high-level expression of a particular protein is all that is 
required, and one of the most common vector systems for such expression is that derived 
from plasmids which contain the SV40 virus ori, and which are subsequently transfected into 
SV40 LTAg expressing cells such as Cos-cells. The LTAg amplifies the plasmid to >10,000 
copies per cell resulting in high-level protein production in the order of 1-lOpg per 10^ cells 
(Levinson, 1990). The LTAg can also be encoded on the same plasmid eliminating the need 
for using Cos-cells.
This system, and other transient systems, may be further enhanced for protein 
expression, for certain plasmids, by the addition of 2-aminopurine to the medium or by co­
transfecting a plasmid encoding the adenovirus VAI genes. Both of these treatments enhance 
expression by inactivating the dsRNA-activated inhibitor kinase (DAI kinase, also known as 
PKR, p68, pi or dsl) which is activated by the presence of dsRNA, and results in a repression 
of translation (Kaufman & Murtha, 1987; Akusjarvi et al., 1987; Tiwari et al., 1988 and 
Tanigawa et al., 1993).
However, for many purposes, the establishment of expressing cell-lines is required 
and suitable vectors must be utilised for this purpose. Establishment of expressing cell-lines 
requires either the transcription unit to be integrated into the cellular genome or to be 
maintained in an episomal form in the cell nucleus. Integration into the cellular genome is a 
rare event and thus plasmids must contain a suitable marker gene, under control of an 
appropriate promoter element, for both selection and maintenance of the expressing cell­
lines.
Such marker genes can be amplifiable or non-amplifiable. Non-amplifiable markers 
include the commonly used neomycin aminoglycoside phosphotransferase (neor ), 
hygromycin B phosphotransferase (hygr ) and histidinol dehydrogenase (hisD ). Commonly 
used amplifiable markers in which the gene copy number within the genome can be 
significantly increased (to over 1000-fold) include dihydrofolate reductase, P-glycoprotein 
170 (multidrug resistance gene) and glutamine synthetase (reviewed in Levinson, 1990 and 
Kane & Gottesman, 1993).
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However, amplification of a gene can be time-consuming, involving several weeks 
work, and does not always lead to a significant increase in protein production even if the 
gene copy number has been significantly increased. Other methods for obtaining high-level 
expressing clones include, the tedious screening of hundreds of unamplified stable clones by 
classical techniques, and by the more "user-friendly" fluorescent activated cell sorting (FACS) 
if the gene of interest (or a marker gene) is cell-surface expressed and antibody is available.
Due to integration occurring rarely, and since positional affects can occur when DNA 
integrates in a random manner, much interest has been directed towards establishing site- 
directed integration vectors. Such vectors have been developed either for homologous 
recombination (widely used in embryonic stem cell technology for the generation of 
transgenic mice) or site-specific recombination, in which the latter relies upon exogenously 
added recombinase (principally from bacteriophage and unicellular yeasts) derived from two 
major families: the integrase family and the resolvase/invertase family (reviewed in Sauer, 
1994). Frequently used recombinases are the simple Cre recombinase from bacteriophage PI 
and the FLP recombinase from S. cerevisiae , both of which do not require additional host- 
specific co-factors for activity.
However, at best, recombinase-mediated integration appears only to be as efficient as 
illegitimate recombination, (albeit, when recombination did occur it was, in the majority of 
cells, at the chosen site (Fukushige & Sauer, 1992)) and also necessitates the introduction of 
appropriate target sites in the genome to begin with, usually via homologous recombination. 
This poor performance is, in part, due to poor introduction of the recombinase into the cells. 
However, Anton & Graham (1995) have constructed an adenovirus vector which expresses 
the Cre recombinase and have demonstrated promising initial results using this strategy.
An alternative approach to using integrating vectors for the construction of 
expressing cell-lines is by utilising vectors which possess sequences/genes required for the 
episomal maintenance of the vector in the host-cell nucleus. Advantages of using such 
vectors, over integrating vectors, is that; (1) the frequency of producing expressing cell-lines 
is increased, (2) positional affects from integration are reduced, (3) generally the gene will 
have a moderately high copy number, (4) the episome can be easily recovered from the cell­
50
line (useful for expression cloning; Levinson, 1990; Margolskee et al., 1988 and Shen et al., 
1995) and (5), maintenance as an episome facilitates the undertaking of replication and
mutagenesis studies.
Sequences/genes for the maintenance of an episomal state are usually derived from 
viruses whose lifecycle includes the autonomous replication of its DNA in an episomal form. 
Examples of viruses whose sequences/genes have been utilised for producing episomal 
vectors are; SV40, BK virus (a human papovavirus), Bovine papilloma virus (BPV), and 
Epstein-Barr virus (EBV). Some of the properties of these vectors are depicted in table 3.
Vector-
System
Host cell Stable Copy
No.
Oncogenic
Proteins
Produced
Vector
Size
Strict Repln 
once per 
Division
Low
mutation
frequency
SV40 Virus Primate ~750 per cell Yes - 5Kbp No No
BK Virus Primate 1-300 per cell Yes -llKbp No No
BPV Virus
Rodent
Canine
Porcine
1-250 per cell Yes - 9Kbp No No
EBV Virus
Primate
Canine
Rodent
1-50 per cell No -llKbp Yes Yes
Table 3 ~ Episomal-based vector systems for the production of expressing cell-lines.
*1 - Approximate size of a eukaryotic/prokaryotic shuttle vector before insertion of the gene 
of interest.
*2 - Can replicate in rodent cells if human sequences are incorporated into the vector. This 
however increases the vector size to ~29Kbp (Krysan & Carlos, 1993).
SV40 has had little use in the production of expressing cell-lines due to the high copy 
number of the vector in the nucleus which frequently leads to cell death, and due to the 
required presence of the LTAg, an oncogene, which could limit studies of other potential 
oncogenes. However, Gerard & Gluzman (1985) have successfully isolated an SV40-based 
cell-line, in which the vector is maintained as an episome (-750 copies per cell), which 
inducibly expresses the influenza virus haemagglutinin protein.
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As with SV40, BK virus-based vectors code for an oncogenic protein, which has 
limited their use. However, the episome copy number is lower (up to ~250 copies per cell 
(Gianni et al., 1988)) than with SV40 and thus facilitates the isolation of expressing cell-lines. 
Human interferon-61 and HSV glycoproteins G-l & G-2 have been successfully expressed in 
human cell-lines using BK virus-based vectors (Gianni et al., 1988 and Sabbioni et al., 1995).
More frequently used are BPV-derived vectors. These vectors are based upon the 
complete BPV genome or a 5.5Kbp transforming fragment and efficiently transform rodent 
cells (but do not produce viral particles), and are maintained at up to -300 copies per cell 
(Sambrook et al., 1989). However, due to the transforming proteins produced, the high 
frequency of DNA rearrangement which can occur, and the lack of replication in primate 
cells, their use has not been extensively widespread.
Episomal vectors based on EBV have become popular and many commercial EBV- 
based vectors are available. Episomal replication of EBV vectors requires the presence of a cis 
-acting region from EBV termed ori P (-1.7 Kbp in length, Yates et al., 1984 and Sugden et al., 
1985), and a trans-acting virally encoded factor EBNA-1 (Epstein-Barr nuclear antigen 1) 
which binds specifically to the ori P region and non-specifically to genomic DNA (Lupton & 
Levine, 1985 and Yates et al., 1985). Numerous cDNAs have been successfully expressed from 
EBV-based vectors including human interferon-y (Young et al., 1988), influenza virus HA 
(Jalanko et al., 1989) and adenovirus pIX (Caravokyri & Leppard, 1995). A further advantage 
of EBV-derived vectors is the possibility of their use in gene therapy/DNA vaccination 
studies. They are episomally maintained, replicate once per cell cycle, possess a low mutation 
frequency, and do not encode an oncogenic protein vital to their episomal maintenance. 
Indeed, recently the EBNA-1 protein has been shown to be inefficiently presented to MHC 1 
restricted cytotoxic T lymphocytes due to the presence of the gly-ala repeats within EBNA-1 
which generate a cis -acting inhibitory signal (Levitskaya et. al., 1995).
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CHAPTER 4
THE MAMMALIAN-CELL EXOCYTOTIC PATHWAY.
1 / Introduction.
Proteins destined for subcellular organelles, the cell-surface or for secretion into the 
external milieu, possess specific signals in their primary amino acid sequence which are 
recognised by the appropriate cellular machinery for the successful targeting of the protein. 
In the last 20 years, an enormous amount of information has become available, on both the 
signals and the machinery involved in protein trafficking within the mammalian cell. Apart 
from the inherent scientific curiosity of elucidating the mechanisms of protein trafficking, a 
major beneficiary of this knowledge will be the biotechnology industry, where the targeting 
of proteins within the mammalian cell can be altered by the addition/deletion of the 
appropriate signals. A recent example of such technology is in the development of 
intracellular targeting of antibodies to subcellular compartments for therapeutic benefit 
(Richardson & Marasco, 1995). Furthermore, it has recently become apparent that diseases 
such as progeria, which result in premature ageing, may be the result of aberrant protein 
targeting (Rosenblum et al., 1996). A diagrammatic representation of the exocytotic pathway 
is shown in figure 14.
2 / Targeting of proteins to the ER,
2.1/ Signal sequences.
Proteins for export to the cell surface or external milieu are generally targeted to the 
ER by the presence of a sequence of about 20-40 amino acids, the signal sequence (SS),
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Figure 14: Protein exocytosis from a mammalian cell (adapted from Chidgey etal
1993).
Proteins destined for secretion or transport to the plasma membrane are usually initially targetted to 
the ER. Unless no signals are present within the protein sequence or conformation, then transport of 
the protein continues through the subcellular compartments of the Golgi complex until the proteins 
either reach the plasma membrane (if the proteins are membrane anchored) or are secreted into the 
external milieu. The latter can occur constitutively from cells, or can be, in addition, regulated as 
found in exocrine and neuronal cells where release occurs via an external stimulus (see text for more 
detail).
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present at the N-terminus of the polypeptide. However, there are notable exceptions to this 
rule where some proteins enter the ER despite lacking a recognisable signal sequence. These 
include the secreted proteins interleukin l ot & lp and factor Xllla. The mechanism of this 
alternative targeting is unknown (but does appear to be cell-type dependent), but may 
involve ABC transporters similar to the MHC peptide transporters TRAP 1&2 (reviewed in 
Kuchler, 1993). Furthermore, secretion of certain proteins from mammalian cells, such as 
basic fibroblast growth factor occurs in an ER-golgi independent process, the mechanism of 
which is unclear (Mignatti et al., 1992).
The original hypothesis for the presence of an N-terminally located signal for the 
targeting of nascent polypeptide to the ER was published by Blobel & Sabatini (1971), which 
was strengthened from experimental evidence compiled by Milstein et al. (1972). Lingappa et 
al. (1984) produced the first secreted chimaeric protein when they demonstrated the secretion 
of alpha-globin (normally located in the cytoplasm) from mammalian cells when the N- 
terminus was altered by the addition of the N-terminal sequence from bacterial ^^l^^t:amase. 
This experiment also demonstrated the ubiquitous nature of the signal sequence from 
organisms as diverse as primates and bacteria.
Kohara et al. (1992) has defined the ER targeting sequence to be composed of 
primarily 3 regions; an N-terminal positively charged region of 1-7 residues containing 1-3 
positive amino acids, a hydrophobic core comprising 6-12 amino acids, with the optimal 
being 8, and a 4-6 amino acid region c-terminal to the hydrophobic core. By definition this 
signal is necessary and sufficient to direct proteins to the ER. Upon arrival at the ER 
membrane the signal can then either be cleaved from the protein (the majority of secretory 
and some membrane-bound proteins) or remain attached and function as the transmembrane 
anchor (signal-anchor membrane proteins). Type l membrane proteins are defined as those 
where the N-terminus is translocated (i.e extra-cytoplasmically located) whilst for type ll 
proteins the C-terminus is translocated. Membrane proteins with a cleavable signal sequence 
always possess a type l topology, membrane proteins with a signal-anchor can have either a 
type l or ll orientation (reviewed in High, 1995).
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2.2/ SRP-dependent targeting.
In 1981, Walter and Blobel discovered the protein complex, present in mammalian 
cells, which recognised the signal sequence: the signal recognition particle, or SRP. 
Equivalents of SRP have been discovered in bacteria and yeast but whether they can function 
co-translationally has not yet been established. The SRP is a cytosolic ribonucleoprotein, 
which may be pre-bound to ribosomes, and is comprised of 6 polypeptides and a 7S ssRNA. 
Recent evidence suggests that the interaction of SRP with the signal sequence is not as 
specific as first postulated and that it is the presence of another cytosolic factor NAC 
(nascent-polypeptide-associated complex) which binds ubiquitously to emerging 
polypeptides, thereby preventing them from being bound by SRP, unless a signal sequence is 
present (Wiedmann et al., 1994; Lauring et al., 1995 a & b; Jrmgnickel & Rapoport, 1995).
The protein subunits within the SRP appear to play 3 roles; (1) signal sequence 
recognition, as performed by the 54Kda polypeptide, (2) control of translation, as carried out 
by the 9 & 14Kda polypeptides, and (3) targeting to the ER membrane, as performed by the 
68 & 72Kda polypeptides. A further result of the interaction of SRP with the signal sequence 
is to retain the signal sequence in an unfolded conformation for membrane insertion. The 
54Kda protein has been resolved to 12-15 Angstrom (Czarnota et al., 1994) and shown to 
possess two domains: an M domain which binds the signal sequence and a G domain which 
binds GTP (binding of the SRP to the SS has been demonstrated to be independent of GTP 
hydrolysis, Rapiejko & Gilmore 1994). The 7S ssRNA is postulated to act as a "scaffold" in 
holding all the polypeptides together.
3 / Translocation of polypeptides across the ER membrane.
The SRP/signal-sequence/ribosome/mRNA complex (translocation complex) is 
recognised by at least three proteins on the ER membrane: the SRP receptor (SR, or docking 
protein), the signal sequence receptor (SSR) and the putative ribosome receptor (RR, a 
18OKda protein). The SRP receptor, which binds GTP, is comprised of two polypeptides; the 
a-subunit (35Kda) and the 6-subunit (22Kda). Upon binding of the translocation complex to 
the ER receptors, hydrolysis of GTP occurs resulting in the release of the SRP and the
55
continuation of translation, followed by translocation of the growing polypeptide chain 
through an aqueous channel present in the ribosome & ER membrane from which the cytosol 
has been sealed of by the binding of the ribosome to the ER membrane (Crowley et al1993). 
In vitro depletion analysis of SSR or SR demonstrated that SR was essential for targeting and 
translocation of the nascent chain, whilst depletion of SR did not have any observatory 
effects (Migliaccio et al., 1992).
How the polypeptide is translocated across the ER membrane and the proteins 
involved in this process are not well understood. In yeast and mammalian cells, several ER 
resident proteins have been identified which are likely to play a role in translocation of some, 
but not all proteins. These include the; SRP, RR, Sec61 protein (which is composed of 3 
polypeptides; a, f and y), TRAM (translocating chain associating membrane protein), TRAPa 
(translocon associated protein a), ribophorins and GRP78-BiP (reviewed in Ng & Walter, 
1994 and Simon, 1993). The latter protein, and other lumenal proteins, may play a role in the 
later stages of translocation via the folding of the newly translocated polypeptide. The 
mechanism of translocation is unclear but current evidence suggests the presence of an 
aqueous pore, which is formed, predominantly, by multi-subunit integral membrane 
proteins such as Sec61 (Crowley et al, 1993; Jungnickel & Rapoport, 1995 and Lyko et al., 
1995).
4 / Modifications of newly translocated polypeptides within the ER.
4.11 Polypeptide folding and oligomerisation.
Upon translocation of the polypeptide into the ER lumen, the polypeptide may be 
modified by numerous processes such as; signal sequence cleavage, N-linked glycosylation, 
disulphide bond formation, folding and subunit assembly. The ER lumen provides an 
oxidising environment, contains high levels of calcium and resident ER enzymes which are 
involved in the above processes (reviewed in Gaut & Hendershot, 1993).
The signal sequence may be cleaved by signal peptidase, a multi-subunit complex 
present on the lumenal side of the ER membrane. Signal peptidase is composed of 5 
polypeptides, 2 of which are homologous to Sec 11 from yeast. There is no apparent
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homology to bacterial leader peptidase (although signal peptidase has been shown to cleave 
bacterial signal sequences) or to other proteases.
Translocation exposes domains on the protein (especially hydrophobic regions) 
which will usually be hidden after folding. There are specific proteins in the ER (termed 
chaperones), such as GRP78-BiP (a member of the heat shock family of proteins), which 
reversibly bind to the translocating polypeptides due to an ATPase activity which is 
stimulated by hydrophobic peptides. This binding appears to aid in the folding of the protein 
by preventing polypeptide aggregation. ER calcium levels may also have a role in protein 
folding and assembly, via calcium-dependant chaperones such as; GRP94, ERp72 and p88 
(also known as calnexin). Calnexin has been shown to bind to the T-cell receptor, MHC class 
I molecules, membrane-bound Igs and numerous viral glycoproteins such as the vesicular 
stomatitis virus (VSV) G protein and the influenza virus HA, and aid in their folding and 
assembly (reviewed in Bergeron et al., 1994; and Hammond et al., 1994). Indeed Hammond et 
al. (1994) have demonstrated that calnexin binds to glucosylated forms of proteins and 
releases the protein upon trimming of the glucose residues by the resident ER proteins 
glucosidases I & II. Properly folded proteins are generally not glucosylated and are thus not 
bound by calnexin, therefore indicating that calnexin acts as a quality control mechanism for 
protein folding via the addition/removal of glucose residues. Pro-collagen has been shown 
to interact with the chaperones hsp74, GRP94 & GRP78-BiP but it is not known whether, in 
this case and others, chaperones act competitively, sequentially or co-operatively (reviewed 
in Gething, 1991). However, at least for the VSV G protein, it has been demonstrated by 
Hammond & Helenius (1994) that Bip bound maximally to early folding intermediates of G 
protein, whereas calnexin bound after a lag period to more folded molecules, thereby 
illustrating a sequential order for chaperone binding.
The oxidising environment within the ER allows the formation of intra & 
intermolecular disulphide bonds which aids the stabilisation of the tertiary structure of the 
polypeptide and, in many cases, allows the formation of homotypic or heterotypic oligomers. 
Disulphide bond formation is carried out by the enzyme protein disulphide isomerase (PDI)
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which is the beta-subunit of the enzyme prolyl 4-hydroxylase. PDI has two catalytic sites 
which function equally and independently.
4.21 Addition of carbohydrates to nascent polypeptide chains.
Glycosylation of newly translocating polypeptides can also occur within the ER. 
Glycosylation may take the form of asparagine-linked oligosaccharides (within the consensus 
tripeptide sequence, or sequon, asn-X-ser / thr / (cys), where X is any amino acid except 
proline), termed N-glycosylation, or serine/ threonine-linked oligosaccharides, termed O- 
glycosylation (O-glycosylation of membrane/secretory proteins in mammalian cells, in 
contrast to yeast cells, does not occur within the ER but occurs exclusively within the golgi 
complex, Trimble & Verostek, 1995). Not all potential N-linked sequons are utilised, and 
those which are may not be glycosylated to the same extent as at other sequons on the same 
polypeptide. This feature appears to be determined by the primary, secondary and tertiary 
structures of the polypeptides. Furthermore, the carbohydrates which are added onto a 
polypeptide is also determined by the enzymes present within a cell, which is thus 
dependent upon the cell type, species and stage of development and differentiation 
(reviewed in Warren, 1993).
Oligosaccharides are added to the translocating polypeptide via a lipid carrier 
intermediate (usually dolichol). Saccharides are added sequentially (via integral membrane- 
bound glycosyl transferases) to the lipid carrier on the cytosolic face of the ER membrane. 
The completed oligosaccharide chain is then transferred to the appropriate sequon on the 
lumenal side of the ER membrane (Wolffe, 1993, and figure 15).
The specification for O-glycosylation is less well understood, but is known to occur at 
serine or threonine residues and is enhanced by clusters of these amino acids and by the 
presence of proximal prolines. Addition of O-linked saccharides does not involve a lipid- 
carrier intermediate and can thus occur in the cytosol, unlike N-glycosylation.
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Figure 15. N-giycosyiation & O-giycosyiation processes occuring within the 
mammalian-ceii exocytotic pathway (adapted from WolOe, 1993).
Oanei A) The assembiy oO N -iinked carbohydrate groups in the ER and goigi compiex. Doi, doiichoi; 
Asn, asparagine. The process begins in the cytosoiic side oO the ER membrane, with tranter oO an acetyi- 
giucosamine residue Orom a nucieoside diphosphate carrier to the doiichoi unit (A). A further acetyi- 
giucosamine residue is added to the Oirst (B). Five mannose residues are then transOerred Orom their 
nucieotide carriers to the doiichoi-sugar compiex, Oorming a branched structure (C). The doiichoi- 
carbohydrate compiex is then transported across the ER membrane by the doiichoi carrier. In the ER 
iumen Oour more mannose units are added (D) with the resuiting structure being transOerred, as a unit, 
Orom doiichoi to an asparagine residue in the nascent poiypeptide chain (E). In some organisms this step 
compietes the core structure, in others three giucose residues are added via nucieoside carriers (F). With 
most giycoproteins the three giucose units and one mannose residue are subsequentiy removed whiie the 
protein is stiii in the ER (G). The giycoprotein is then transported to the Goigi compiex, where three 
mannose residues are usuaiiy removed, ieaving the core structure shown in (H). Steps (I through M) 
outiine a typicai mammaiian pathway removing Ourther mannose residues and adding; acetyi- 
giucosamine, Oucose, gaiactose and siaiic acid to compiete the carbohydrate group. Aiso shown are tiie 
cieavage sites Oor the giycosidases FNCase F and EndoH (ONGase F cieaves most types of carbohydrate 
chains Orom giycoproteins. EndoH does not cieave the carbohydrate chains oO compiex type 
oiigosaccharide additions (Lanzetta et al, 1979)).
Oanei B) The assembiy oO O -iinked carbohydrate groups in the exocytotic pathway. Ser, serine. A singie 
mannose or acetyigaiactosamine residue is transOerred Orom a nucieotide carrier directiy to a serine or 
threonine residue or, more rareiy, to a hydroxyproiine or hydroxyiysine unit. This initiai core 
giycosyiation apparentiy occurs on the iumen side oO ER membranes or whiie the giycoprotein is in 
transit Orom the ER to the Goigi compiex. To this, or to other simpie core structures, additionai sugars, 
inciuding the same variety used in N -giycosyiation, are transOerred Orom nucieotide carriers within the 
Golgi compiex to compiete the oiigosaccharide group. The structures shownare one oO many possibiiities.
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5 / Retention of proteins within the ER.
Proteins are retained within the ER primarily for two reasons: they are naturally 
located to the ER, or they are malfolded and are thus destined for degradation. In the latter 
scenario, malfolded proteins appear to have a stable association with ER chaperone proteins 
such as GRP78-BiP and do not exit the ER. These malfolded proteins are eventually degraded 
by, as yet, uncharacterised ER proteases, although possibly involving a 60Kda thiol protease 
(reviewed in Gaut & Hendershot, 1993). In the former case, proteins are located to the ER by 
two possible mechanisms; via a retrieval receptor located in the golgi complex, or by inherent 
properties of the protein preventing forward transport. Of these mechanisms the retrieval 
mechanism is the best understood.
Proteins containing the sequence lys-asp-glu-leu (KDEL) or related sequences at the 
C-terminus of the protein are generally located to the ER via retrieval from the CGN by a 
KDEL-recognising receptor, hERD2, which binds the ligand in a pH-dependant manner. 
Intriguingly, some bacterial toxins (e.g. Pseudomonas exotoxin A, cholera toxin & E.coli heat- 
labile toxins) possess KDEL or related sequences and may gain access to the cytoplasm via 
the ER (reviewed in Pelham, 1990; Lewis & Pelham, 1992; and Pelham, 1992). Furthermore, 
studies have shown that at least two other ER localisation signals (dilysine and diarginine) 
occur, which, like KDEL, act as retrieval signals. Various type I glycoproteins (N-terminus in 
the lumen) possess a dilysine signal (K(X)KXX, where X is any amino acid) at positions -3 & - 
4/-5 relative to their C-terminus, which appears to be sufficient and necessary for localisation 
to the ER. Moreover, with various type II glycoproteins (C-terminus in the lumen) the signal 
appears to consist of two arginine residues (RR) which are located within the first five amino 
acids of the N-terminus. Whether a specific receptor is required is not known, but the 
dilysine motif has been shown to bind to coatomer, a component involved in vesicular 
transport (Letourneur et al. 1994 and Cosson & Letourneur, 1994). KDEL, dilysine and 
diarginine are not absolutely required for ER localisation since proteins occur which possess 
these signals and are not localised to the ER. Furthermore, removal of these motifs from 
some resident ER proteins does not always result in the loss of ER-localisation (reviewed in 
Nilsson & Warren, 1994). Recently, Mallabiabarrena et al. (1995) characterised a possible third
59
ER retention-signal based upon a tyrosine helix-motif, which was reminiscent of the 6-turn 
structure adopted by tyrosine-containing endocytosis signals.
6 / Transport of proteins from the ER to the Trans golgi network (TGN).
Upon exiting the ER, proteins enter a series of membranous organelles termed the 
Golgi complex (figure 12). The traditional view of the Golgi complex is of flattened cisternal 
membranes arranged in polarised stacks termed the; cis Golgi network (CGN), cis Golgi, 
medial Golgi, trans Golgi and the trans Golgi network (TGN). Proteins move vectorally 
through the Golgi complex (see below) from the CGN to the TGN unless they possess 
appropriate retention signals (see below). The Golgi complex plays a pivotal role in the 
sorting and post-translational modification of lipids and proteins. Well characterised resident 
Golgi proteins include the integral membrane glycosyl transferases {medial & trans Golgi), of 
which there are an estimated 200 enzymes, which trim and add various sugars to 
glycoproteins and glycolipids (figure 13). Also present are numerous proteases, such as the 
furin/PACE protease which is resident in the TGN and is involved in the post-translational 
cleavage of many cellular and viral glycoproteins (reviewed in Rehemtulla & Kaufman, 
1992).
Proteins which are destined only for the Golgi complex possess signals for their 
appropriate localisation. Golgi localisation signals (GLS) appear not to be as simple, and as 
well characterised, as those for ER localisation. GLS may be composed of uncharged polar 
residues (mainly asn, thr & gin) which lie on one face of a predicted alpha-helix within the 
first transmembrane domain of the protein. This was determined from work carried out with 
the resident glycosyl transferases and with the infectious bronchitis virus (avian coronavirus) 
M protein. The localisation signal for resident TGN proteins appears to be located in the 
cytoplasmic tail, possibly involving tyrosine residues (tyr-gln-arg-leu) as also found on some 
proteins which are recycled from the cell-surface to the TGN. The mechanism of retention is, 
as with the signal, not well understood and may be composed of a retrieval receptor 
analogous to hERD2 for KDEL signals. The other possibility is that of a true retention
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mechanism due to the formation of a high molecular weight oligomer or lattice structure, as 
found with the IBV M protein.
Exactly how proteins travel through the Golgi complex is unclear and currently three 
models have been hypothesised. (1) Travel by bulk flow, where proteins exit the ER and 
travel to their destination by massive non-selective vesicular transport. (2) Trapping, where 
initial transport to the CGN is by bulk flow where, in the CGN, the secretory and cell-surface 
proteins interact with receptors which flow to the next stage and release their cargo. (3) 
Receptor-mediated transport, where proteins bind to receptors within the ER and are 
transported by a small number of vesicles to the CGN (reviewed in Pelham, 1991).
7 / Transport of proteins from the TGN to lysosomes or the cell-surface & external
milieu.
When a protein reaches the TGN a variety of options await. Lysosomal proteins 
(which possess a mannose-6-phosphate targeting signal) are directed to lysosomes, whilst 
secretory and cell-surface proteins are packaged into secretory vesicles for transport to the 
plasmamembrane or the external milieu. This latter pathway of transport is constitutive to 
most cell-types. However, specialised secretory cells such as those found in exocrine, 
endocrine and neuronal tissue can, in addition to constitutive secretion, regulate secretion 
through the formation of dense secretory granules which are released upon receiving an 
external stimulus. A sorting mechanism for the different pathways has not been clearly 
elucidated yet (reviewed in Chidgey, 1993).
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CHAPTER 5
OBJECTIVES OF THE PROJECT
Epitope-tagging of proteins has recently gained widespread use for the detection and 
affinity-purification of recombinantly expressed proteins, and involves the addition of a set 
of amino acid residues, via recombinant DNA technology, to either terminus, both termini or 
within the protein sequence of choice. Oligopeptides which have been utilised for the 
labelling of proteins include; HA-tag (derived from the haemagglutinin of influenza virus), 
Myc-tag (derived from the myc oncogene), BTag (derived from the major core protein, VP7, 
of bluetongue virus (Wang et al., 1996)), flag-tag and His-tag (linear sequence of variable 
length, but usually 6 histidine residues). These tags possess different characteristics to each 
other in terms of length, charge and affinity of interaction to their respective mAbs (or 
chelating agent), and therefore there is no universal epitope tag which can be employed to 
successfully label every type of protein, expressed in any expression system.
A further addition to the epitope-tagging repertoire is a 14 amino acid oligopeptide, 
termed Pk-tag, which was derived from the P/V proteins of the paramyxovirus SV5. The Pk- 
tag has previously been shown to retain its antigenicity to a mAb (termed anti-Pk) when 
attached to the N or C-terminus of proteins expressed in bacteria or baculovirus infected 
insect cells (Hanke et al. 1992, 1994a & 1995). Furthermore, Pk-tag & anti-Pk mAb have 
successfully been utilised for the detection of proteins expressed in yeast cells as part of the 
yeast-two-hybrid system (R.E. Randall, personal communication).
Furthermore, the addition of the Pk-tag to proteins destined for secretion from 
bacteria, did not interfere with the secretion process (T. Hanke (unpublished observations)
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and E.A. Green (in press)). Similarly, the presence of the Pk-tag on the C-terminus of the 
envelope glycoprotein from simian immunodeficiency virus (SIV) gpl60, was shown not to 
alter the conformation, binding to CD4, or antigenicity of the Pk-tagged gpl60, when 
expressed in an insect-cell system and compared to the parental gpl60 (Hanke et al., 1995). 
Further beneficial features of the Pk-tag epitope are the weak immunogenicity of the peptide 
(Randall et al., 1993), and the lack of cross-reactivity to host-cell proteins in the systems 
tested. Furthermore, in the context of multivalent recombinant subunit vaccine development 
it has been demonstrated that the Pk-tag and anti-Pk mAbs are useful reagents for the 
construction of SMAA complexes as a delivery system for multiple immunogens.
An extensive analysis of the processing of Pk-tagged glycoproteins when produced in 
mammalian cells has not been carried out. For many purposes, including recombinant 
subunit vaccine development, proteins may have to be produced in mammalian cells to 
ensure correct processing and post-translational modification. Moreover, it has been 
demonstrated that the addition or deletion of amino acids at the N or C-terminus of 
mammalian-cell membrane-bound glycoproteins may affect their processing through the 
exocytotic pathway, resulting in retarded transport, aberrant glycosylation and inhibition of 
oligomer formation (Parks & Lamb, 1990; Simpson & Lamb, 1992 and Sergei & Morrison, 
1995), all of which may alter the conformation of the protein relative to the wildtype protein.
Therefore, an investigation was carried out to determine whether the addition of the 
14 amino acid Pk-tag to the N or C terminus of a model type II glycoprotein (and of 
truncated secretory forms), and to the C-terminus of a model type I glycoprotein (and of a 
truncated secretory form), would result in aberrant processing and antigenicity of the 
protein. The model proteins used in this thesis were the well characterised envelope 
glycoproteins derived from the paramyxovirus SV5: haemagglutinin-neuraminidase (type II 
topology) and Fusion (type I topology).
Initially the Pk-tagged proteins would be transiently expressed in mammalian cells 
via the vaccinia virus/T7-RDRP system with subsequent analysis of exocytotic processing 
and antigenicity. In addition, if the Pk-tagged glycoproteins were successfully expressed in a 
transient system, then the construction of expressing cell-lines, via the construction of EBV-
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based vectors, would be attempted so as to produce enough protein for immunogenicity and
protection trials.
Furthermore, conventional methods for producing large quantities of recombinant 
protein in mammalian cells have relied upon the amplification of the gene copy number 
when integrated into the cellular genome. Such methods are extremely time-consuming and 
employ large quantities of toxic compounds. Therefore, the construction of a novel inducible 
system, based-upon the SV40 LTAg and SV40 ori-containing EBV-based plasmids, in which 
episomal plasmids can be transiently amplified for a short-term increase in recombinant 
protein production, was attempted.
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MATERIALS AND METHODS
1/ (Bacteriat strains.
E. coli K12 strains; XL-1 blues (in house supply) [genotype->mc Al, end Al, gyr A96, 
thi -1, hsd R17, sup E44, rel Al, lac , {Fs pro AB, lac ITZAM15, TnlO (tetr)}] or Top 10s 
(Invitrogen Corporation) [genotype->wcr A, Mmrr-hsd RMS-mcr BC), 08OA/0C AM15, Mac 
X74:,deo R,rec Al, end Al, ara D139, A(«m,, leu ) 7679, gal U, gal K, rps L(Strr), nup G] were used 
for routine propagation of plasmids. Bacteria were grown in Luria-Bertani (LB) broth with 
antibiotics added when required.
2/ Mammalian tissue culture ceils and antibodies.
293s (transformed human embryonic kidney cells) at low passage number (initially 
no. 28) for efficient transfection were a kind gift from F. Graham (McMaster University). 293 
cells were cultured in Glasgow's' Modified Essential Medium (GMEM) supplemented with 
10% Foetal Calf Serum (GMEM-10) and passaged weekly. Cos-7 cells (transformed African 
Green- monkey kidney cells) were generously donated by F. Arenzana-Seisdedos (Institute 
Pasteur) and passaged twice weekly in GMEM -10. Hela cells (human cervical carcinoma 
cells) were passaged twice weekly in GMEM-10. The 293 cell-line that constitutively 
expresses the Epstein-Barr virus nuclear antigen 1 (EBNA-1) gene product was purchased 
from Invitrogen Corporation and maintained as described for parental 293s. Monoclonal 
antibody SV5-P-k recognising an epitope on SV5 phospho (P) and V proteins and monoclonal 
antibody K3 recognising dinitrophenol were isolated (mAb SV5-P-k,Randall et al., 1987) and 
their specificity's were determined (mAb SV5-P-k, Southern et al., 1991) in our laboratory.
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Monoclonal antibody to bacterial 6-galactosidase was purchased from Boehringer 
Mannheim. Conformationally-dependant mAbs to SV5 HN and F were isolated and 
characterised in our laboratory (Randall et al 1987). MAb (FAB 416) to SV40 LTAg was 
generously donated by D. Lane (University of Dundee, Scotland).
3/ Plasmids.
Plasmids pGEM-3zf(+) and pGEM-9zf(-) were purchased from Promega 
Corporation. The EBV mammalian expression vectors; pCEP4, pREP4 & pREP8 and the 
transient mammalian expression vectors pcDNAl/AMP & pcDNA3 were obtained from 
R&D Systems Europe Ltd. The tetracycline-responsive mammalian expression vectors 
pUHDlO-13 (tTa-driver), pUHDlO-15 (6-gal. reporter) and pUHD13-3 (Luciferase reporter) 
were a kind gift from A.G.H. Bujard. Plasmids containing the cDNA of the HN protein of 
SV5 and the cDNA of the SV5 Fusion protein were generously donated by R.A. Lamb 
(Evanston, Illinois). Plasmid pPE346 which contains the 6-galactosidase gene under control 
of the hCMV IE enhancer/promoter was kindly supplied by N, Stow (MRC Virology, 
Glasgow). Plasmid pMRlOl containing the Foot and Mouth Disease virus 2A cleavage 
sequence adjoined to the aminoglycoside phosphotransferase gene was obtained from M. 
Ryan. Plasmid pSVori encoding the SV40 LTAg was obtained from J. Doherty (Bute Medical 
Building, University of St, Andrews). Plasmid pMHVA encoding the Adenovirus VAI I gene 
was donated by R.E. Randall (University of St. Andrews). Plasmids pEBV--Ta/neo and 
pMRtTa/neo were generously donated by B. Precious (St.Andrews Uni). Plasmid pCMVluc 
was generously donated by J.E. Wright (Univ. of St. Andrews).
4/ Sgarose-gd eJkctropfwresis.
DNA samples were separated via horizontal agarose-gel electrophoresis using a mini­
gel (10cm x 10cm) apparatus (Bioscience 101). T.B.E. or T.A.E. buffer was used depending on 
the particular application. The agarose (molecular biology grade, Sigma) concentration 
ranged from 0.8% to 2% depending on the size of the DNA fragments to be separated. Gels
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were ran at varying voltages and for differing times, again depending on the application. The 
DNA was subsequently analysed by ethidium bromide staining and visualisation under U.V.
5/ “Extraction ofDNftfragmentsfrom agarose-ge[s.
DNA fragments were separated on an agarose-gel prepared from TAE buffer. Gel 
fragments containing the DNA band of interest were excised from the agarose gel and 
processed using Qiaquick gel-extraction spin- columns (Hybaid Ltd.) according to the 
manufacturers recommendations. To assess recovery of the DNA fragments, 1 /Qth aliquots 
(5|xls) were visualised after electrophoresis through agarose-gels and staining with ethidium 
bromide.
6/2)9$. [infers andprimers.
Oligonucleotides used for PCR amplification of SV5 genes were synthesised in-house 
using an Applied Eiosystems oligonucleotide synthesiser. Oligonucleotides were purified via 
ethanol precipitation as described in Manniatis etal. Oligonucleotides used for the generation 
of Pk-tag-linkers were synthesised and H.P.L.C. purified by Oswell's DNA service 
(Chemistry department, University of Edinburgh, now located at the University of 
Southhampton).
Oligonucleotides of positive and negative sense for the generation of the C-terminal 
Pk-tag linker were -> GEM ctPkpos 5'-CTC CCC CCC CCA ATA ATC TTA ACC CAA ACC 
CCA TCC CAA ACC CTT TCC TCC CAT TCC ACT CCA CCT AAC -'3 and CEMctPkneg 
5 1 -TCC ACT TAC CTC CAC TCC AAT CCC ACC AAA CCC TTT CCC ATC CCC TTT 
CCC TTA ACA TTA TTC CCC CCC CCA C - '3. The two oligonucleotides were annealed 
together and 5' phosphorylated using standard protocols (Manniatis etal ). Oligonucleotides 
of positive and negative sense for the generation of the N-terminal Pk-tag linker were -> 
CEM' ntPkpos 5 ' -CCC CCA CCA TCC CAA ACC CCA TCC CAA ACC CTT TCC TCC 
CAT TCC ACT CCA CCT CCC CCC CCT ACA ACC TTA ACT AAT -'3 and CEMntPkneg 
5'-CTA CAT TAC TTA ACC TTC TAC CCC CCC CAC CTC CAC TCC AAT CCC ACC 
AAA CCC TTT CCC ATC CCC TTT CCC ATC CTC -'3. The two oligonucleotides were
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processed as for the ctPk oligonucleotides. Underlined sequences correspond to the Pk- 
oligonucleotide sequence.
Primers annealing to the non-coding and coding strands of SV5 genes, designated 
FOR (forward) and BACK (backward), respectively, were as follows; hn, FOR 5'- ATT ATA 
AGG CGC GCC ATG GTT GCA GAA GAT GCC CCT G -'3, hn,BACK 5'- TTA AAT ACT 
TAA GGG ATA GTG TCA CCT GAC GGA T -’3, f, FOR 5’-ATT ATA AGG CGC GCC ATG 
GGT ACT ATA ATT CAA TTT CTG -3, f,BACK 5'-TTA AAT ACT TAA GTT TAT GAT AAA 
CAA AAT TCT C -'3. The primer used for the generation of the secretable form of the fusion 
protein was, sf, BACK 5’-TTA AAT ACT TAA GGT CAC TTT GTG CTA AGT GTT G -'3. The 
primer used for the secretable form of the HN protein was, sHN, FOR 5'- ATC TGG CGC 
GCC GAG AGT TTA ATA ACC CAA AAG -'3. The primer used in the repair of mutated Pk- 
tag sequence in pT7ctPk/ss was, MR, BACK 5'- ACT CAA GCT TGC ATG CCT GCA GGT 
CGA G -'3. The primer used for the generation of native HN protein was, hn(taa), BACK 5'- 
TTA AAT CTT AAG TTA GGA TAG TGT CAC CTG ACG GAT- '3.
The Primers used for the amplification of the hygromycin B phosphotrans-ferase gene 
and thymidine kinase poly A sequence were,hygB, FOR 5-ATT AGG GCC CAT GAA AAA 
GCC TGA ACT CAC C-’3, and TKpA, BACK 5'- ATT AGG GCC CTC AGT CCA GTC GTG 
GAC CAG A. The primers used for the amplification of the SV40 virus large T-antigen were 
as follows; LTAg, FOR 5 - ATA TGA ATT CAC CAT GGA TAA AGT TTT AAA CAG AG­
'S, and LTAg, BACK 5'- TAT ATG CAT GCT TAT GTT TCA GGT TCA GGG GG-'3. The 
positive and negative sense 5'-phosphorylated oligonucleotide linkers used for the 
introduction of a second Xhol restriction endonuclease site in pTETHNntPk and 
pTETHNctPk were; Xhol, pos 5-AGC TTA CTC GAG GA-’3 and Xhol, neg 5'- ATG AGC 
TCC TTC GA-'3. The two oligonucleotides were annealed together using standard protocols 
(Manniatis etal ). 5-phosphorylated oligonucleotides of positive and negative sense used for 
the construction of an optimal Kozak sequence linker were; Kozak, pos 5'- GAA TTC GCC 
GCC AC-'3 and, Kozak, neg 5'- GTG GCG GCG AAT TC-'3. The two oligonucleotides were 
annealed together using standard protocols (Manniatis etal ).
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7/ PoCymerase Chain Reaction (PCR).
Amplification of cDNAs was carried out using P.C.R. methodology. The 100(il 
reaction mixture consisted of 0.2mM of each dNTP, approximately lng of template DNA, 
ljxM of each primer and PCR buffer ( xl: lOmM Tris-Cl pH8.8,1.5mM MgCl2,50mM KC1 and 
0.1% Triton X-100). Dynazyme I or Dynazyme II DNA polymerases (Finnzymes Ltd.) were 
the last components added to the mixture, which was then overlain with SOjLils of liquid 
paraffin to minimise evaporation. Typically, 30 cycles of; 94°C for 1.5 mins., 55°C for 1.5 
mins, and 72 °C for 2 mins, with the last cycle being 72 °C for 9.9 mins.
8/ Processing of CLmpCified cWf&sfor Ligation.
The liquid paraffin was pippetted from the reaction mixture and subsequent removal 
of polymerase, primers and salts was achieved by utilising PCR-purification spin columns 
(Flowgen Ltd.) which were used according to the manufacturers recommendations. Purified 
DNA was digested with the appropriate restriction endonucleases for 10-16 hrs according to 
the vendors instructions. The digested products were agarose-gel-purified (above) and used 
for subsequent ligations.
3/ DRIfl Ligations.
Depending on the size of DNA fragments to be ligated, an approximate 3:1 (large 
DNA inserts, >500bp) to 15:1 (small DNA inserts, <100bp) molar ratio of insert to vector 
fragments were combined in a total volume of 10-20pl of ligation buffer (xl: 50mM Tris-Cl 
pH7.8, lOmM MgCl2,10mM DTT, ImM ATP and 25mgml-l BSA) where-upon 200-1000U of 
T4 DNA ligase (New England Biolabs) were added and the ligation reaction incubated at 
16°C for 10-16 hrs. Half of the ligation reaction was used for subsequent transformation of 
competent bacteria.
10/ (Preparation of competent bacteria.
E. coli strains were made chemically- competent using MgCl2 and CaCl2 as follows. 
A 100ml bacterial culture was grown to an OD^OO = 0.4-0.6, cooled on ice and pelleted at
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x3,000g for 10 mins at 4®C. The pellet was gently resuspended in 10ml of ice-cold, sterile, 
O.1M MgCl2 and left on ice for approximately 3mins. The suspension was spun as above and 
the pellet resuspended in 2mls of ice-cold, sterile, O.1M CaCl2 .The bacteria were optimally 
competent for transformation 12-24hrs after preparation.
11/Transformation of competent bacteria.
200pls of competent cells were incubated with lOpls of ligation reaction, on ice, for 30 
mins. with periodic mixing end-over-end. lng of pUC19 plasmid DNA or no DNA were 
added to competent cells as positive and negative controls respectively (typically 10° to 10° 
transformants per (Lg of DNA was observed). After incubation, the bacteria were heat- 
shocked for 1.5 mins. at 42°C and returned to ice for 5 mins. The transformation mix was 
added to O.8mls of LE- broth and incubated at 37®C for lhr, to allow expression of 6- 
lactamase for ampicillin selection, after which 0.2ml of the transformed bacteria were plated 
on LE-agar containing relevant antibiotics.
12/ ofpCcamid (DJ/L.
Small-scale preparations of DNA, mini- preps., were prepared using the alkaline-lysis
method of Eirmboim and Doly (1979). Large-scale preparations, maxi- preps., were prepared 
either by utilising Qiagen DNA maxi-prep, ion- exchange columns (Hybaid Ltd.) as used 
according to the manufacturer, or by a modified large scale alkaline-lysis procedure, as 
follows. Eriefly, a 500ml O/N culture was centrifuged at xlO,OOOg and the pellet resuspended 
in 4mls of TE buffer (lOmM Tris-Cl pH8.0 & lmM EDTA pH8.0). Eight mis of lysis solution 
(0.2M NaOH & 1% SDS) were added and the viscous suspension was mixed end- over- end 
for no longer than 5 mins.. Six mis of ice-cold neutralisation buffer (3M potassium ethanoate 
pH5.5) were added and the mixture briefly mixed end-over-end and incubated in ice for 15 
mins. The precipitate was pelleted at x23,000g for 30 mins. at 4°C. where-upon the plasmid- 
containing supernatant was precipitated with 1 volume of iso-propanol and pelleted as 
above. The pellet was resuspended in 2 mis lOmM Tris-Cl pH8.0, added to 2.5 mis of 4.4M
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LiCl and incubated on ice for 15 mins, to precipitate out high molecular weight RNA. After 
centrifuging as above, the supernatant was precipitated with 2.5 volumes of ethanol, pelleted 
and resuspended in 0.7 mis lOmM Tris-Cl pH8.0. Seven microlitres of DNAse-free RNAse 
(Boehringer Mannheim) were added and incubated for 30-60 mins, at 37°C. An equal volume 
of PEG solution (1.6M NaCl, 16% polyethylene glycol 6000) was added and the mixture 
vortexed then incubated at 4°C for 10 mins, after which centrifugation was carried out at 
4°C, 14,000rpm in a benchtop rotor. The pellet was resuspended in 0.4mls of TE and the 
plasmid preparation was phenol/chloroform- extracted x3, chloroform- extracted x2 and 
ether- extracted xl, precipitated with 1/10 vol. NaAc/2.5 volumes of ethanol, pelleted at 4°C, 
14,000 rpm in a benchtop microfuge then resuspended in 200-500(ils of lOmM Tris-Cl pH8.0. 
Quality and quantity of DNA was analysed by spectrophotometric readings at 260nm & 
280nm and by visualisation on an agarose-gel (Manniatis et al.).
13/ Sequencing.
DNA sequencing was performed on double-stranded plasmid DNA templates using 
the dideoxy chain- termination procedure. Plasmid DNA for sequencing was prepared using 
Qiagen plasmid preparation columns (Hybaid Ltd.), as above. 5ju,gs of plasmid DNA per 
primer-reaction were sequenced using the Sequenase® version 2.0 sequencing kit 
(Amersham International), [a^S]dATP (1x10^ Ci.mmol"^; Amersham International) and 
used exactly according to the vendor's recommendations.
14/ Preparation of cationic Ciposomesfor transfection.
The following procedure was kindly given by R. Elliott (MRC Virology, Glasgow) and 
results in a lipid mixture equivalent to Gibco-BRL's TransfectACE. Briefly, 1ml DOPE 
(dioleoyl L-a-phosphatidyl ethanolamine, Sigma) was pippeted into a glass universal where­
upon 4mgs of DDAB (dimethyldioctadecyl ammonium bromide, Sigma), w/w ratio of 1:2.5 
DDAB:DOPE, were added and briefly vortexed till dissolved. The chloroform was 
evaporated using a stream of nitrogen whilst rotating the universal to ensure an even film of 
lipid dispersed around the walls. The dried lipids were resuspended in lOmls of sterile
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distilled water by a 10-15 min. sonication in a sonicating waterbath. Once resuspended, the 
turbid mixture was sonicated with a soniprobe (15 microns amplitude) using 30 second 
pulses and incubating on ice in between, until, or as close to, clear (approx. 20-40 mins.). 
Lipids were tested against previous batches for transfection efficiency using a 6-galactosidase 
expressing plasmid, pPE346, then stored in 1ml aliquots at 4°C.
13/ Staining protocoCfor detection offl-gaCactosidase eqmssing ceds.
Transfected cells were washed once with PBS then fixed for 5 minutes at room 
temperature by the addition of 1ml of fixative (5% formaldehyde, 2% sucrose in PBS ) per 
3.5cm diameter dish. The fixative was removed and the cells washed with PBS. Three 
millilitres of freshly prepared staining solution ( 5mM potassium ferricyanide, 5mM 
potassium ferrocyanide, 2mM MgCl2 and 0.5mgmT'l X-gal, in PBS) was added to the washed 
cells which were then incubated at 37 OC overnight.
16/ Quantitative [uciferase assays.
Cells grown in 6-well plates were transiently transfected with appropriate luciferase 
reporter vectors, as detailed above. Thirty six hours post-transfection the cells were washed 
twice with PBS and lysed with 200|xls of luciferase lysis buffer (25mM Tris-phosphate pH7.8, 
8mM MgCl2/ ImM DTT, 1% Triton X-100 and 15% glycerol). The lysate was scraped off the 
culture dish and the cellular debris was pelleted by a brief 10 second centrifugation. 100|ils of 
soluble cell extract was assayed for luciferase activity in a Lumat LB9501 luminometer 
(Berthold, Wildbad, Germany) using the integral mode (10 seconds). Luciferin buffer was: 
ImM ATP, 0.25mM D-luciferin (SIGMA), 1%BSA in luciferase lysis buffer. Luciferase activity 
is expressed as relative light units (RLUs) per jig of protein. Protein determination was 
performed using the Bradford assay.
17/ (Production of 1/accinia Virus %Pf7-3 stofs.
For the production of small stocks of virus, a recently confluent Hela monolayer 
(25cm^ flat) was infected with virus (in house supply) at a m.o.i. of 1, in GMEM
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supplemented with 1% FCS (CMEM-1) for 1-2 hrs, where-upon CMEM-10 was added and 
the cells incubated at 37°C for 48 hrs. The cells were scraped into the medium, pelleted and 
resuspended in 2mls lOmM Tris-Cl, lmM EDTA, pH 7.0 and the virus released by three 
cycles of freeze-thawing, and stored at -70°C. Medium stock of virus were prepared as above 
with the whole of the small virus stock being used to infect xlO 75cm° flats of recently 
confluent Hela cells. The titre of the midi-prep, was determined (see below).
Large stocks of semi-purified virus was prepared as follows; lL of Hela S3 spinner 
cells (5 x 10° cells ml“l) were concentrated to a density of 5 x 10° cells ml"° by low-speed 
centrifugation and resuspension in CMEM-1.. Virus at a m.o.i. of 5 (previously treated with 
0.1 vol. of trypsin (2.5 mgml"!. Sigma) for 30 mins. at 37°C) was added to the concentrated 
cells and incubated, with constant stirring, at 37°C for 1-2 hrs, where-upon 900mls of 
CMEM-10 were added and incubation was continued for a further 48 hrs. lnfected cells were 
pelleted and resuspended in 20mls of lOmM Tris-Cl pH 9.0 at 4°C (all subsequent steps were 
carried out on ice). The suspensions were homogenised with 30 strokes of a dounce 
homogeniser and the nuclei pelleted by centrifugation at 750xg for 5 mins.The supernatant 
was decanted and the pellet resuspended in 20mls lOm.M Tris-Cl pH 9.0 and homogenised 
and pelleted as above. The supernatants were combined, 0.1 vol. of trypsin was added and 
incubated as above. The trypsin treated virus stock was layered onto an equal volume of 36% 
sucrose in lOmM Tris-Cl pH 9.0 in a Eeckman SW28 swingout tube and centrifuged at 13,500 
rpm (25,000xg) for 80 mins. at 4°C. The pellet was resuspended in 2mls of lmM Tris-Cl pH 
9.0 and stored in aliquots at -77OC .
18/ [RiraHon of ‘Vaccinia vims stocCs.
Duplicate 35 mm dishes of 293 cells which had just reached confluence were washed 
with CMEM-1 and infected with 10-fold dilutions of virus in CMEM-1 for 1-2 hrs at 37°C .
The viral inoculum was removed, CMEM-10 was added, and the infected cells incubated for 
a further 48 hrs at 37°C, where-upon the medium was removed and the monolayer stained 
with a solution of 0.1% Crystal Violet in 2% ethanol for 2-3 mins. at room temperature to 
visualise the areas of cell degeneration (plaques).
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19/ 9/ransientproteinproduction.
a) Expression from T7ol0 promoter.
Mammalian cells were passed into 9cm diameter petri dishes or individual wells 
(3.5cm diameter) of a 6-well dish in numbers sufficient to be confluent the next day. 
Confluent monolayers were washed once in Optimem- 1 (Gibco-BRL) and recombinant 
vaccinia virus which expresses T7 RNA polymerase, diluted in Optimem- 1 to give a m.o.i. 
of 2, was added to the monolayers and incubated at 37 °C, with periodic agitation, for lhr. 
Plasmid DNA was introduced into the infected cells using a liposome-mediated procedure. 
Briefly, for one 3.5 cm diameter well, three micrograms of DNA were added to lOOpls of 
Optimem-1 and mixed. lOpls of the liposome mixture were added to the lOOpls of Optimem- 
1/DNA, gently mixed and left to stand for 10 - 15 mins, at room temperature. All steps were 
carried out in polystyrene tubes or glass bijoux due to the affinity of the liposomes for 
polypropylene. The liposome/DNA mixture was carefully added to the infected cells which 
were incubated for a further 12-18 hrs.
b) Expression from the human CMV I.E. enhancer/promoter in 293 cells.
Dishes were seeded with cells to obtain 40-50% confluency the next day. 
Liposome/DNA mixtures were prepared as above except that after the 10 -15 minute 
incubation, the volume was adjusted to 1ml which was directly added to cells which had 
been washed once with Optimem-1. The Optimem-1/liposome/ DNA mixture was left on 
the cells for 12-16 hrs after which the cells were washed once with GMEM-10 and incubated
for a further 24-72 hrs in GMEM-10.
c) Expression from the human CMV I.E. enhancer/promoter in Cos-7 cells.
Dishes were seeded with cells to obtain 40-50% confluency the next day. Transfections 
were carried out using DEAE-Dextran methodology. Briefly, for each 35mm dish, l.Opg of 
DNA were added to 500|ils Optimem-1 where-upon 50(ils of a lmgmH filter-sterilised 
DEAE-Dextran (5x10 5 mwt., Sigma) solution (prepared in TBS) were added and the mixture 
mixed. The DNA/DEAE-Dextran mixture was incubated for 15 mins, at room temperature. 
Medium from the cells was aspirated and the cells washed twice with PBS. The DNA/DEAE-
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Dextran mixture was brought up to 1ml with Optimem-1 and the mixture added to the cells 
for 1 hr, 37 OC, 5% CO2 with periodic rocking. The transfection mixture was removed and the
cells washed twice with PBS where-upon 3mls of GMEM-10 containing 100|xM chloroquine 
(Sigma) were added and the cells incubated for 4 hrs at 37°C, 5% CO2 • The medium was
removed and the cells were washed once with GMEM-10 and incubated for a further 48­
72hrs in GMEM-10.
d) Expression from the tetracycline-responsive promoter irr c^ll^.
Transfections were carried out as for vectors containing the hCMV IE 
enhancer / promoter except that a 1:1 ratio of driver to responder plasmids were mixed 
together to give a final amount of 3|xgs which was used to transfect 1x10° cells, in the absence 
or presence of tetracycline.
20/ Synchronisation ofMtammaCian cef at Q2/Mphase.
Cells were pesdrd at 40-50% confluency in tissue culture vessels. Synchronisation at 
the Gl/S phase of the cell cycle was achieved by an overnight (usually 16-18 hrs) treatment 
with 3.3mM thymidine (Sigma, prepared as a 0.2M stock in water, filter pterrlrped and stored 
at -20°C ). The cells were released from the thymidine blockade and set-up for G2/M 
synchronisation by washing the cells in growth medium followed by an overnight incubation 
in growth medium containing O.lpgml"* Hoechst 33342 (Sigma, prepared as a O'l^^gmH 
stock in DMSO, stored at -20OC Os a light-proof eppendorf).
21/Production of sta6k cell Ones.
A 40% confluent 25 cm° flat of tissue culture cells, synchronised at the G2/M phase of 
the cell-cycle, was traesfected with the required amount of DNA, as above. Twelve hours 
after transfection the cells were washed with GMEM-10 and incubated for approximately 24 
hrs in GMEM-10 to revive from the transfectioe. The cells were then seeded into 12cm 
diameter petri dishes, where-upoe selective agent was added (hygromycin B (Boehringer 
Mannheim), Histidinol dihydrochloride (Sigma or Fluka) and Geeelicin (Gibco BRL) were 
used at working concentrations of 200|±gmH, ImM to 5mM, and 400pgml° respectively. The
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cells were incubated in selective medium, replaced every 3 days with fresh selective medium, 
until individual colonies grew-up which were then isolated by ring-cloning. lsolated colonies 
were screened for expression by immun.rfluoeetence/ Western Eliot and immuneprecipitaSion 
analysis. For the production of stable clones expressing from the tetracycline-responsive 
promoter, tet° at a working concentration of 3|^L5ml"° was included in all the above steps and 
removed 24-48hrs prior to screening by washing the cells x4 with growth medium.
22/ Determination of protein concentration.
Protein concentrations were determined using either the method of Eradford (if DTT 
or fi-mercaptrethanrl was present in the sample) or the ECA protein assay (Pierce Ltd.). For 
the Eradfords assay lOpls of sample was mixed with 990pls of Eradford's reagent (lOOmg of 
coomassie blue C250,100ml of orthophosphoric acid, and 50ml of absolute ethanol, made up 
to lL with distilled water) and incubated at room temperature for 5 minutes followed by 
measuring the absorbance at 595nm on an LKE Eiochrom Ultraspec ll spectrophotometer, 
with concentrations been determined from a ESA standard curve. The ECA assay was 
performed using the microt^er plate method as described in the manufacturers instructions, 
again with ESA as the standard curve.
23/ SES-EELCfE and iVestem ‘Bfot Snadysis.
Protein samples were suspended in disruption buffer (xl; 2% w/v SDS, 5% v/v E- 
meecaptoethanol, 2.5% v/v glycerol and 0.25 % w/v bromophenol blue) boiled for 5 mins. 
and separated through 6-12% SDS-polyacrylamide gels using thin (0.75 mm) mini-slab gels of 
the Eio-Rad mini-protean ll electrophoresis system. Separated polypeptides were transferred 
(transfer buffer- 48mM Tris, 39mM glycine, 20%v/v methanol and 0.0375% SDS) onto 
nitrocellulose or P.V.D.F. filters using a semidry gel electroblotter (CES Scientific Co.). The 
filters were blocked with PES containing 5% (w/v) skimmed milk powder and 0.1% (v/v) 
tween 20 then incubated with monoclonal or polyclonal antibodies diluted 1:200 to 1:1000 in 
blocking buffer. After washing in blocking buffer, bound antibodies were detected using 
HRP-conjugated protein A (Amersham lnternational) or HRP-conjugated anti-mouse
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antibodies (Amersham International) diluted in blocking buffer, washed as above, then 
developed by the enhanced chemiluminiscence (ECL; Amersham International) protocol 
according to the manufacturers recommendations.
24/ Stripping of 9{trocetfu(ose orP/V/D.f/ membranes.
Membranes were incubated in stripping buffer (0.15ml 6-mercaptoethanol, 2ml 20% 
SDS, 1.25ml 1M Tris pH6.7,16.6ml H2 O) in a hybridisation oven at 72OC for 30 minutes. The 
membrane was washed once for 5 mins, then for 15 mins three times, in 250ml PBS 
containing 0.1% (v/v) Tween 20. The membrane was subsequently blocked for 1 hour in PBS 
containing 5% skimmed milk powder and 0.1% (v/v) Tween 20 and probed with anti-sera as 
detailed above.
25/ Immuneprecipitation.
Soluble antigen extracts (SAE) were prepared by washing transfected cells with ice- 
cold PBS followed by lysis using ice-cold immuneprecipitation buffer (IPB, 0.1% SDS, 0.5% 
NP40, 0.1% NaN3, 0.65M NaCl, 1mM EDTA and 20mM Tris-Cl pH 7.5) and a 15 min. 
incubation on ice. The viscous cellular debris was scraped off the dish, briefly sonicated and 
insoluble material pelleted by ultra-centrifugation at 400Kg, at 4®C. Soluble antigen extracts 
were incubated with 1pl of ascites fluid per 200jxls of SAE for 1-2 hrs on ice followed by the 
addition of 20pls of a 10% killed and fixed suspension of the Cowan A strain of S. aureus for 
1-2 hrs on ice. The precipitates were pelleted by a 3 min. centrifugation at 6,500 rpm in a 
bench top microfuge and the pellet washed x3 by the addition of IPB and subsequent 
pelleting. The washed pellet was resuspended in 20-50 pis of xl.5 SDS-disruption buffer and 
processed as above for SDS-PAGE/W. blot.
26/ ImmunofCuoresence.
Cells to be probed were grown on 10;mim or 13mm glass coverslips in individual wells 
of a 6 well or 24 well tissue culture plate. Cells to be fixed were washed twice with PBS 
followed by a 10 minute incubation in fixative (5% formaldehyde, 2% sucrose in PBS). The
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fixative was aspirated and the cells were washed twice in PBS followed by a 5 min. 
incubation in permeabilisation buffer (0.5% NP40,10% sucrose, 1% calf serum(CS) in PBS ) if 
required. The cells were washed x3, in PBS/1% CS. 10-20pls of a 1:100 dilution of primary 
antibody was spotted onto siliconised glass microscope slides and the fixed coverslips were 
placed onto the antibodies and incubated for 30 mins, at 37°C in a humidified chamber. The 
coverslips were washed by sequential multiple dipping in permeabilisation buffer xl, 
PBS/1% CS x3, then PBS x2. The coverslips were then placed onto 10-20pls of 1:100 diluted 
Texas Red-conjugated second antibody and incubated for 30 mins, at 37°C in the dark, again 
in a humidified chamber. The coverslips were washed as previous and mounted on glass 
microscope slides using 2.5|ils of Citifluor Af~l mountant.
27/ Co Cony 9Cy6ridisation.
A 9cm diameter nylon membrane (Hybond-N, Amersham International) was overlain 
onto an agar plate containing the colonies arising from the transformation of a DNA ligation 
reaction into competent E. coli . The membrane was left to moisten for approximately 3 mins., 
carefully peeled off the plate and placed, for 2 mins., colony-side up onto a 3MM Whatman 
filter pre-soaked in lysis solution (10% SDS). The membrane was then transferred for 2 mins, 
colony-side up, onto a 3MM Whatman filter pre-soaked in denaturing buffer (0.5M NaOH, 
1.5M NaCl). Next, the membrane was again transferred colony side-up onto a 3MM filter 
pre-soaked in neutralisation buffer ( 1M Tris-HCl, 1.5M NaCl) for 5 mins., this step being 
repeated once more. After washing the membrane briefly in x2 S.S.C. the denatured DNA 
was cross-linked to the nylon membrane by illumination with ultraviolet light for 3 mins. 
The filter was covered in prehybridisation buffer ( x6 SSC, x5 Denhardts, 0.1% SDS and 
50pgml"l ssDNA ) and incubated at 60°C for 4hrs , the pre-hybridisation buffer was 
decanted and hybridisation buffer (as for prehybridisation buffer but also containing 
radiolabelled probe) added. Incubation was continued at 60°C overnight. The filter was 
washed as follows; 6x SSC, 0.1% SDS for 30 mins, at 60°C, 2xSSC, 0.1% SDS for 30 mins, at 
60°C, 0.2x SSC, 0.1% SDS for 30 mins, at 60 °C, last step repeated then a final brief rinse in 2x 
SSC before exposure to X-ray film.
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28/ CfemicaC CCvss-Cnking fTcti^u^ns.
Chemical cross-linking was performed by a method similar to that described by 
Paterson and Lamb 1993. 293 cells were infected with Vaccinia virus and transfected with the 
appropriate plasmid as described above. Twelve hours post-transfection the cells were 
washed with PES and removed from the dish using the EDTA solution: Versene. The cells 
were pelleted by centrifugation at 6,500 rpm, for 1 minute, in a benchtop microfuge. The 
pellet was resuspended in 70|ils of PES and the cells solubilised by addition of NP40 to a final 
concentration of 0.5%. The NHS-ester chemical crosslinker ES° (Eis(Sulpho-succinimidyl) 
Suberate, Sigma Ltd.) was prepared as a 30mM stock solution in O.1M Hepes pH7.4 
immediately prior to use and kept on ice throughout the procedure. Cross-linking reactions 
were carried out with final ES° concentrations of; 0, 0.05, 0.2, 2.0, and 5.0mM and incubated 
at 4°C for 1 hour and then quenched with 50mM Tris-HCL pH8.5 for 5 minutes at 4°C. 
Proteins were analysed by SDS-6% PACE under reducing and non-reducing conditions.
23/ T9(§nse jF Treatment of Whole Cell Extracts.
293 cells were transfected with the appropriate T7-based vectors, as described above. 
Transfected cells were then harvested by washing and scrapping the cells into PES, pelleting 
on a benchtop microcenSrifuge and finally resuspended into xl disruption buffer. The whole 
cell extract (WCE) was further denatured by boiling for 5 minutes, whereupon 1/10*° 
volumes of reaction buffer (xlO: 0.5M sodium phosphate pH7.5) and 10% Nonidet P40 
(NP40) were added. lOOOUs of PNCase F (reaction buffer, 10% NP40 and enzyme was 
purchased from New England Eiolabs) were added to the reaction mixture, which was then 
incubated for 2hrs at 37°C. The extracts were analysed on SDS-PACels under reducing 
conditions followed by Western blotting using the anti-Pk monoclonal antibody and 
enhanced chemiluminesence detection (ECL) detection.
30/ Tunicamycin (Treatment Of transfected ceCs.
Tunicamycin (Sigma) was prepared as a lpgpll° stock in DMSO and kept in a light­
proof eppendorf at 4°C. 293 cells were transfected with the appropriate vectors as described
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above except that tunicamycin at a final concentration of 2|igml“ was added to the medium, 
4hrs post-transfection. The cells were harvested 16hrs later and WCEs were analysed by a 
separation through SDS-PAGels under reducing conditions, followed by Western blotting
using the anti-Pk monoclonal antibody and ECL detection.
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RESULTS
As the following results section contains a large amount of information on the construction 
and analysis of a number of plasmid vectors, a summary of the vectors used throughout, 
including some of their major features, is depicted in table 4.
SECTION JL: ANALYSIS . OF TRANSIENTLY EXPRESSED Pk-
TAGGED SV5 GLYCOPROTEINS.
The vector initially chosen for transient expression of Pk-tagged glycoproteins in 
mammalian cells was the plasmid pGEM-3zf(+) (from now on referred to as pT7, figure 19). 
This vector possesses a promoter derived from the T7 bacteriophage, from which expression 
is driven by the T7 RNA-dependant RNA polymerase (T7-RDRP). The T7-RDRP was 
introduced into mammalian cell lines by infection with a recombinant vaccinia virus (vTF7-3) 
which encodes the T7-RDRP, as described by Elroy-Stein et al (1989). Expression from the 
vector was achieved by liposome-mediated transfection of the circular plasmid into the 
infected cells which were subsequently analysed for protein production 12 to 18 hrs post­
transfection.
1.1) Construction of vectors for the expression of Pk-tagged HN & F glycoproteins.
1.1.1 I Constrsction ofthe veetons encoding en N on C-teeminsl Ck-tagg
Two oligonucleotide linkers, encoding the Pk- tag sequence (figures 16 & 17) for
positioning at the N or C - terminus of an expressed protein, were cloned into pT7, producing 
the plasmids pT7ntPk and pT7ctPk respectively (figure 19). Both oligonucleotide linkers 
possessed restriction endonuclease (RE) recognition sites for the directional cloning of 
cDNAs and, where appropriate, translational initiation and termination signals. Plasmids
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TABLE 4 Summary of plasmid vectors used throughout this thesis and some of 
their major features.
The symbol * refers to vectors constructed within this laboratory by either B. Precious or A. 
Bermingham. The symbol ** refers to vectors constructed outwith this laboratory. N/A - not 
applicable. The punctuation mark ? - unknown. The character (-> ->) refers to the 
favourable orientation, (-> <-) refers to the unfavourable orientation, as discussed in the text 
to follow. CMV refers to the human CMV major immediate-early enhancer/promoter 
element. Pol III refers to transcription initiating from an RNA pol III promoter. TRP refers to 
the tetracycline responsive promoter.
Vector Promoter Gene
EBNA-1/
EBV-ori Orientation
SV40-
ori
Detectable 
gene expression
pT7ctPk T7ol0 N/A No N/A No N/A
pT7ntPk II N/A II 11 N/A
pT7HN SV5HN II It Yes
pT7HNctPk HNctPk II It
pT7HNntPk HNntPk II It
pT7FctPk FctPk II II
pT7AHNctPk AHNctPk II It
pT7AHNntPk AHNntPk 11 11
pT7AFctPk AFctPk tl It
pCT7HNctPk CMV & T7 HNctPk No N/A Yes Yes, T7 only
pCT7HNntPk II HNntPk 11 It tl Yes, T7 only
pCT7LTAg II LTAg 11 II II Yes
pCT7figal 11 figal. ft II II Yes
pMR-tTa/neo * CMV tTa/neo No N/A Yes Yes
pEBV-tTa/neo * II tTa/neo Yes (->->) No II
pMR-tTa/hygB n tTa/hygB No N/A Yes If
pGEM-tT a / hygB ll It No N/A No II
pEBV-tTa/hygB it 11 Yes (->->) No 11
pTET/V * TRP SV5V No N/A No Yes
pTETHNctPk II HNctPk No N/A II No
pTETHNntPk II HNntPk No N/A 11 Yes
pTEP4HNctPk II HNctPk Yes (->->) It No
pTEP4HNctPk II HNctPk 11 (-><-) No
pTEP4HNntPk II HNntPk II (->->) It Yes
pTEP4HNntPk 11 II It (-><-) <1 11
pTEP8HNntPk 11 II II (->->) Yes II
pTEP8HNntPk H 11 11 (-><-) Yes 11
pREP4HNctPk RSV LTR HNctPk Yes (-><-) No No
pCEP4HNctPk CMV tl 11 (-><-) It 11
pCEP4HNctPk It II II (->->) tl 11
pCEP8/P II SV5P 11 (-><-) Yes Yes
pCEP8/P II SV5P II (->->) Yes Yes
pSVori ** SV40 LTAg No N/A Yes Yes
pCMVluc ** CMV Luciferase II II ? Yes
pMHVA** Pol in VAI RNA II II ? Yes
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<-af12->
<—ascl--> leu lys gly lys pro ile
CT GGG CGC GCC AAT AAT CTT AAG GGA AAG CCG ATC
GA CGC GCG CGG TTA TTA GAA TTC CCT TTC GGC TAG
pro asn pro leu leu crlv leu asp ser thr OCH
CCA AAC CCT TTG CTG GGA TTG GAC TCC ACC TAA C
GGT TTG GGA AAC GAG CCT AAC CTG AGG TGG ATT GAGCT
Figure 16. DNA linker coding for the C-terminally positioned Pk-tag.
The schematic depicts a sequence for a double stranded oligonucleotide which 
encodes the Pk-tag oligopeptide derived from amino acids 95-108 of SV5 P&V proteins 
(bold). Amino acids in plain text are derived from the afl2 restriction site. After annealing, 
the oligonucleotide possesses a Pvu2 blunt - end and an Xhol cohesive-end. Underlined 
region corresponds to the synthetic nonapeptide which was used in competition studies with 
the P and V proteins for binding to SV5-P-k antibody (Southern et al, 1991). Sio^n is the ascl 
& afl2 sites used for the introduction of the gene of interest. The linker also possesses an 
ochre codon (OCH) as a signal for the termination of translation.
gly lys pro ile pro asn pro leu leu
CC GGG ACC ATT GGA AAG CCG ATC CCA AAC CCT TTG CTG
C TGG TAG CCT TTC GGC TAG GGGT TTG GGA GAAC GAG
gly leu asp ser thr trp arg ala leu lys OCH
GGA TTG GAG TCC ACC TGG CGC GCC TAG AAC CTT AAG TAA T
CCT AAC CTG AGG TGG ACC GCG CGG ATC TTG GAA TTC ATT AGATC
<--ascl--> <-afl2->
Figure 17. DNA linker coding for the N-terminally positioned Pk-tag.
The schematic depicts a sequence for a double stranded oligonucleotide which 
encodes the Pk-tag oligopeptide derived from amino acids 95-108 of SV5 P&V proteins 
(bold). Amino acids in plain text are derived from the ascl and afl2 restriction sites. After 
annealing, the oligonucleotide possesses an Xmal cohesive-end and a Sail cohesive-end. 
Shown is the ascl & afl2 sites used for the introduction of the gene of interest. Upstream of 
the ATG codon is the tri-nucleotide sequence ACC conferring an optimal Kozak sequence for 
translation initiation (Kozak, 1989). The linker also possesses an ochre codon (OCH) as a 
signal for the termination of translation.
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pT7ntPk & pT7ctPk were sequenced to ensure the fidelity of the sequence(figure 18).
1.1.2 /Construction ofthe vectors encoding native SV5 HN and N or C - terminally Pk-tagged
HN (figure 19).
The gene encoding the haemagglutinin/Neuraminidase protein from SV5 was 
amplified from the plasmid HN177 using PCR technology. Primers were used in which ascl 
& afl2 RE recognition sequences were incorporated for the directional cloning of the PCR 
product into the pT7ctPk plasmid to produce the plasmid pT7HNctPk. The vector 
pT7HNntPk was constructed by the digestion of the plasmid pT7HNctPk with the REs ascl 
& afl2 followed by a ligation of the excised HN gene into the similarly digested plasmid 
pT7ntPk. In addition, a vector termed pT7HN, encoding the native HN glycoprotein was 
constructed. pT7HN was produced in a manner similar to that of the pT7HNctPk plasmid, 
except that a TAA stop codon (which terminated translation after the last amino acid 
encoded by the HN gene) was incorporated into the PCR primer. Appropriate portions of the 
plasmids; pT7HN, pT7HNctPk & pT7HNntPk were sequenced to ensure fidelity (data not 
shown).
1.1.3 /Construction ofthe vector for the expression of C-terminally tagged SV5 F (figure 20).
The gene encoding the fusion protein from SV5 was PCR-amplified from a plasmid 
containing the full length SV5 F gene (generously donated by R.A. Lamb) such that the PCR 
product contained a 5' ascl RE site and a 3' afl2 RE site. The PCR product was subsequently 
digested with ascl & afl2 and ligated into the similarly digested pT7HNctPk plasmid to 
produce the expression vector, pT7FctPk. The F gene was sequenced to ensure fidelity of the 
sequence (data not shown).
1.2 Transient protein production from the vectors which encode Pk-tagged HN & F
glycoproteins.
1.2.1 /Expression of Pk-tagged SV5 HN & F.
Infection of 293 cells with vaccinia virus encoding the T7-RDRP followed by the 
subsequent transfection with the expression vectors was as described in the methods section.
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A) CT Pk-tag B) NT Pk-tag
ACGT
A C G T
»— TAA (STOP) 
Afl 2
Asc 1
Pk-tag
H- ATG (START)
Figure 18: Sequence analysis of the CT & NT Pk-tag.
A schematic depicting the coding strand of the DNA sequence for the CT (A) & NT (B) 
Pk-tag oligopeptide epitope cloned into a pGEM plasmid to produce the vectors pT7ctPk 
& pT7ntPk. Also shown are the TAA translation termination (STOP) codons, ATG 
translation initiation (START) codon, and the recognition sequences for the restriction 
endonucleases Asc 1 (GGCGCGCC) and Afl 2 (CTTAAG). The sequence reads from the 
bottom to the top.
ctPk-tag linker
f1 ori
Amp
Sma1/Xma1
Xba1
ntPk-tag linker
Asc1/Afl2
HN
(PCR of HN 177) 
Asc1/Afl2 |
Asc1/Afl2
Ligase
(Asc1/Afl2 excised)
Ligase HN
Afl2 Afl2
Figure 19: Construction of pT7HNntPk and pT7HNctPk vectors.
Two oligonucleotides encoding the Pk-tag sequence (figs. 16 & 17) were cloned into 
the vector pT7 producing the plasmids pT7ntPk or pT7ctPk, using the restriction 
endonuclease (RE) sites as shown. The gene coding for HN was amplified from the 
vector HN177 by PCR such that it could be directionally cloned into pT7ctPk, via the 
ascl & afl2 RE sites, producing pT7HNctPk. To construct pT7HNntPk, the HN insert 
from pT7HNctPk was excised by ascl & afl2 digestion and ligated into the similarly 
digested, pT7ntPk.
Ascl
Afl2
Ascl
Afl2
Ligase
Ascl | F/AF , Ascl
Afl2 (PCR from R.A. Lamb's Afl2
F-plasmid) Ligase
I I
Figure 20: Construction of the vectors which encode the SV5 F glycoprotein and a 
truncated form, AF.
The gene encoding the SV5 F protein was amplified from a plasmid containing 
the entire SV5 F gene (donated by R.A. Lamb) by PCR such that it could be 
directionally cloned into pT7HNctPk, via the ascl & afl2 RE sites, producing the 
plasmid pT7FctPk. To construct pT7AFctPk, the nucleotide sequence 
corresponding to amino acids 1 to 471 of the SV5 F gene was PCR amplified from 
pTTFctPk and the PCR product was digested with the REs Ascl & Afl2 and ligated 
into the similarly digested vector pT7ctPk using the ascl & afl2 RE sites, producing 
the vector pT7AFctPk. Transcription from both vectors was from the 
bacteriophage T7ol0 promoter.
18 hrs post-transfection, the cells transfected with the plasmids; pT7HNctPk, pT7HNntPk or 
pT7FctPk were washed once with PBS, detached from the plastic by scrapping, pelleted and 
then resuspended in xl disruption buffer. After sonication, the whole cell extracts (WCEs) 
were separated through a 10% SDS-PAGel under reducing conditions, transferred to a PVDF 
membrane by electroblotting and probed with the anti-Pk mAb. Figure 21 shows that 
products of -70Kda were detected from cells transfected with vectors encoding the N or C- 
terminally Pk-tagged HN (lanes 1 & 2), and products of ~ 66Kda & 56Kda were detected 
from cells transfected with the pT7FctPk construct (lane 3). No products were detected from 
mock transfections (lane 4).
1.2.2 filuc^c^si^li^tie^fi at^g^l-^sis of Pk-tatused SV5 SHN & S.
N-linked glycosylation adds approximately 6-10 Kda to the molecular weight of the 
polypeptide backbone of native F and HN glycoproteins, O-linked glycosylation does not 
appear to be involved. To determine whether a protein has undergone the addition of N- 
linked sugar residues, the use of the enzyme PNGase F (peptide-N4-(N-acetyl-B- 
glucosaminyl)asparagine amidase), which hydrolyses the asparginyl-oligosaccharide bond 
on the polypeptide, can be employed. From figure 21, indirect evidence for glycosylation of 
Pk-tagged HN and F could be inferred from the relative molecular weights of the detected 
proteins.
To directly ascertain whether Pk-tagged HN and F were N-linked glycosylated, WCEs 
were treated with PNGase F as described in the methods section. Treated and untreated 
WCEs were separated through a 10% SDS-PAGel under reducing conditions, transferred to a 
PVDF membrane by electroblotting and probed with the anti-Pk mAb. Figure 22 shows that 
when WCEs from pT7HNctPk, pT7HNntPk & pT7FctPk transfected cells were treated with 
the enzyme PNGase F, the molecular weights of the expressed products were decreased by 
approximately 6-10 Kda directly indicating that the Pk-tagged glycoproteins had undergone 
N-linked glycosylation.
An alternative method of determining whether N-linked glycosylation of a 
glycoprotein occurs is by employing reagents which block the formation of the dolichol
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1 2 3 4
200 Kd-*-
97 Kd*
68 Kd*
1) HNctPk.
2) HNntPk.
3) FctPk.
4) Mock.
45 Kd*
Figure 21: Transient expression of Pk-tagged HN and F glycoproteins and their 
antigenicity to the anti-Pk mAb.
vTF7-3 infected 293 cells were transfected with the plasmids; pT7HNctPk (lane 1), 
pT7HNntPk (lane 2), pT7FctPk (lane 3) or were mock transfected (lane 4). 16hrs 
post-transfection WCEs were prepared in disruption buffer and aliquots separated 
through a 10% SDS-PAGel under reducing conditions, electroblotted and probed with 
the anti-Pk mAb. Detection was by ECL.
1 2 34 5678
200Kd
97Kd
68Kd
45Kd
U HNctPk - PNGase F.
2) HNctPk ♦ PNGase F.
3) HNntPk - PNGase F.
4) HNntPk • PNGase F.
5) FctPk - PNGase F.
6) FctPk • PNGase F.
7) AFctPk - PNGase F.
8) AFctPk ♦ PNGase F.
Figure 22: PNGase F analysis of Pk-tagged HN, F and AF.
vTF7-3 infected 293 cells were transfected with the vectors; pT7HNctPk (lanes 1 & 2), 
pT7HNntPk (lanes 3& 4), pT7FctPk (lanes 5 & 6) and pT7AFctPk (lanes 7 & 8). 16hrs 
post-transfection, WCEs were prepared in disruption buffer. Half of the samples were 
treated with the enzyme PNGase F, as detailed in the methods. Untreated / treated 
extracts were separated through a 10% SDS-PAGel under reducing conditions, 
electroblotted and probed with the anti-Pk mAb. Detection was by ECL.
phosphate-linked oligosaccharide donor, thereby preventing N-linked glycosylation of the 
polypeptide backbone. An example of such an agent is the antibiotic tunicamycin. Treatment 
of transfected cells with tunicamycin was carried out as detailed in the methods section. 
Transfected cells showed a similar decrease of approximately 6-10 Kda in the relative 
molecular weights of the expressed proteins when tunicamycin was present, (data not 
shown).
1.2.3 /Localisation of Pk-tagged SV5SRN & F.
Having shown that Pk-tagged forms of HN and F are N-linked glycosylated, as 
previously shown for native HN and F, the cellular localisation of expressed Pk-tagged HN 
and F was determined. Native SV5 HN and F are located in the plasma-membrane on the 
surface of infected or appropriately transfected cells. Therefore, it was investigated using 
indirect immunofluoresence, whether or not the Pk-tagged forms of the membrane-bound 
HN and F are also localised to the surface of transfected cells. Furthermore, the correct 
topology of Pk-tagged HN & F within the plasma-membrane, was investigated by analysis of 
cells which had either been fixed only, or fixed then permeabilised.
vTF7-3 infected 293 cells, grown on glass coverslips in 35mm petri dishes, were 
transfected with plasmids expressing; FctPk, HNctPk, HNntPk, native HN and, as a control, 
fi-galactosidase, and processed for indirect immunofluoresence as detailed in the methods 
section. Figure 23 shows that native HN was detected on the surface of transfected cells by a 
pool of anti-HN mAbs, but not with the anti-Pk mAb, as expected. N-terminally Pk-tagged 
HN was detected on the surface of the majority of transfected cells using the pool of anti-HN 
mAbs (figure 24), with only a small number of cells showing a specific staining with the anti- 
Pk mAb [the most likely reason that some cells did show specific staining with the anti-Pk 
mAb, is due to a few cells which have lost their plasma-membrane integrity. This can be 
observed with the staining for the cytoplasmic protein 6-galactosidase (figure 25) where 
transfected monolayers, which were not permeabilised, possessed a small number of cells 
with specific intracellular staining]. Permeabilisation of the pT7HNntPk transfected cells did 
result in the detection of N-terminally Pk-tagged HN in the majority of transfected cells using
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Anti-Pk Anti-HN
Fixed only.
Fixed & 
Penneabilised
Figure 23: Immunofluoresence analysis of untagged HN glycoprotein.
vTF7-3 infected 293 cells were transfected with the vector pT7HN. 12hrs 
post-transfection, cells were fixed only or fixed & permeabilised and incubated with 
anti-Pk or a pool of anti-HN mAbs (lb, 4b & 5d) followed by an incubation with 
Texas Red conjugated anti-mouse Ig. Exposure times are constant.
Anti-Pk Anti-HN
Fixed only.
Fixed & 
Penneabilised.
Figure 24: Immunofluoresence analysis of N-terminally Pk-tagged HN 
glycoprotein.
vTF7-3 infected 293 cells were transfected with the vector pT7HNntPk. 12hrs 
post-transfection, cells were fixed only or fixed & permeabilised and incubated with 
anti-Pk or a pool of anti-HN mAbs (lb, 4b & 5d) followed by an incubation with 
Texas Red conjugated anti-mouse Ig. Exposure times are constant.
Fixed only.
Anti-6 gal
Fixed & 
Permeabilised.
Figure 25: Immunofluoresence analysis of 293 cells expressing fi-galactosidase.
293 cells infected with vaccinia virus vTF7-3 were transfected with the vector 
pCT7figal. 16 hrs post-transfection, cells were either fixed-only or fixed & 
permeabilised then incubated with an anti-Sgal mAb followed by an incubation with 
Texas Red conjugated anti-mouse Ig. Exposure times are constant.
the anti-Pk mAb (figure 24), thus confirming that the Pk epitope was concealed within the
cytoplasm, as expected.
Cells transfected with the vector expressing the C-terminally Pk-tagged HN were 
specifically stained for surface immunofluoresence using both the pool of anti-HN mAbs and 
the anti-Pk mAb, thus confirming the presence of the Pk-tag epitope on the exterior of the 
cell, as expected (figure 26) Permeabilisation of the above transfected cells, also resulted in 
the specific intracellular staining with both the pool of anti-HN mAbs and the anti-Pk mAb.
The majority of pT7FctPk transfected cells, which were fixed only, could be 
specifically stained with the anti-F mAb, with only a small number showed specific staining 
with the anti-Pk mAb, figure 27. The reason for this detection is most likely due to a similar 
situation as described above for the ntPk-tagged HN construct. Permeabilisation of the 
transfected cells resulted in the specific staining of the majority of the transfected cells, by 
both the anti-F & anti-Pk mAbs, thus confirming the presence of the Pk epitope in the interior 
of the cell, as expected (figure 27).
1.2.4 /Oligomeric structure of Pk-taggsrl SV5HN &&.
As previously mentioned, the HN glycoprotein of SV5 forms a mixture of covalently 
and non-covalently linked homotetramers composed of disulphide-linked dimers. The SV5 F 
glycoprotein appears to form non-covalently linked homotrimers. Therefore, it was 
investigated to determine whether or not the Pk-tagged forms of these glycoproteins also 
formed similar oligomeric structures. This was achieved by using non-reducing SDS-PAGE 
and chemical cross-linking analysis for the study of the oligomeric structures of Pk-tagged 
HN and F, respectively. Figure 28 shows WCEs from pT7HNntPk and pT7HNctPk 
transfected cells which have been separated through an SDS-PAGel under reducing (6- 
mercaptoethanol present in the disruption buffer) or non-reducing (fi-mercaptoethanol 
absent) conditions, electroblotted and probed with the anti-Pk mAb. A single band 
representing monomeric Pk-tagged HN was detected in the reduced sample, and to a lesser 
extent in the non-reduced sample. However, diffuse bands corresponding to molecular 
weights of approximately 140 and 280 Kda were detected in the non-reduced sample, but
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Figure 26: Immunofluoresence analysis of C-terminally Pk-tagged HN 
glycoprotein.
vTF7-3 infected 293 cells were transfected with the vector pT7HNctPk. 12hrs 
post-transfection, cells were fixed only or fixed & permeabilised and incubated with 
anti-Pk or a pool of anti-HN mAbs (lb, 4b & 5d) followed by an incubation with 
Texas Red conjugated anti-mouse Ig. Exposure times are constant.
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Figure 27: Immunofluoresence analysis of C-terminally Pk-tagged F 
glycoprotein.
vTF7-3 infected 293 cells were transfected with the vector pT7FctPk. 12hrs 
post-transfection, cells were fixed only or fixed & permeabilised and incubated 
with anti-Pk or anti-F (mAbs followed by an incubation with Texas Red 
conjugated anti-mouse Ig. Exposure times are constant.
1 2 3 4 5 6
2OOKd->-
97Kd-^
68Kd-^
45Kd->-
1) HNctPk + B.M.E.
2) HNntPk + B.M.E.
3) Mock + B.M.E.
4) HNctPk - B.M.E.
5) HNntPk - B.M.E.
6) Mock - B.M.E.
Figure 28: Analysis of the oligomeric structure of Pk-tagged SV5 HN.
vTF7-3 infected 293 cells were transfected with the vectors pT7HNctPk (lanes 1 & 4), 
pT7HNntPk (lanes 2 & 5) or were mock transfected (lanes 3 & 6). 16hrs 
post-transfection WCEs were prepared in disruption buffer in the presence or absence 
of the reducing agent 6-mercaptoethanol (B.M.E.). The WCEs were separated through 
a 10% SDS-PAGel, electroblotted and probed with the anti-Pk mAb. Detection was by 
ECL.
were absent from the reduced sample. These bands correspond to dimeric and tetrameric 
forms of the C and N-terminally Pk-tagged HN.
Chemical cross-linking reactions performed on WCEs from pT7FctPk transfected cells 
were carried out as detailed in the methods section. Results from the chemical cross-linking 
analysis of C-terminally Pk-tagged F are shown in figure 29 and demonstrated that, under 
non-reducing conditions (panel A), specific bands corresponding to monomers (~66Kda), 
dimers (~132Kda) and trimers (-198Kda) were observed. Increasing the concentration of the 
BS cross-linking reagent from 0-5mM influenced the molecular weight of the bands 
detected, ranging from predominantly monomers to predominantly trimers. Analysis of the 
cross-linked extracts under reducing conditions (panel B) demonstrated the reduction of the 
Fo subunits to F i & F2 subunits.
1.2.5 lAntigenicity of Pk-ta^ed SV5 HN & F to mAbs raised against native SV5 HN & F,
which recognise conformationally-dependent epitopes.
Preliminary characterisation of the Pk-tagged glycoproteins has suggested that the 
presence of the Pk-tag did not significantly affect the processing of the Pk-tagged 
glycoproteins through the mammalian-cell exocytotic pathway. However, with a view to 
producing Pk-tagged glycoproteins for immunisation purposes, it was imperative to 
determine whether the Pk-tagged glycoproteins bind to conformationally-dependant mAbs, 
which were raised against the native glycoproteins. This was investigated by performing 
immuneprecipitation experiments.
A panel of 18 mAbs to the SV5 HN glycoprotein and one mAb to the SV5 F 
glycoprotein have been produced and their specificity determined in our laboratory (Randall 
et al., 1987). vTF7-3 infected 293 cells were transfected with the plasmids pT7HNntPk and 
pT7HNctPk. 16hrs post-transfection, soluble cell extracts (SCEs) were prepared and 
immunoprecipitations were performed as detailed in the methods section, using the anti-Pk 
mAb (positive control), anti-DNP mAb (negative control) and 8 anti-HN mAbs; lb, 5d, 5a, 4a, 
z, 4b, 4d & 4f, (where a number/letter refers to the antigenic group that a particular mAb was 
assigned to, see Randall et at., 1987).
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Figure 29: Oligomeric structure of the Pk-tagged form of SV5 F and of a truncated form 
AF, by chemical cross-linking analysis.
vTF7-3 infected 293 cells were transfected with the plasmids pT7FctPk and pT7AFctPk. 12 
hrs post-transfection, SCEs were prepared by lysis of the cells with 1% NP40 in PBS, 
followed by a 1 minute centrifugation at 10,000g. The supernatant was divided into 5 
aliquots one of which was left untreated (lane 1). The other 4 aliquots were incubated, for 
1 hr on ice, with increasing concentrations of the NHS-ester cross-linking reagent BS3 
(lanes 2 to 5). The cross-linking reaction was quenched by the addition of Tris-CL pH 8.0 
to 50mM. The SCEs were then made upto xl disruption buffer (minus 6-mercaptoethanol) 
and separated through a 6% SDS-PAGel under non-reducing conditions (panel A) or 
reducing conditions (plus 6-mercaptoethanol, panel B), electroblotted and probed with 
the anti-Pk mAb. Detection was by ECL.
Figure 30 shows that the N and C-terminal Pk-tagged forms of the HN glycoprotein 
(corresponding to bands detected at ~70Kda) were recognised by 7 out of the 8 anti-HN 
mAbs tested. Lane 7 in panel A and lane 10 in panel B were negative because that particular 
anti-HN mAb (190) was not recognised by protein A present on the fixed and killed S. aureus. 
Bands present at ~55Kda correspond to the heavy chains of the mAbs employed in the 
immune precipitation. An immunoprecipitation analysis of the reactivity of the anti-F mAb 
with C-terminally Pk-tagged F was not performed because, from immunofluoresence data, 
figure 27, it was clear that the anti-F mAb did recognise the Pk-tagged form of F. 
Quantification of the reactivity of the seven anti-HN mAbs to the N and C-terminally Pk- 
tagged forms of the HN glycoprotein, was investigated using phosphoimaging technology. 
This was achieved by separating the immuneprecipitated samples through a 10% SDS- 
PAGel, electroblotting and probing with the anti-Pk mAb as the primary detection agent, 
with 1^5 iodine-labelled anti-mouse immunoglobulin being used as the secondary detection 
reagent. The results were then analysed using a Fuji BAS 1000 phoshoimager. However, 
consistent data was not produced by this approach (data not shown).
1.3 I Construction of vectors Oor the expression of truncated Pk--agged HN & F.
From the preceding results, the addition of the 14 amino acid oligopeptide to the 
termini of recombinantly produced SV5 HN & F glycoproteins did not significantly affect 
their processing through the mammalian-cell exocytotic pathway. Hence, N-linked 
glycosylation, oligomerisation, surface localisation and antigenicity to monoclonal antibodies 
raised against the native glycoproteins, were all retained. For the purpose of large-scale 
recombinant protein production, it may be beneficial to produce recombinant membrane- 
bound glycoproteins which are in a secretable form for increased productivity and ease of 
purification. Therefore, the genes encoding the Pk-tagged HN & F glycoproteins were altered 
such that the expressed proteins should be capable of being secreted from mammalian cells.
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Figure 30: Immuneprecipitation analysis demonstrating the antigenicity of 
transiently expressed Pk-tagged HN glycoproteins for a panel of conformationally 
sensitive anti-HN mAbs.
vTF7-3 infected 293 cells were transfected with the plasmids pT7HNntPk (A) or 
pT7HNctPk (B). 16hrs post-transfection SCEs were prepared in immuneprecipitation 
buffer and aliquots were immuneprecipitated individually with 8 different anti-HN 
mAbs (lanes 3-10), anti-Pk mAb (lane 2) or anti-K3 mAb (-ve control, lane 1). 
Immuneprecipitates were separated through a 10% SDS-PAGel under reducing 
conditions, electroblotted and probed with the anti-Pk mAh. Detection was by ECL. 
(Note - mAb 190, panel A, is not bound by protein A and therefore HN was not 
pulled down. Bands at ~55Kda correspond to immunoglobulin heavy chain).
1.3.1 /Con^^itucCio^ ooveeCorr ffrrt^eexprresio^oofrr^u^cated^I)P^--^^si^(id JOHN (figurr 32).
In collaboration with Dr. Mike Mackett, (Paterson Institute for Cancer Research, Univ. 
of Manchester) the plasmids pT7ctPk and pT7ntPk were altered by the addition of 
oligonucleotides encoding amino acids 1-22 (figure 31) of the EBV major surface glycoprotein 
gp360/220, the sequence of which encodes a putative type I cleavable signal sequence. A 
truncated HN gene from base 109 (amino acid 37, (see appendix A for the ORF sequence of 
SV5 HN)) of the ORF up to and including the C-terminal Pk-tag, was PCR-amplified from the 
plasmid pT7HNctPk. The PGR product was digested with the REs ascl & HindS and ligated 
into the similarly digested vector pT7ctPk/ss (figure 32, B) to produce pT7AHNctPk (figure 
32, C).
ATG GAG GCA GCC TTG CTT GTG TGT GAG TAC ACC 
met glu ala ala leu leu val cys gin tyr thr
ATG GAG AGG CTG ATG GAT GTG AGG GGG GTA GGG 
ile gin ser leu ile his leu thr gly val pro
Figure 31. Putative cleavable signal sequence from the EBV type I glycoprotein gp360/220
To construct the vector pT7AHNntTk, the sequence comprising the HN ORF and N- 
terminal Pk-tag was excised from the plasmid pT7HNntPk using the REs Kpnl & Hind3 and 
ligated into the similarly digested vector pT7ntPk/ss to produce pT7HNntPk/ss. A 
truncated HN gene, from base 109 (amino acid 37) to the 3' end of the HN ORF, was PGR 
amplified from plasmid pT7HNctPk. The PGR product was digested with ascl & afl2 REs 
and ligated into the similarly digested plasmid pT7HNntPk/ss to produce pT7AHNntPk 
(figure 32, C). The plasmids pT7AHNntPk and pT7AHNctPk were sequenced at the 5' and 3' 
ends of the inserted genes to ensure the fidelity of the sequence (data not shown).
1.3.2 /ConcSoucCton of eeCorrfir the exprresionoriouncatoXPk~tau%eX Jf (figurr (0).
To construct pT7AFctPk, a truncated version of the F gene lacking the nucleotides 
coding for the cytoplasmic tail and G-terminal membrane-spanning-domain (bases 1414 to
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Schematic of Secretable forms of Type 1&2 Glycoproteins.
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Figure 32. A Schematic depicting potentially secretable forms of type I and 
type II glycoproteins respresented by the SV5 F and HN glycoproteins 
respectively.
Plasmids pT7ntPk & pT7ctPk (A) were modified by the addition of a putative 
cleavable signal sequence from the Epstein-Barr virus surface glycoprotein gp 220/360, a 
type I glycoprotein (B). A truncated version of the SV5 HN glycoprotein, lacking its N- 
terminal signal sequence and membrane-spanning-domain, was cloned into the modified 
plasmids to produce vectors which should putatively secrete Pk-tagged truncated HN (C). 
A truncated version of the SV5 F glycoprotein, lacking its C-terminal cytoplasmic tail and 
membrane-spanning-domain, was cloned into the plasmid pT7FctPk to produce a vector 
which should putatively secrete C-terminally Pk-tagged F (D). The plasmid for the 
expression of N-terminally Pk-tagged truncated F was not constructed.
1587, amino acids 472 to 529 (see appendix B for the ORF sequence of SV5 F) was PCR 
amplified from the plasmid pT7FctPk. The PCR product was digested with the REs ascl & 
afl2 and ligated into the similarly digested plasmid pT7FctPk to produce the vector 
pT7AFctPk. The full length truncated F gene was sequenced to ensure fidelity of the sequence
(data not shown).
1,4 Transient protein production from the vectors which emco<de truncated Pk-
tagged SV5 HN & F.
1.4.1 /OxprussaonanClocalisanion af thetruncaleSN & (-terminally Pk-tanasSSV5 JHN
1x10* 293 cells were infected with the vaccinia virus recombinant vTF7-3 and 
subsequently transfected with 3Lgs of the expression vectors; pT7HNctPk, pT7HNntPk, 
pT7AHNntPk & pT7AHNctPk, as detailed in the materials and methods section. 16 hrs post­
transfection WCEs were prepared in xl disruption buffer and separated through a 10% SDS- 
PAGel under reducing conditions, transferred to a nitrocellulose membrane by 
electroblotting and probed with the anti-Pk mAb. Figure 33 shows that products of -70Kda 
were detected from cells transfected with vectors encoding the N or C-terminally Pk-tagged 
HN and that doublet bands of -55-60Kda were detected from WCEs transfected with the 
truncated vectors, with a minor band occurring at ~68Kda from transfected pT7AlHNntPk but 
not pT7AHNctPk. A band of < 30Kda was detected from WCEs of cells transfected with the 
truncated C-terminally tagged HN, which is also present from the extract of cells transfected 
with the full length C-terminally tagged HN.
To ascertain whether any AHN was secreted into the external milieu, vTF7-3 infected 
293 cells were transfected with the vectors pT7AHNntPk & pT7AHNctPk. 18hrs post­
transfection the medium was aspirated from the cells, centrifuged at 13Krpm for 1 minute in 
a benchtop microcentaur and an immuneprecipitation carried out using the anti-Pk mAb 
together with a pool of anti-HN mAbs (lb, 4b & 5d), as detailed in the methods section. 
Furthermore, the cellular fraction was washed twice with PBS, detached from the plastic by 
scraping, pelleted, resuspended in immuneprecipitation buffer and incubated with a pool of 
anti-HN mAbs (lb, 4b & 5d). This was performed to ascertain whether the minor band at 
~68Kda reacted with conformationally sensitive anti-HN mAbs. From figure 34, no specific
92
1 2 3 4 5
A
84Kd
67Kd
SSKd
33Kd
DAHNntPk
2) HNntPk
3) AHNctPk
4) HNctPk
5) Mock
1 2 3 4 5
B
84Kd
67Kd
SSKd
33Kd
DAHNntPk
2) HNntPk
3) AHNctPk
4) HNctPk
5) Mock
Figure 33: Transient expression of Pk-tagged truncated HN (AHN) glycoproteins and 
their antigenicity to the anti-Pk mAb.
vTF7-3 infected 293 cells were transfected with the plasmids; pT7AHNntPk (lane 1), 
pT7HNntPk (lane 2), pT7AHNctPk (lane 3), pT7HNctPk (lane 4) or were mock 
transfected (lane 5). 16hrs post-transfection WCEs were prepared in xl disruption buffer 
and aliquots separated through a 10% SDS-PAGel under reducing conditions, 
electroblotted and probed with the anti-Pk mAb followed by detection using ECL. Panel 
A corresponds to a short exposure (lOsec.). Panel B corresponds to a longer exposure (2 
mins.).
pT7sHNntPk 
1 2 3 4 5 6 7
84 Kd 
67Kd 
55Kd
SSKd
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Figure 34: Immuneprecipitation (IP) analysis of ntPk-tagged truncated HN (AHN) 
glyco- protein.
vTF7-3 infected 293 cells were transfected with three different clones of the vector 
pT7AHNntPk. 16hrs post-transfection the medium was aspirated, centrifuged to 
remove cellular debris and IP with anti-Pk mAb and a pool of anti-HN mAbs (lb, 4b & 
5d), (lanes 3, 5 & 7). The cells were washed twice with PBS and SCE were prepared in 
immuneprecipitation buffer and immuneprecipitated as above (lanes 2, 4 & 6). The 
precipitated samples were separated through a 10% SDS-PAGel under reducing 
conditions, electroblotted and probed with the anti-Pk mAh. Detection was by ECL. A 
WCE from cells transfected with pTZHNntPk was also ran for a positive control. Note - 
exposure time for the immuneprecipitates was 15 mins. while only 20 secs, for the 
positive control (bands at ~55Kda correspond to immunoglobulin heavy chain).
bands were observed from the immuneprecipitation analysis performed on the supernatant 
fractions but a band of -68Kda (bands at -55Kda correspond to immunoglobulin heavy 
chain) was detected from the cellular fraction of pT7AHNntPk transfected cells, but not the 
pT7AHNctPk transfected cells (data not shown for pT7AHNctPk).
1.4.2 /Expression and localisation of the truncated C-terminally Pk-tagged SV5 F.
1x103 293 cells were infected with vTF7-3 and then transfected with 3pgs of the 
expression vectors pT7FctPk & pT7AFctPk, as detailed in the methods section. 16 hrs post­
transfection the supernatant fractions were aspirated from the cells, centrifuged at 13Krpm 
for 1 minute in a benchtop microcentaur and the medium was concentrated eight-fold using 
an amicon 30Kda cut-off filter. The cellular fraction was washed twice with PBS, detached 
from the plastic by scrapping, pelleted and then resuspended in xl disruption buffer. After 
sonication, the whole cell extracts (WCEs) along with the unconcentrated and concentrated 
supernatant samples, were separated through a 10% SDS-PAGel under reducing conditions, 
transferred to a PVDF membrane by electroblotting and probed with the anti-Pk mAb. Figure 
35 shows that doublet bands of ~60-63Kda were visible from the cellular fraction after a 
short exposure, and a further 2 bands of -58 & 53Kda were detected after a longer exposure. 
No bands were observed from the supernatant samples.
1.4.3 / N-linked glycosylation analysis of truncated Pk-tag«ed SV5 HN & F.
From figure 33, it could be inferred from the molecular weight of the majority of the 
expressed molecules, that the truncated Pk-tagged HN proteins have not undergone 
extensive post-translational modification. However, indirect evidence for the modification of 
a small proportion of the truncated HPk-tagged HN, could be inferred from the relative 
molecular weight of a minor protein species detected at ~ 68 Kda(figure 33, lanel). This was 
not observed for the truncated Pk-tagged F as shown in figure 35, where the majority of the 
expressed molecules were of a molecular weight which would indicate some form of post­
translational modification has occurred.
To directly ascertain whether the truncated forms of Pk-tagged HN & F were N- 
linked glycosylated, WCEs were treated with PNGase F as described in the methods section.
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Figure 35: Transient expression and localisation of Pk-tagged truncated F (AF) 
glycoprotein.
vTF7-3 infected 293 cells were transfected with the plasmid pT7AFctPk. 16hrs 
post-transfection the medium was aspirated and centrifuged to remove cellular debris. 
An aliquot of this unconcentrated sample was made up to xl disruption buffer. The 
remainder of the medium was concentrated 8-fold using a Amicon 30Kda cut-off 
membrane, where another aliquot was made up to xl disruption buffer. WCEs were also 
prepared in xl disruption buffer (after washing the cells twice with PBS). Samples from 
each preparation were separated through a 10% SDS-PAGel under reducing conditions, 
electroblotted and probed with the anti-Pk mAb followed by detection using ECL. Panel 
A corresponds to a short exposure (20sec.). Panel B corresponds to a longer exposure (2 
mins.). Panel C is an overnight exposure.
Treated and untreated WCEs were separated through a 10% SDS-PAGel under reducing 
conditions, transferred to a nitrocellulose membrane by electroblotting and probed with the 
anti-Pk mAb. Figure 36 shows that when WCEs from pT7AHNctPk and pT7AHNntPk 
transfected cells were treated with the enzyme PNGase F, the molecular weight of the minor 
~68Kda band from the ntPk-tagged AHN expressed product was decreased by -5Kda (lane
2) directly indicating that the ntPk-tagged glycoprotein had undergone N-linked 
glycosylation, albeit on only a small fraction of the expressed molecules. No reduction in 
mwt. was observed for the ct Pk-tagged AHN protein when incubated with PNGase F (lane 
4). Furthermore, figure 22 shows that when WCEs from cells transfected with DNA encoding 
the truncated form of the Pk-tagged F are incubated with PNGase F, a decrease in the relative 
molecular weight is observed in the majority of the detectable molecules indicating the 
presence of N-linked oligosaccharides.
1.4.4 / Olopomcsio sSruutunu of ((C^ti^^ihiaUool^^k-tr^ns^sS^ j^^runcalrS (V5 F.
Chemical cross-linking analysis was performed as detailed in the methods section.
Results from the chemical cross-linking analysis of C-terminally Pk-tagged truncated SV5 F 
are shown in figure 29 and demonstrated that, under non-reducing conditions, specific bands 
corresponding to monomers (-62Kda) and dimers (~124Kda) were produced. However, the 
gel was too smeared to be able to determine whether trimers (-188Kda) were formed. 
Increasing the concentration of the BS* cross-linking reagent from 0-5mM influenced the 
molecular weight of the bands detected, ranging from predominantly monomers through to 
dimers and possibly trimers. The cross-linked extracts were also analysed under reducing 
conditions but no further evidence for the formation of trimers could be inferred.
1.51 Swnmnuy.
Preliminary evidence suggests that:
a) The presence of the Pk--ag at tHe t^r^mirai of HN and F diil not prevent their transient 
expression and subsequent detection with the anti-Pk mAb.
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Figure 36: PNGase F analysis of Pk-tagged truncated SV5 HN (AHN) glycoproteins.
vTF7-3 infected 293 cells were transfected with the vectors; pT7AHNntPk (lanes 1 & 2), 
pT7AHNctPk (lanes 3 & 4) and pT7HNntPk (lanes 5 & 6). 16hrs post-transfection, 
WCEs were prepared in disruption buffer. Half of the samples were treated with the 
enzyme PNGase F, as detailed in the methods. Untreated /treated extracts were 
separated through a 10% SDS-PAGel under reducing conditions, electroblotted and 
probed with the anti-Pk mAh. Detection was by ECL.
b) The Pk-tag was not apparently degraded, or clipped from the Pk-tagged HN & F proteins, 
by proteolytic activity from mammalian-cell proteases, or proteases encoded by the vTF7-3
vaccinia virus.
c) Addition of the Pk-tag to the C-terminus of SV5 F did not prevent signal peptidase 
cleavage of the signal sequence to produce the type I glycoprotein topology,
d) Addition of the Pk-tag to the C-terminus of the F glycoprotein did not prevent the post­
translational proteolytic cleavage of F o to the disulphide-linked Fi & F2 subunits.
e) The Pk-tagged HN and F glycoproteins were post-translationally modified by the addition 
of 6-10 Kda of N-linked oligosaccharides.
f) The presence of the Pk-tag did not prevent the surface localisation and oligomerisation of 
the Pk-tagged HN & F glycoproteins.
g) The presence of the Pk-tag did not prevent the recognition of the Pk-tagged HN & F 
glycoproteins by conformationally sensitive mAbs, which were raised against the native 
glycoproteins.
h) Truncated forms of Pk-tagged HN & F were not secreted in a detectable form..
i) AHNntPk was only N-linked glycosylated in a small proportion of the detected molecules. 
There was no evidence for N-linked glycosylation of the AHNctPk protein.
j) The majority of AFctPk molecules were not in an oligomeric form, as determined by 
chemical cross-linking analysis.
SECTION 2 : ATTEMPTS AT PRODUCING CELL-LINES WHICH
EXPRESSED Pk-TACCED SV5 HN. ....... ... .. .... ....... .....
As demonstrated above, transient production and subsequent characterisation of Pk- 
tagged HN & F glycoproteins was achieved by utilising the vaccinia virus/T7-RDRP 
expression system. However, although this system is excellent for transient protein 
production for the initial characterisation studies, it can not be used for the production of 
stabily expressing cell-lines with a view to the scale-up of protein production. For this
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purpose, promoters which are recognised by endogenous cellular RNA polymerase II are 
utilised in plasmid vectors for the construction of stabily expressing cell-lines.
2.1 / Attempts at the construction of cell-lines which tnnstitnUivsOy expressed Pk-
tagged SV5 HN.
The hCMV IE enhancer/promoter and RSV LTR are commonly used for driving gene 
expression in a variety of mammalian cells. Vectors containing these promoters, and 
sequences from Epstein-Barr virus for the episomal maintenance of the plasmid, were 
initially used in an attempt to produce stabily expressing Pk-tagged HN cell-lines. For details 
on EBV-based vectors see chapter 3 in the introduction.
2.1.1 /Cnnstunatinn nfXBVtbnssd vsatnus which snands C - tsuminnOOy Pktrnaasd SV5 HN.
Two EBV-based vectors, pREP4 (RSV LTR) and pCEP4 (hCMV IE enhancer/ 
promoter), were initially used to try and produce cell-lines which stabily expressed C- 
terminally Pk-tagged HN. The plasmids pREP4HNctPk and pCEP4HNctPk (figure 37) were 
constructed by digestion of the plasmid pT7HNctPk with the REs Kpnl and Hind3 with the 
insert containing the gene encoding the HNctPk glycoprotein being ligated into the similarly 
digested EBV-based vectors. The 5' and 3' regions of the sequence coding for Pk-tagged HN, 
within the plasmids pREP4HNctPk and pCEP4HNctPk, were sequenced to ensure fidelity of 
ligation.
2.1.2 / Tunnsisnt runtsin rundnatinn fenm ths vsatnus rRXP4HNatPk nnd rCXP4HNatPk.
293 and 293/E (constitutively express the Epstein-Barr virus EBNA-1) cells were 
transfected with the expression vectors pREP4HNctPk and pCEP4HNctPk, as detailed in the 
methods section. At 24, 36 and 48hrs post-transfection, the cells were processed for; Western 
blot analysis of WCEs, immuneprecipitation analysis of SCEs (using a pool of anti-HN mAbs 
(lb, 4b & 5d) & the anti-Pk mAb) or immunofluoresence analysis (again using anti-HN & 
anti-Pk mAbs). However, no protein production could be detected from either vector, 
transfected into either of the cell-lines, harvested at any of the times specified post­
transfection, using the aforementioned means of detection (data not shown). Transfection
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Figure 37: Construction of the EBV-based vectors which express the C-terminally 
Pk-tagged SV5 HN g’protein from the hCMV IE enhancer/promoter.
The plasmid pT7HNctPk was digested with the REs Kpnl & Hind3, and the gene 
encoding the C-terminally Pk-tagged HN glycoprotein was ligated into the similarly 
digested EBV-based vector pCEP4z producing the vector - pCEP4HNctPk (-><-). 
pCEP4HNctPk (-><-) was digested with the RE Sail, ligated and the vector pCEP4HNctPk 
(->->) was isolated in which the the HNctPk transcription unit was in the reverse 
orientation.
efficiency was monitored, in this experiment and throughout the work, by transfection of 
cells with the vector pCT76gal which encodes the 6-galactosidase gene, where expression is 
driven by the hCMV major IE promoter. Transfection efficiencies were consistently in the 
range of 10-25% as determined by the iSgal assay (details of this assay are given in the
methods section).
2.1.3 /Attempts at the production of stabily expressing cell-lines using the vectors
pREP4HNctPk and pCEP4HNctPk.
Although no protein production could be detected in a transient expression analysis, 
drug-resistant cell-lines were produced as detailed in the methods section. This step was 
carried out in the hope that expression levels in a transient assay were too low to be readily 
detectable, and that if the majority of cells within a given population were expressing the Pk- 
tagged HN then detectable levels of protein may be produced. Briefly, 1x103 293 or 293/E 
cells were transfected with the above vectors. 48hrs post-transfection, the cells were passed 
into 12cm diameter petri dishes and the selective agent, hygromycin B, was added. 24 
individual colonies were ring-cloned and expanded, with a master culture being prepared 
from the remaining colonies. Both the 24 individual cell-lines and the master cultures were 
analysed for protein expression using the techniques as described above. No production of 
Pk-tagged-HN was detected in any cell-line or master culture.
2.1.4 /Construction of the EBV-based vector encoding C - terminally Pk-tasged SV5 HN with
a reversed transcription unit (figure 38).
Young et al. (1988) have observed that, at least for the EBV-based vector & gene of 
interest (goi) in use by them, the orientation of the goi transcription unit in relation to the 
transcription unit of the EBNA-1 gene was critical to the successful expression of the goi. 
When the goi transcription unit was in an opposite orientation to that of the EBNA-1 
transcription unit then expression was negligible. However, upon reversing the goi 
transcription unit, high levels of expression of their goi was achieved. The HNctPk 
transcription unit within the vector pCEP4HNctPk was in this "unfavourable orientation". 
Therefore, the transcription unit of HNctPk was reversed to produce the more "favourable"
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orientation. This was achieved by digesting the vector pCEP4HNctPk (now termed 
pCEP4HNctPk (-><-) to signify that the two transcription units are running in opposite 
directions) with Sail and religating the two fragments together where 50% of recombinants 
should have the transcription unit in the reversed direction. Such recombinants were 
determined by a diagnostic RE digestion. The vector in which the two transcription units are 
in the "favourable" orientation was designated pCEP4HNctPk
2.1.5 I TrancaosCprufrio prundction f(um the vestrfpCEPk4IHctUk (->->).
293/E cells were transfected with the expression vector pCEP4HNctPk (->->), as 
detailed in the methods section. At 24, 36 and 48hrs post-transfection, the cells were 
processed for; Western Blot analysis of WCEs, immuneprecipitation analysis of SCEs (using 
anti-HN & anti-Pk mAbs) or immunofluoresence analysis (again using anti-HN & anti-Pk 
mAbs). However, no protein production could be detected from WCEs from cells transfected 
with the more "favourable" vector, harvested at any of the times specified post-transfection, 
using the aforementioned means of detection (data not shown). Due to the lack of detecting 
protein expression, and the poor result from producing drug-resistant cell-lines with the 
previous vector when an initial transient result was negative, the isolation of drug-resistant 
cell-lines from cells transfected with the vector pCEP4HNctPk (->->) was not attempted.
2.2 I Construction, of transse^!: expression vectors which produce Pk--agged SV5
HN via an hCMV IE promoter.
Due to the inability to detect recombinant protein production from the EBV-based 
vectors described above, an alternative vector, pcDNAl/amp (figure 38), was employed to 
try and detect protein production driven by the hCMV IE enhancer/promoter in a transient 
assay. This vector had the advantage over the EBV-based vectors in that downstream of the 
hCMV IE enhancer/promoter was the T7{10 promoter which could be used as a control for 
Pk-tagged HN expression. Furthermore, pcDNAl/amp also possesses the simian virus 40 
origin of replication, which should result in the amplification of the plasmid when 
transfected into Cos cells (which express the SV40 large T antigen) with a subsequent 
increase in protein production. Furthermore, n-terminally Pk-tagged HN was also tested for
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Figure 38: Construction of the vectors which express the Pk-tagged SV5 HN g’proteins 
from the hCMV IE enhancer/promoter.
The plasmids pT7HNctPk & pT7HNntPk were digested with the REs EcoRl & Sphl, and 
the genes encoding the Pk-tagged HN glycoproteins were ligated into the similarly 
digested vector pCT7 (pcDNAl/amp), producing the vectors - pCT7HNntPk & 
pCT7HNctPk.
expression under the hCMV IE promoter since a lack of expression from the previous 
experiments may be due to an inherent property of the c-terminally Pk-tagged HN.
2.2.1 / Construction of pcDNA-hased vectors for the transient production of N & C-
terminally Pk-tas«ed SV5 HN (figure 38).
The expression vectors pCT7HNctPk and pCT7HNntPk were constructed by 
digestion of the plasmids pT7HNctPk & pT7HNntPk with the restriction endonucleases 
EcoRl & Sphl. The inserts containing the genes encoding the HNctPk and HNntPk 
glycoproteins were ligated into the similarly digested plasmid pcDNAl/ amp. Positive 
recombinants were screened by a diagnostic restriction endonuclease digestion analysis.
2.2.2 /Production ofN & C-terminally Pk-tagged SV5 HN from the pcDNA-based vectors.
To test whether the pcDNA-based constructs expressed Pk-tagged-HN glycoproteins, 
expression was initially driven from the T701O promoter, in combination with the 
recombinant vaccinia virus encoding the T7-RDRP. Figure 39 shows the result of analysing 
WCEs from transfected 293 cells which were separated through an SDS-PAGel, electroblotted 
and probed with the anti-Pk mAb. Bands of -70 Kda were easily detected from cells 
transfected with two different clones of the pCT7HNctPk & pCT7HNntPk constructs.
Since the Pk-tagged-HN glycoproteins could be detected when expression was driven 
from the T701O promoter, the ability to detect tagged-HN when expression was driven by the 
hCMV IE enhancer/promoter, when transfected into 293 or Cos-7 cells, was investigated. The 
transfections were performed in combination (in a 1:1 ratio) with a plasmid (pMHVA) 
expressing the adenovirus VAl product, (with or without 2-amin0pur-ne, 2-ap, added 32hrs 
post-transfection) or with the plasmid pUC19 (for details of the influence of VAI and 2-ap on 
transcription/translation, see chapter 4 in the introduction). Figure 40 shows the result of 
preparing WCEs 48hrs post-transfection and processing as for the T7 driven analysis above. 
No bands could be detected even after an overnight ECL exposure.
Furthermore, since proteolytic cleavage of the Pk-tag epitope maybe occurring and 
thus preventing detection of expressed protein by Western blot analysis using the anti-Pk 
mAb, an indirect immunofluoresence analysis using anti-Pk or a pool of anti-HN mAbs (lb,
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Figure 39: Transient expression of Pk-tagged HN glycoproteins from the 
pcDNA-based vectors under control of the T7 promoter.
vTF7-3 infected 293 cells were transfected with 2 clones of the plasmids pCT7HNctPk 
(lanes 1 & 2) & pCT7HNntPk (lanes 3 & 4), or were mock transfected (lane 5). 16hrs 
post-transfection WCEs were prepared in xl disruption buffer and were separated 
through a 10% SDS-PAGel under reducing conditions, electroblotted and probed with 
the anti-Pk mAb followed by detection using ECL. Clone 2 of pCT7HNctPk and clone 1 
of pCT7HNntPk were used for further analysis (see below).
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Figure 40: Transient expression of Pk-tagged HN glycoproteins from the pcDNA-based 
vectors under control of the hCMV major IE enhancer/promoter.
293 cells were transfected with the plasmids pCT7HNctPk (lanes 2 & 3) & pCT7HNntPk 
(lanes 4-6) in combination with a 1:1 ratio of the adenovirus VAI-expressing plasmid 
pMHVA (lanes 3, 5 & 6) or pUC19 (lanes 2 & 4). 32hrs post-transfection 2-aminopurine 
(2-AP) was added to a final concentration of lOmM to one set of transfections (lane 6). 
48hrs post-transfection WCEs were prepared in xl disruption buffer and were separated 
through a 10% SDS-PAGel under reducing conditions, electroblotted and probed with the 
anti-Pk mAb followed by detection using ECL (exposure was overnight). As a positive 
control, an extract of T7 expressed (via vaccinia virus, V/V) HNctPk was included.
4b & 5d) was carried out. Unfortunately, no expression of HN was detected in transfected 
Cos-7 or 293 cells, even with the anti-HN mAbs (data not shown).
To ascertain whether the hCMV IE enhancer/promoter was functional, the gene 
encoding the enzyme J-galactosidase was cloned into the vector pCTZHNctPk, thereby 
replacing the HNctPk gene. This vector, pCT7figal, was transfected into 293 or Cos-7 cells 
and 48hrs post-transfection the cells were stained for evidence of E-galactosidase activity, as 
detailed in materials and methods. Between 20-30% of the cells stained blue indicating a 
functional hCMV IE enhancer/promoter element (data not shown).
2.3 I Attempts at the construction of cell-lines which inducibly expressed Pk-
tagged SV5 HN.
Due to the inability to detect the production of Pk-tagged HN when transcription was 
driven by the hCMV IE enhancer / promoter or the RSV LTR, an alternative, inducible, 
expression system first developed by Gossen & Bujard based upon the tetracycline 
transactivator, was employed (for details of this system see chapter 3 in the introduction). 
This approach was chosen due to the above failures when expression was driven from a 
constitutive promoter and from findings from other groups (R.A. Lamb, personal 
communication) in which stable cell-lines which constitutively express SV5 HN could not be 
isolated. Therefore, this may indicate that the SV5 HN protein is toxic to cells if expressed 
constitutively.
2.3.1 /ConstruciinnofpTTT vecOorswhinit torsofu N & C- OicininsllyPk-taztttC 0V5 JHN.
The plasmids pTETHNctPk and pTETHNntPk (figure 41) which encode Pk-tagged 
HN under the control of the tetracycline responsive promoter (TRP) were constructed by 
digestion of the plasmids pCTZHNctPk & pCT7HNntPk with the restriction endonucleases 
EcoRl and Xbal. The inserts containing the genes encoding the HNctPk or HNntPk 
glycoproteins were ligated into the similarly digested pTET vector (pUHD 10-3). The 5' 
region of the sequence encoding the Pk-tagged HN, within the plasmids pTETHNctPk and 
pTETHNntPk, was sequenced to ensure fidelity of ligation.
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Figure 41: Construction of the vectors which inducibly express Pk-tagged SV5 HN 
glycoproteins.
The plasmids pCT7HNctPk & pCT7HNntPk were digested with the REs EcoRl & Xbal, 
and the genes encoding the Pk-tagged HN g'proteins were ligated into the similarly 
digested vector pTET, producing the tetracycline-responsive vectors - pTETHNntPk & 
pTETHNctPk.
2.3.2 /Tuasticst psnicis psnUcoiins fsnm ihc ecoinst pTETHNotPk asU pTETHNctPk.
293/E cells were transfected with the expression vectors pTETHNctPk and 
pTETHNntPk and the driver plasmid pMR-tTa/neo (in a 1:1 ratio), in the absence of 
tetracycline, as detailed in the methods section. The plasmid pMR-tTa/neo, figure 44, 
expresses the tTa transactivator as an in-frame fusion protein with the neor gene. The two 
genes are separated by a sequence coding for the foot & mouth disease virus 2A cleavage site 
which is cleaved, co-translationally, resulting in the separation of the fusion protein into the 
two active gene products: tTa & neo1 (Precious ci al., 1995). At 48hrs post-transfection, the 
cells were processed for Western blot analysis of WCEs and immuneprecipitation analysis of 
SCEs (using the anti-Pk mAb). Figure 43 shows that a band of ~70Kda was clearly detectable 
from extracts of cells transfected with the vector encoding the N-terminally Pk-tagged HN 
glycoprotein. However, no band was detected from extracts of cells transfected with the 
plasmid encoding the C-terminally Pk-tagged HN glycoprotein.
2.3.3 / Oncttscotwc nfpTEP4 ecoinst which cconUc N & 0- tcsmically Pk-taggcU SV5 HN.
The pTET vectors do not possess drug-resistant markers and are not stabily retained 
as episomes in the nucleus of cells. Therefore, the pTETHNct & pTETHNntPk vectors were 
altered by the addition of the EBV-based backbone from the pCEP4 series of vectors. The 
plasmids pTETHNctPk & pTETHNntPk were digested with the RE Hind3 and a dsDNA 
oligonucleotide containing an Xhol RE site and Hind3 cohesive-ends was ligated into the 
digested vectors to produce the plasmids, pTETHNctPk/X2 and pTETHNntPk/X2. These 
plasmids were then digested with the RE Xhol, with the inserts containing the transcription 
unit encompassing the TRP/HNct or ntPk/SV40 pA being ligated into the EBV-backbone of 
the vector pCEP4HNctPk (->->), which had been previously digested with the RE Sail. The 
orientation of the inserted transcription unit in relation to the direction of transcription of the 
EBNA-1 gene was determined by a diagnostic restriction endonuclease digestion. Plasmids 
of both orientation were chosen for further analysis and were designated: pTEP4HNctPk (->- 
>) & (-><-) and pTEP4HNntPk (->->) & (-><-), (figure 42).
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Figure 42: Construction of EBV-based vectors for the inducible expression of Pk-tagged 
SV5 HN glycoproteins.
T ▼
A second Xhol RE site was incorporated into the plasmids pTETHNctPk & 
pTETHNntPk via a dsDNA oligonucleotide linker which was ligated into the Hind3 
digested vectors. The TRP/HN/pA transcription units were excised from the 
plasmids by a Xhol digestion and cloned into the EBV-backbone of the Sail digested 
vector pCEP4HNctPk (->->) to produce the vectors pTEPHNntPk (->->) & (-><-) and 
pTEPHNctPk (->->) & (-><-). Orientations were determined by a diagnostic RE 
digestion. (->->) orientations are not shown.
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1) pT7HNntPk (WCE).
2) Mock (WCE).
S) pTETHNntPk (IP).
4) pTETHNctPk (IP).
5) pTEP4HNntPk (->->) (IP).
6) pTEP4HNctPk (->->) (IP).
7) Mock (IP).
8) pTETHNntPk (WCE).
9) pTETHNctPk (WCE).
10) pTEPHNntPk (->->) (WCE). 
11 ) pTEPHNctPk (->->) (WCE).
Figure 43; Transient expression analysis of Pk-tagged SV5 HN expressed from a 
tetracycline responsive promoter.
293/E cells were transfected with the plasmids; pTETHNntPk (lanes 3 & 8), pTETHNctPk 
(lanes 4 & 9), pTEP4HNntPk (-> ->) (lanes 5 & 10), pTEP4HNctPk (-> ->) (lanes 6 & 11), in 
a 1:1 ratio with the tTa driver plasmid pMR-tTa/neo, or were mock transfected (lanes 7 & 
12). 48 hrs post-transfection, WCEs were prepared in disruption buffer from which an 
aliquot was adjusted to xl disruption buffer. The remainder of the extract was centrifuged 
and the resulting SCEs was immuneprecipitated (IP) using the anti-Pk mAb together with 
a pool of anti-HN mAbs (lb, 4b & 5d). Samples of both the WCEs (lanes 8-12) and the IPs 
(lanes 3-7) were electrophoresed through a 10% SDS-PAGel, electroblotted and probed 
with the anti-Pk mAh. Detection was by ECL. A WCE from vTF7-3 infected 293 cells 
transfected with the plasmid pT7HNctPk, was included as a positive control (lane 1).
2.3.4 I Tsasticict punicis psnUuotinc fsnm thc ecoinst pTEP4HNotPk (->->) asU pTEP4HN-
ctPk (->->).
293/E cells were transfected with the expression vectors pTEP4HNctPk (->->) & 
pTEP4HNntPk (-> ->) and the driver plasmid pMR-tTa/neo (in a 1:1 ratio) in the absence of 
tetracycline, as detailed in the methods section. At 48hrs post-transfection, the cells were 
processed for Western blot analysis of WCEs and immuneprecipitation analysis of SCEs 
(using the anti-Pk mAb). Figure 43 shows the result of separating the WCE or 
immuneprecipitate through a 10%o SDS-PAGel, electroblotting and probing with the anti-Pk 
mAb. A band of ~70Kda is clearly detectable from extracts of cells transfected with the vector 
encoding the N-terminally Pk-tagged HN glycoprotein. However, as with the pTETHNctPk 
vector, no band was detected from extracts of cells transfected with the EBV-based plasmid 
encoding the C-terminally Pk-tagged HN glycoprotein. Immunofluoresence analysis in 293 
cells, using a pool of anti-HN mAbs (lb, 4b & 5d), also failed to detect any expression from 
the pTEP4HNctPk (->->) construct (data not shown).
2.3.5 I Attcmpt at thc rtiablishmcsi nf ttablc oclltlicct whioh icUuoibly cxpscttcU N-
irsmisally Pk-taggcU SV5 HN titicz thc ecotnst pEBVtiTa/srf & pTEP4HNntPk (->->).
1x10r 293 cells were transfected with the EBV-based vectors pEBV-TTa/neo (a 
modified version of the vector pMR-tTa/neo, in which EBV sequences have been added to 
the vector for episomal maintenance, B. Precious Univ. of St. Andrews) and pTEP4HNntPk 
(->->) in a 1:1 ratio in the presence of 3|pgmT1 tetracycline. Forty eight hours post-transfection, 
the cells were passed into 12cm diameter petri dishes and the selective agents, G418 and 
hygromycin B were added, again with tetracycline present. After 4 weeks in the selective 
medium only one colony was produced. This single colony was analysed for expression of 
HNntPk and tTa by immunofluoresence analysis using anti-VP16 anti-serum (recognises the 
acidic domain of VP16 from Herpes simplex virus, which comprises one half of the tTa fusion 
protein. For more detail on tTa see chapter 4 in the introduction) and anti-HN (lb, 4b & 5d) & 
anti-Pk mAbs. However, no expression could be detected for either proteins (data not 
shown).
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Due to only one drug-resistant colony being produced from the transfection/selection 
procedure, two approaches to try and increase the number of colonies produced, and 
therefore the probability of isolating HNntPk expressing cells, were adopted.
(1) 293 cells which constitutively express the EBV EBNA-1 protein (293/Es) were utilised to 
try and increase the number of drug-resistant colonies produced. [Cell-lines which express 
EBNA-1 appear to better facilitate the isolation of stable cell-lines when employing EBV- 
based vectors. This is most probably due to the initial presence of the EBNA-1 protein in the 
nucleus, which aids in the replication of the incoming EBV-based vectors and thus of their 
stable maintenance]. Unfortunately, these 293/E cells expressed the neor gene product and 
are thus G418 resistant. Therefore, the various tTa/neo constructs developed in our 
laboratory could not be employed, and new vectors possessing the gene encoding 
hygromycin B phosphotransferase (tTa/hygB) were constructed, as detailed in section 2.3.6. 
Furthermore, since the inducibly expressing HNntPk EBV-based plasmids encode a gene for 
resistance to hygB then new EBV-based vectors were constructed in which resistance was 
conferred by the histidinol dehydrogenase gene, see section 2.3.7( the construction of these 
particular vectors was also necessary for experiments performed in section 3 in which the 
presence of an SV40 ori was required).
(2) The production of a 293-based cell-line which constitutively expressed high levels of the 
tTa protein from the EBV-based vector pEBV-tTa/neo was attempted (as detailed in section 
2.3.8). This should render the 293 cells EBNA-1 expressing and should thus aid in the 
isolation of drug-resistant colonies, as described above. Furthermore, since the cells will 
already be constitutively expressing the tTa protein, this will result in only the one large 
EBV-based plasmid (pTEP4HNntPk (->->)-hygr, or pTEPSIHNntPk (->->)-hisr (will be 
described in section 2.3.7)) being transfected, thus increasing the transfection efficiency.
2.3.6 ICoosatucCioo of, andexpressioo^ f room occtorrTvl^ic^^ encode tTya/h/gB.
The gene encoding hygB was PCR amplified from the vector pCEP4 together with the 
thymidine kinase pA sequence using primers which had Apal RE sites incorporated. The 
PCR product was subsequently digested with Apal and ligated into the similarly digested
103
vector pMRlOl, thereby replacing the neor gene, SV40pA and polyoma origin of replication 
to produce the plasmid pMR-2A/hygB (figure 44). The gene encoding the tTa fusion protein 
was excised from the plasmid pMR-tTa/neo using the REs BamHl & Afl2 and ligated into 
the similarly digested plasmid pMR-2A/hygB to produce the vector pMR-tTa/hygB (figure 
44). This vector was tested in a transient expression assay together with the vector 
pTEP4HNntPk (->->) in 293/E cells. N-terminally Pk-tagged HN could be detected from a 
WCE used in a Western blot analysis when probed with the anti-Pk mAb (data not shown).
As with the vector pMR-tTa/neo, pMR-tTa/hygB has to integrate into the cellular 
genome before drug-resistant cells can be produced. Therefore, pMR-tTa/hygB was modified 
by the addition of EBV sequences for the episomal maintenance of the vector in primate-cell 
nuclei. Thus, pMR-tTa/hygB was digested with the REs Spel & Sfil and the tTa/hygB 
transcription unit was ligated into the plasmid pREP8 which had been digested with the REs 
Tbal & Sfil, producing the vector pEBV-tTa/hygB (figure 45). This vector was also tested in 
a transient expression assay and shown to express functional tTa (figure 50).
For future experiments (see section 3), a driver plasmid without the SV40 origin of 
replication and which can only integrate into the cellular genome was required. Therefore, 
pMR-tTa/hygB was digested with the REs Spel & Sfil and the tTa/hygB transcription unit 
was ligated into the plasmid pGEM-9zf(-) which had been digested with the REs Spel & Sfil, 
producing the vector pGEM-tTa/hygB (figure 45). This vector was also tested in an 
expression assay as detailed below, and shown to express functional tTa (figure 46).
Furthermore, to ensure that the hygB1 gene product was expressed and functional, 
stable cell lines expressing E-galactosidase were constructed as follows. 1x10^ 293/E cells 
were transfected, in the presence of tetracycline, with the vectors pGEM-tTa/hygB & 
pTETfigal (pUHD-15) in a 1:1 ratio. 48 hrs post-transfection hygB was added to the 
transfected cells and to naive cells. All the cells in the control plate were dead within 1 week, 
and drug-resistant colonies grew within 2 weeks from the transfected pool of cells (thereby 
demonstrating the presence of a functional hygBr gene product). These colonies were mixed 
together to form a drug-resistant master culture. The cells were seeded into two 35mm petri 
dishes, with tetracycline either absent or present. Cells were fixed 36hrs later and stained for
104
Apal
HygB/TK pA
I-------------------- ---------- H--------1
(PCR from pCEP4)
Apal
Ligase
Afl2BamHl
Ligase
BamHl/
vAfl2
„ ... ■ 
tTa/2A
I
Figure 44: Construction of the vector for the co-translation of tTa and hygB.
The open reading frame of hygB and the TK pA were PCR amplified from the vector 
pCEP4 using primers which contained Apal RE sites. The PCR product was digested 
with Apal and subsequently ligated into the similarly digested vector pMRIOl. The 
DNA sequence encoding tTa/2A was excised from the vector pMR-tTa/ neo using 
the REs BamHl & Afl2 and ligated into the similarly digested plasmid, pMR-2A/hygB 
to produce the vector pMR-tTa/hygB.
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Figure 45: Construction of pEBV-tTa/hygB and pGEM-tTa/hygB vectors.
The DNA sequence containing the transcription unit encoding the tTa/hygB fusion 
protein was excised from the plasmid pMR-tTa/hygB using the REs Spel & Sfil, and 
ligated into the similarly digested plasmid pGEM-9zf(-) to produce the vector 
pGEM-tTa/hygB. The EBV-based vector pREP8 was digested with the REs Xbal & Sfi 1 
and the insert excised from pMR-tTa/hygB was ligated into the plasmid to produce 
the vector pEBV-tTa/hygB.
A)
B)
v
Figure 46: Functional analysis of tTa & hygromycin B phosphotransferase (hygB PT).
293 cells were transfected with the plasmids pGEM-tTa/hygB and pTRPSgal in the 
presence of tetracycline (3pg/ml). 48 hrs post-transfection, transfected cells, and an 
untransfected control population, were incubated in medium containing hygromycin B 
(and tetracycline) at a final concentration of 250|iLg/ml. Within two weeks of incubation in 
selective medium all the control cells had died. Approximately 50 colonies grew from the 
transfected cell population, thereby demonstrating the production of functional hygB PT. 
The colonies were passed into two 35 mm petri dishes, in the presence (panel B) or 
absence (panel A) of tetracycline. 48 hrs post-passing the cells were fixed and stained for 
detection of 6-galactosidase, as detailed in the methods section.
E-gal activity as detailed in materials and methods. Figure 46 clearly shows the expression of 
E-gal in cells grown in the absence of tetr, with very little E-galactosidase activity being 
evident from the cells grown in the presence of tetr.
2.3.7 / Cnctisuoiifc nf, acU cxpscstifs fsnm, thc EBV-batcU ecotnst whioh icUuoibly
cxpscttcU thc HNctPk gl■^cfpsficic acU oncfcs sctittacoc tn h/siiUisfl (figusc 47).
The vectors pTEP8HNntPk (->->) & (-><-) were constructed as follows. The 
transcription unit encompassing the hCMV IE promoter/P gene/pA was excised from the 
plasmids pCEP8/P (->->) & (-><-) using the RE Sail. The transcription unit comprising the 
TRP/HNntPk/pA was excised from the plasmid pTETHNntPk using the RE Xhol and 
ligated into the EBV-backbone of the Sail digested pCEP8/P (->->) & (-><-) vectors to 
produce the desired plasmids pTEPSHNntPk (->->) & (-><-). pTEPSHNntPk (->->) was 
shown to express HNntPk, initially via an immunofluoresence analysis using anti-Pk mAb 
(figure 48). [A comparison of the levels of HNntPk protein produced when expressed from 
the two vectors was performed via a transient expression assay, see section 2.4].
2.3.8 nf ocII-I/ccs whioh ofcttiiuiiecly cxpscttcU tTa fsnm ac rpitnisally
maisiaiccU EBV-batcU ecoifs.
1x101 293 cells were transfected with 3jigs of the vector pEBV-TTa/neo. 48hrs post­
transfection the cells were passed into a 25cm1 flat and geneticin was added to a 
concentration of 400jLigmlH Resistant cells had begun to grow approximately 1 week later 
when the drug-resistant population were pooled together and seeded into individual wells of 
a 96-well dish, at ~ 10-20 cells per well. Individual wells were then screened for tTa 
expression by immunofluoresence using the anti-VP16 anti-serum. The clone showing the 
most number of cells expressing tTa at the highest level was then passed into a 12cm 
diameter petri and individual colonies (10 in total) were ring-cloned and screened for tTa 
expression as detailed above. 4 clones & 1, 92, 93 & showing variable levels of tTa 
expression (figure 49) were further analysed. To confirm that the tTa produced is of the 
correct mwt., and to compare the level of tTa expression between the four clones, a Western 
blot analysis, was performed. WCEs from the four tTa expressing cell-lines were prepared in 
1% NP40 and their protein content was assayed using the BCA method. The WCE was
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Figure 47: Construction of LTAg-amplifiable EBV-based vectors which inducibly 
expressed N-terminally Pk-tagged SV5 HN.
The plasmids pCEP8/P (->->) & (-><-) were digested with the RE Sail and the 
transcription unit TRP/HNntPk/pA was excised, from the plasmid pTETHNntPk/X2 
via a Xho 1 digestion, and ligated into the Sal 1 digested vectors.
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Figure 48: Immunofluoresence analysis of pTEP8HNntPk (->->) transfected 293/E 
cells.
293/E cells were transfected with the vectors pTEP8HNntPk (->->) & 
pGEM-tTA/hygB (1:1 ratio) or pCEP4 & pGEM-tTA/hygB (1:1 ratio, mock 
transfection). 48hrs post-transfection, cells were fixed & permeabilised then 
incubated with the anti-Pk mAb followed by an incubation with Texas Red 
conjugated anti-mouse Ig. Exposure times are constant. Low magnification xlO. 
High magnification x40.
Anti-VP16 DAPI-
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Figure 49: Immunofluoresence analysis of 4 isolated 293-based cell-lines transfected 
with an EBV-based plasmid producing the tTa protein.
293 cells were transfected with the vector (pEBV--Ta/neo). Drug-resistant cell-lines 
were isolated by selection in geneticin for two weeks (see text for details). Four clones 
were tested for tTa production by an immunofluoresence analysis using anti-serum to 
the acidic domain of herpes simplex virus virion protein 16 (VP16: one half of the tTa 
fusion protein).
adjusted to xl disruption buffer and equivalent amounts of protein, from the four cell-lines, 
were separated through a 10% SDS-PAGel, electroblotted and probed antiserum to the acidic 
domain of virion protein 16 (VP16) from herpes simplex virus. Figure 50 shows that bands of 
~ 40Kda, corresponding to the predicted mwt. of full length tTa could be detected from the 
WCEs of clones 2, 3 & 6 and that clones 2 & 6 produced the highest level of tTa expression 
(lanes 3 & 5). Clone 1 appeared to produce an uncleaved from of tTa/2A/neor, with clone 3 
only being partially cleaved. To determine whether the tTa which was expressed from the 
cell lines was functional, luciferase & assays were performed. Briefly, the 4
tTa expressing cell-lines were transfected either with plasmids encoding 6-galactosidase or 
luciferase, under control of the TRP, in the absence of tetracycline. 48 hrs post-transfection 
the cells were assayed for luciferase activity or 6-galactosidase activity as detailed in the 
methods section. The results of the luciferase & 6-gal. assays are shown in table 5 and 
demonstrate that clone c6 produced the highest activity of luciferase and was thus used for 
further experiments (see section 2.3.8).
An analysis to determine whether the plasmid pEBV-tTa/neo has been retained as an 
episome, and whether EBNA-1 was being constitutively expressed has not been carried out 
due to time constraints.
2.3.9 / Attempt at the establishment of stable cell-lines which inducibly expressed N-
terminally Pk-ta$%ed SV5 HN, using the vectors pTEP4HNntPk (->->) or pTEPSHNntPk (->
->) and a tTa expressing cell-line.
Having successfully isolated a 293 cell-line which constitutively expresses the tTa 
protein (293/tTa), an attempt was made to isolate cell-lines which would inducibly express 
the HNntPk protein encoded from an EBV-based plasmid. 5x10^ 293/tTa cells were 
transfected with 15jtgs of the vector pTEP4HNntPk (->->) or pTEP8HNntPk (->->) in the 
presence of 3|igml“ tetc. 72 hrs post-transfection, hygromycin B or histidinol was added to 
the medium for the selection of cells stabily maintaining the HN plasmid. The cells are 
currently still undergoing selection.
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Figure 50: Western blot analysis of 4 isolated 293-based cell-lines transfected with 
an EBV-based plasmid producing the tTa protein.
293 cells were transfected with the vector (pEBV-tTa/neo). Drug-resistant cell-lines 
were isolated by selection in geneticin for two weeks (see text for details). Four clones 
were tested for tTa production. WCEs were separated through a 10% 8D8-PAGel 
under reducing conditions, electroblotted and incubated with anti-serum to the acidic 
domain of herpes simplex virus virion protein 16 (VP16: one half of the tTa fusion 
protein), followed by an incubation with anti-rabbit HRP. Detection was by ECL. 
(Panel A-short exposure (10 secs), panel B-long exposure (2 mins). The positions of the 
bands corresponding to tTa and the uncleaved form tTa/2A/neo are indicated. MM- 
molecular weight markers, band detected was probably due to cross-reactivity of the 
anti-serum to a protein within the marker preparation.
Cell-line Veetor(s)
Lucile/ase
Actieity
(RLUs/pg)
% cells positiee 
lor
fi-gnlnctosedase
nniee 293s N/A 8 0%
naiee 293s pTRPluc. 62 N/A
nniee 293s pTRPluc & d/ieer. 156,725 N/A
nniee 293s pCMVluc. 20,129 N/A
naiee 293s pTRPfigal. N/A ^00^0^1^%
nniee 293s pTRPfigal & drieer. N/A -25%
293 EBV-tTa *1 pTRPluc or pTRPfigal. 363 -3%
293 EBV-tTa ?2 pTRPluc or pTRPfigal. 454 ~7%
293 EBV-tTa *3 pTRPluc or pTRPfigal. 40,746 -15%
293 EBV-tTa *6 pTRPluc or pTRPfigal. 244,824 -40%
Table 5 - Luciferase & fi-galactosidase assays of 4 cell-lines which constitutively express the 
tTa fusion protein encoded from an EBV-based vector.
1x10^ 293 cells and 4 clones of tTa-expressing 293 cells were transfected with the 
vectors as detailed above. 48 hrs post-transfection the cells were processed for luciferase or 6- 
galactosidase assays, as explained in the methods section. Luciferase activity was measured 
as relative light units per of total protein (RLUs/gg/Plasmids pTRPluc and pTRPfigal 
express the luciferase and fi-galactosidase genes, respectively, under control of the 
tetracycline responsive promoter. Plasmid pCMVluc expresses the luciferase gene under 
control of the hCMV major IE enhancer/promoter. The driver plasmid used was the pGEM- 
tTa/hygB vector. N/A-not applicable.
2.4 / Influence of the drivee/reepondee veetor--vpee on transient protein production
from the inducible expression system.
As detailed above, a wide range of different driver/responder vectors have been 
constructed. Therefore, it was investigated to determine whether or not the particular type of
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vector, i.e. EBV-based or non-EBV-based and (->->) or (-><-) orientated has a beneficial or 
detrimental effect on protein production in a transient assay.
To ensure equivalent amounts of the vectors, listed below, were transfected into the 
293/E cells, Ipl of each DNA preparation (all prepared using Qiagen maxi-prep, columns) 
was linearised using appropriate REs. Doubling dilutions were prepared and electro- 
phoresed through a 1% TBE agarose gel, stained using ethidium bromide and visualised by 
UV illumination. The fluorescent intensity was analysed using a UVP Imagestore 5000 & the 
SW 5000 programme (data not shown). Optical density readings of the DNA preps, at 260 & 
280nm were also performed and double checked. Consistent readings of 1.78->1.81 for all 
preparations of DNA were obtained. Therefore, having standardised the two DNA 
preparations, transfections into 293/E were performed. Briefly, 5xiof 293/E cells, in 75 cm 2 
flats were transfected with the following combinations of vectors all in a 1:1 (w/w) ratio.
EBV-based driver vector non-EBV-based driver vector
Al pEBV-tTa/hygB + pTEPSHNntPk (->->) pGEM-tTa/hygB + pTEPSHNntPk (->->)
A2 pEBV-tTa/hygB + pTEPS HNntPk (-><-) pGEM-tTa/hygB + pTEPSIHNntPk (-><-)
B pEBV-fTa/hygB + pTETHNntPk pGEM-tTa/hygB + pTETHNntPk
A) EBV-based responder vectors: 1- "favourable" orientation.
2- "unfavourabll" oriintation.
B) non-EBV-based responder vector.
Forty eight hours post-transfection, SCEs were prepared in immuneprecipitation 
buffer and their protein content was determined using the BCA method. An 
immunepretipitation was performed, on equivalent protein amounts, using the anti-Pk mAb. 
The immuneprecipitate was electrophoresed through a 10% SDS-PAGel, electroblotted and 
probed with the anti-Pk mAb followed by an incubation with 125Iodine-labelled anti-mouse 
immunoglobulin. The results were then analysed using a Fuji BAS 1000 phoshoimager 
(figure 52) or exposed to X-ray film (figure 51). Bands at - 55Kda correspond to IgH.
The results from this experiment showed that, at least in a transient system, when the 
responder gene was part of an EBV-based vector the nature of the driver plasmid did not
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significantly influence expression levels (figure 51, groups A & B and figure 52, columns 1 & 
3 and 2 & 4). However, when the responder gene was part of a non-EBV-based vector then an 
EBV-based driver vector appeared to produce a greater amount of protein (figure 51 lanes 5 
& 6 and figure 52, columns 5 & 6).
The EBV-based responder plasmid which had the goi transcription unit in the 
"favourable" orientation (figure 51, lanes 1 & 3 and figure 52, columns 1 & 3) produced a 
consistently greater amount of gene product than the "unfavourable" orientation (figure 51, 
lanes 2 & 4 and figure 52, columns 2 & 4) - approximately 2 fold - when either type of driver 
plasmid was co-transfected. Furthermore, both orientations of EBV-based responder vectors 
(figure 51, group A & B and figure 52, columns 1,2,3 & 4) produced greater amounts of gene- 
product than the non-EBV-based responder plasmid - approximately 3-8 fold (figure 51, 
group C and figure 52, columns 5 & 6).
2.51 Summary.
a) No expression of C-terminally Pk-tagged HN could be detected from EBV-based vectors, 
when transcription was driven by the hCMV enhancer/promoter or RSV LTR, in either 
transiently transfected cells or from drug-resistant cell-lines.
b) Production of Pk-tagged HN could be detected from the pcDNA-based vectors when 
transcription was driven by the T70lO promoter, but not from the hCMV promoter.
c) Production of N-terminally Pk-tagged HN, but not C-terminally Pk-tagged HN, could be 
detected when expression was driven from the tetracycline-responsive promoter.
d) In a transient expression analysis, the use of EBV-based driver & responder plasmids 
resulted in significant increases in Pk-tagged HN production in 293/E cells.
e) Transfection of EBV-based plasmids into an EBNA-1 expressing 293 cell-line, followed by 
subsequent drug-selection, did not increase the number of drug-resistant colonies produced 
when compared to a similar transfection/selection procedure performed in native 293 cells.
f) EBV-based and non-EBV-based plasmids encoding the genes for tTa and hyg B PT, 
separated by the FMDV 2A sequence, were constructed and shown to co-express functional 
tTa and hyg B PT.
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g) A tTa expressing cell-line was isolated which expressed high-levels of functional tTa 
protein from an EBV-based vector. Episomal maintenance of the plasmid has not yet been 
investigated.
h) A cell-line which inducibly expresses Pk-tagged HN has not yet been produced.
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Fi^^iuirif 51: Phosphoimaging analysis of the influence of vector-type on 8V5 HNntPk
gene expression in a transient assay.
293 /E cells were transfected with the shown vector combinations in a 1:1 ratio, in the 
absence of tetracycline. 48 hours post-transfection, 8CEs were prepared in 
immuneprecipitation buffer, and the protein content was standardised using the BCA 
assay. An immuneprecipitation was performed, on equivalent protein amounts, using 
the anti-Pk mAb. The immuneprecipitate was electrophoresed through a 10% 
8D8-PAGel, electroblotted and probed with the anti-Pk mAb followed by an 
incubation with 125Iodine-labelled anti-mouse immunoglobulin and exposure to X-ray 
film (panel A) The results were then analysed using a Fuji BA8 1000 phoshoimager 
(panel B). Results are given as arbitrary units.
A)
ABC 
1 2 3 4 5 6 7
84Kd—►
67Kd—► «■*
33Kd—
A) pGEM-tTa/HygB.
B) pEBV-tTa/HygB.
C) pTETHNntPk.
1) pTEPSHNntPk (->->).
2) pTEPSHNntPk (-><-).
3) pTEPSHNntPk (->->).
4) pTEPSHNntPk (-><-).
5) pGEM-fTa/HygB.
6) pEBV-tTa/HygB.
7) Mock transfected.
B)
Arbituary
units
Vector Combination
Vector Combination Numerical Value
EBV-responder (->->) / GEM-tTa driver 1
EBV-responder (-><-) / GEM-tTa driver 2
EBV-tesponder (->->) / EBV-tTa driver 3
EBV-tesponder (-><-) / EBV-tTa driver 4
Non-EBV-responder / GEM-tTa driver 5
Non-EBV-responder / EBV-tTa driver 6
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SECTION 3 : A NOVEL APPROACH FOR THE AMPLIFICATION OF
THE COPY NUMBER OF EPISOMES STABILY MAINTAINED
WITHIN PRIMATE CELL-LINES.
EBV-based episomal vectors are maintained at a low copy number (between 1- 50 
copies per cell) in the primate cell nucleus. Transient expression systems utilising the Simian 
Virus 40 (SV40) Large T Antigen (LTAg), as expressed constitutively in Cos cells, and the 
SV40 origin of replication ( ori), as located on the vector DNA, can produce copious amounts 
of product due to the rapid replication of the vector DNA by the LTAg, resulting in up to 
10,000 copies per cell. Replication continues unchecked until cell death occurs approximately 
3-4 days post-transfection. It was envisaged that a system could be developed whereby stable 
cell-lines would be produced, which inducibly express the SV40 LTAg under tTa inducible 
control. Such stable cell-lines, when in a repressed state, could then be used for the isolation 
of cells which constitutively express a gene of interest encoded from a stabily maintained 
SV40 on-containing EBV-based plasmid. Upon induction of the LTAg, the LTAg would 
amplify the copy number of the SV40 ori-containing EBV-based plasmids with the 
expectation that:, upon amplification, significant increases in the level of recombinant protein 
production may be achieved. As a model to investigate the feasibility of such an 
amplification system, a non-toxic protein - the SV5 P protein - which could thus be expressed 
constitutively from the hCMV major IE enhancer/promoter, was employed.
3.1 I Construction po an SV40 on-containing EBV-based vectoo which consttiuttvelv
expressed the SV5 P protein (figure 53).
The vectors pCEP8/P (->->) & (-><-) were constructed as follows. The transcription 
unit encompassing the hCMV lE/HNPk/pA was excised from the plasmid pCEP4HNctPk 
(->->) using the RE Sail and ligated into the similarly digested vector pREP8 to produce the 
plasmid pCEP8HNctPk (->->). The gene encoding the SV5 P protein was excised from the 
plasmid pGEM/P using the REs Kpnl/Sall and ligated into the Kpnl/Xhol digested 
pCEP8HNctPk (->->) vector to produce the desired plasmid pCEP8/P (->->). The vector was 
tested for P protein expression as detailed below. pCEP8/P (->->) was modified by a
112
Sail
OriP HN
EBNA-1
SV40 pA 
San
pTK
Amp_
San
Sali
ColEl
Ligase
OriP
EBNA-1
ColE1
HisD
pSV40
Xho1
SV40 pA 
Sali
San
Amp
Kpn1
Xho1
Ligase
Sali
OriP
EBNA-1
Sal1/Ligase
EBNA-1
Amp ColEl
SV40 pA
OriP
San
EBNA-1
HisD
pSV40
ColEl
Amp
Amp
ColEl
Kpn1
F 1 ori
|T7
“Kpnl
Sali
Sali
V40 pA
OriP
Sali
Amp ColEl
Figure 53: Construction of LTAg-amplifiable EBV-based vectors which constitutively 
express the SV5 P protein.
HissD
pSV40
The plasmid pCEP4HNctPk (->->) was digested with the RE Sail and the transcription 
unit containing the hCMV/HN/pA was ligated into the similarly digested vector pREP8. 
This new plasmid, pCEP8HNctPk (->->) was digested with the REs Kpnl & Xhol into 
which the gene encoding the SV5 P protein was ligated, thus producing the vector 
pCEP8/P (->->). This plasmid was further modified by a Sail digestion, then ligation, to 
produce the vector pCEP8/P (-><-).
digestion with the RE Sail and subsequent ligation of the two fragmlntt. Constructs in which 
the hCMV IE/P/pA transcription unit was ligated in the opposite orientation to the (->->) 
parental vector were isolated, and named pCEP8/P (-><-).
3.2 / Transient o/dreen orodueridn from the eeetor pCEP8/P (->->).
lxl(& 293/E cells were transfected with the vectors pCEP8/P (->->), pGEM-tTa/- 
hygB & pTET/V (expresses the SV5 V protein which is also recognised by the anti-Pk mAb 
and is used as a positive control for the Western blot) and pCEP4 (negative control - mock 
transfected). 48hrs post-transfection, WCEs were prepared in xl disruption buffer and 
separated through a 10% SDS-PAGel, ellctroblotted then probed with the anti-Pk mAb. 
Figure 54'shows that the 46Kda P protein was clearly detected from WCEs prepared from 
pCEP8/P (->->) transfected cells (lane 2), along with the 23Kda V protein (lane 1). The 
cytoplasmic localisation of the P protein was demonstrated by indirect immunofluoretence 
analysis (using the anti-Pk mAb) on transfected 293/E cells, the result of which is depicted in 
figure
3.3 / Manipulations to ine/ease the expression of the SV5 P protein encoded from
EBV-based eeero/s.
3.3.1 / Infuencc of ftth orientation of tth SV5 P gene trnnssription umt on -prc^^d^ctii^n of
P protein in a transient expression analysis.
To ensure equivalent amounts of the vectors pCEP8/P (->->) & (-><-) were 
transfected into the 293/E cells, Ipl of each DNA preparation (both prepared using Qiagen 
maxi-prep, columns) was linearised using the RE Sphl. Doubling dilutions were prepared 
and electrophoresed through a 1% TBE agarose gel, stained using ethidium bromide and 
visualised by UV illumination. The fluorescent intensity was analysed using a HVP 
Imagestore 5000 & the SW 5000 programme (Data not shown). Optical density readings of 
the DNA preps, at 260 & 280nm were also performed and double checked. Consistent 
readings of 1.78->1.80 for both preparations of DNA were obtained.
Therefore, having standardised the two DNA preparations, transfections into 293/E 
cells, grown to 40% confluency in 35mm petri dishes, were performed. 48hrs post-
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84Kd
67Kd
55Kd
1) pTET-V.
2) pCEPP8P(->->).
3) Mock transfected.
33Kd
Figure 53: Transient expression of the SV5 P protein from an SV40oW -containing 
EBV-based vector.
293/E cells were transfected with the plasmids pTET/V & pGEM-tTa/bygB (lane 1) 
and pCEP8/P (->->) (lane 2) or were mock transfected (lane 3). 48hrs post-transfection 
WCEs were prepared in xl disruption buffer and then separated through a 10% 
SDS-PAGel under reducing conditions, electroblotted and probed with the anti-Pk 
mAh followed by detection using ECL. Included was aWCE from cells transiently 
expressing the SV5 V protein, which is also recognised by the anti-Pk mAh and thus 
acted as a positive control (lane 1).
pCEP8/ P(->->) 
Transfected
Mock
Transfected
Low-
Magnification
High
Magnification
Figure 54: Immunofluoresence analysis of pCEP8/P transfected 293/E cells.
293/E cells were transfected with the vector pCEP8/P (->->) or mock transfected. 
48hrs post-transfection the cells were fixed & permeabilised then incubated with the 
anti-Pk mAb followed by an incubation with Texas Red conjugated anti-mouse Ig. 
Exposure times are constant. Low magnification xlO, high magnification x40.
transfection WCEs were prepared, in lOOjpls of 1% NP40 in PBS, by sonication and the 
samples standardised for protein content by the BCA assay. The standardised samples were 
then adjusted to xl disruption buffer and 5|xl, 10 jll1 & 15 g1 of equivalent protein amounts 
were separated through a 10% SDS-PACel, electroblotted, probed with the anti-Pk mAb, 
followed by secondary detection with ^Iodine-labelled anti-mouse immunoglobulin. The 
blots were then analysed using a Fuji BAS 1000 phoshoimager and exposed to X-ray film 
(figure 5i8). The results show that for the SV5 P protein, produced in a transient expression 
assay, the vector pCEP8/F (->->) produced more P protein compared to the vector pCEP8/P 
(-><-). Analysis by phosphoimaging quantitated this difference to be -3 fold (data not 
shown).
3.3.2 I Effect of synchronising thrmammatian cells ot the G2/M. phass of ShectlS-ctcl-prior
to transfection.
Experiments carried out by Teshigawara & Katsura (1992) demonstrated that 
synchronisation of the EBV transformed B cell-line, Raji, at the C2/M phase of the cell-cycle 
immediately prior to transfection, significantly increased the level of IL-2 receptor E-chain 
production, encoded on an EBV-based plasmid, by approximately 10-fold. Therefore, 293/E 
cells grown in 35mm petri dishes to 40% confluency, were synchronised at the G2/M phase 
of the cell-cycle, as described in materials & methods. The synchronised cells, and an 
unsynchronised population grown to a similar density, were transfected with the vector 
pCEP8/P (->->). 48hrs post-transfection, WCEs were prepared in lOOpls of 1% NP40 in PBS 
by sonication and the samples standardised for protein content by the BCA assay. The 
standardised samples were then adjusted to xl disruption buffer and equivalent protein 
amounts were separated through a 10% SDS-PACel, electroblotted, probed with the anti-Pk 
mAb, followed by secondary detection with Iodine-labelled anti-mouse immunoglobulin. 
The blots were then analysed using a Fuji BAS 1000 phoshoimager and exposed to X-ray film 
(figure 57). No substantial difference between P protein detection levels were observed 
between the synchronised and unsynchronised cell populations, in a transient expression 
analysis.
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1) 5pl W.C.E.
2) lOpI W.C.E.
3) 1 5a/I W.C.E.
4) Mock rrissfeored.
5) 5aI W.C.E.
6) lOA W.C.E.
7) 1 5aI W.C.E.
Figure 55: Elfeer of r/anseriotidn uner orienrarion upon the transient expression level 
of the SV5 P protein from an SV^on' -containing EBV-based vector.
293/E cells were transfected with the plasmids pCEP8/P (->->) (lanes 1-3) and 
pCEP8/P (-><-) (lanes 5-7) or were mock transfected (lane 4). 48hrs poer-rranefeorion, 
WCEs were prepared in immunepreoipitarion buffer and their protein content was 
standardised using the BCA assay. Equivalent amounts of protein were then separated 
through a 10% SDS-PAGel under reducing conditions, electroalorted and probed with 
the anti-Pk mAb followed by 125-Iodinated anti-mouse Ig and exposure to X-ray film.
1 2 3
84 Kd 
67Kd 
55Kd
1) Unsynchronised.
2) G2/M Synchronised.
3) Mock transfected.
33Kd
Figure 56: Effect of cell synchronisation apon the transient expression level of the 
SV5 P protein from an SV40ori -containing EBV-based vector.
293/E cells were synchronised at the G2/M phase of the cell-cycle by an overnight 
treatment with thymidine followed by an overnight incubation with Hoechst 33342. 
Synchronised and unsynchronised cells (grown to a similar density) were transfected 
with the plasmid pCEP8/P (->->) (lanes 1 & 2) or were mock transfected (lane 3). 48hrs 
post-transfection WCEs were prepared in immuneprecipita­
tion buffer and their protein content was standardised using the BCA assay. 
Equivalent amounts of protein were then separated through a 10% 3D3-PAGel under 
reducing conditions, electroblotted and probed with the anti-Pk mAb followed by 
125-Iodinated anti-mouse Ig and exposure to X-ray film.
3.4 I Construction of the pCT7-based vector which encodes the SV40 LTAg.
Having successfully constructed appropriate SV40-ori-containing FBV-based vectors 
which were shown to constitutively express the SV5 P protein, or inducibly express the N- 
terminally Pk-tagged SV5 HN glycoprotein, the plasmid which inducible expresses the SV40 
LTAg was constructed. However, prior to producing a vector which would inducibly express 
the SV40 LTAg, a vector which expresses the LTAg under the hCMV IE enhancer/promoter 
or the T701O promoter was constructed. The ORF for the SV40 LTAg was PCR amplified 
from the vector pSVori using primers containing the RFs FcoRl or Sphl. The PCR product 
was digested with the aforementioned RFs and ligated into the similarly digested plasmid 
pCT7, to produce the vector pCT7LTAg, (figure 58).
3.5 I Transient production of the SV40 LTAg from the vector pCT7LTAg.
Expression from the vector pCT7LTAg was initially detected by an indirect 
immunofluoresence analysis. Briefly, 293/F cells were grown on glass coverslips and then 
transfected with the plasmids pCT7LTAg or pcDNAl/amp (pCT7-mock transfected). 48hrs 
post-transfection the cells were processed for immunofluoresence using the anti-LTAg mAb.
Figure 5Xclearly shows the nuclear localisation of LTAg in cells transfected with the plasmid
o
pCT7LTAg,
To confirm that the LTAg was of the correct molecular weight, a Western blot analysis 
of WCFs was performed. Briefly, 293/F cells grown in 35mm petri dishes were transfected 
with the plasmids; pCT7LTAg, pSVori and pCT7 (mock transfection) as detailed in the 
materials & methods section. At 48hrs post-transfection, WCFs were prepared in xl 
disruption buffer, including a WCF from Cos-7 cells (positive control). Figure ^?(panel A) 
shows the result of separating the WCFs through a 10% SDS-PAGel, electroblotting and 
probing with the anti-LTAg mAb. A band of -90Kda is clearly detectable from extracts of 
Cos-7 cells and from cells transfected with the pSVori vector, albeit at a much lower level. 
However, extracts from cells transfected with the vector pCT7LTAg showed only a very 
weak signal for an ~90Kda band with a prominent signal at 33Kda and minor signals at 
~55Kda & 40Kda. All of these latter signals were not present in the Cos-7 cell extract or the
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Figure 5^ Construction of the vector for the transient expression of the SV40 LTAg.
The DNA sequence encoding the open reading frame of the LTAg was PCR amplified 
from the vector pSVori, employing PCR primers which contain either EcoRl or Sphl 
RE sites. The PCR product was digested with the REs Sphl & EcoRl, and ligated into 
the similarly digested plasmid pCT7 to produce the vector pCT7LTAg, from which 
transient expression of the LTAg can be driven by the hCMV promoter.
pCT7LTAg Mock
Tonssfeeted Tealsifected
Anti-LTAg
DAPI stained
Figure 58: Immunoflud/esenee analysis of pCT7LTAg transfected 293/E cells.
293/E cells were transfected with the vectors pCT7LTAg or pcDNAl/Amp (mock 
transfected). 48hrs poet-trantfeotion, cells were fixed & permeabili^d then 
incubated with the anti-LTAg mAh (PAb 416) followed by an incubation with Texas 
Red conjugated anti-mouse Ig. Exposure times are constant. The cell nuclei were 
stained with DAPI.
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4) Mock transfected.
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Figure 59: Transient Expression of SV40LTAg from hCMV IE promoter in 293/E cells
(A) 40% confluent 35mm petris of cells were transiently transfected with 3pgs of either; 
pCT7LTAg (lane 2), pSVori (+ve for LTAg, lane 3) or pcDNAl/amp (mock transfected, 
-ve for LTAg, lane 4). 48hrs post transfection, WCEs were prepared and separated 
through a 10% SDS-PACel under reducing conditions, electroblotted and probed with 
the anti-SV40 LTAg mAb - PAb 416. Detection was by ECL. A sample of WCE derived 
from Cos-7 cells was also incorporated as a positive control (lane 1). (B) A 40% 
confluent 35mm petri of cells was transiently transfected with 3pgs of DNA 
(pCT7LTAg, lanes2-6) isolated from 5 different transformants showing positive 
restriction endonuclease digestion pattern. 48hrs post transfection, WCEs were 
prepared and analysed as above.
extract from the pSVori transfected cells. However, since the ORF was PCR amplified from
the vector pSVori, mutations could have been introduced into the LTAg ORF sequence
resulting in the predominance of the lower molecular weight bands. Therefore, DNA
minipreps from 5 separate transformants (which gave a positive diagnostic RF digestion)
from the same ligation reaction were prepared. A transient expression experiment in 293/F
cells was performed using the DNA minipreps, with the transfected cells being processed as 
j-q
detailed above. Figure ,60 (panel B) shows that for all the clones tested, the ~33Kda, 40Kda 
and 55Kda bands were present, with only a weak signal corresponding to the full length 
LTAg being detected (note- a longer exposure was needed to observe the 55Kda and 90Kda 
bands detected from the WCF of cells transfected with clones 2-5. Data not shown).
3.6 I Establishment of cell-lines which constitutively expressed the SYS P protein
encoded from an EBV-based vector.
Although the inducible LTAg expressing construct has, as yet, not been constructed, 
the ability to increase protein production after amplification of a stabily maintained low copy 
number episome can be tested by the transient transfection of LTAg into a stable cell-line 
possessing an episome. For this purpose, cell-lines which constitutively express the SV5 P 
protein encoded on the vector pCFP8/P (->->) were produced by transfection of naive low 
passage no. 293 cells followed by histidinol selection, in a procedure similar to that described 
for the isolation of tTa expressing cell-lines. Initially five clones {±2, ±3, 94, 95 & 9ll) with 
different properties were isolated from the initial screening of 24 clones by 
immunofluoresence analysis using the anti-Pk mAb (data not shown). Clone ±2 expresses P 
protein in a high proportion of cells with low expression (HNLF). Clones 93 & 94 express the 
P protein in a high proportion of cells with high expression (HNHF). Clone 95 expresses P 
protein in a high proportion of cells with intermediate expression (HNIF). Clone 9=11 
expresses P protein in a low proportion of cells with high expression (LNHF).
3.7 I Transient expression of SV40 LTAg in cell-lines which express the SV5 P
protein encoded from an SV40 ori -containing EBV-based vector.
All five P-expressing cell-lines were used in a transient transfection assay to 
determine whether LTAg expression could increase P protein expression. The five cell-lines
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were grown, in duplicate, to ~40% confluency in 35mm petri dishes where-upon each cell­
line was transfected with the plasmid pSVori or mock transfected. 72hrs postltrantfeotion the 
cells were harvested by washing twice with PBS followed by lysis with immuneprlcipitation 
buffer. Samples were standardised for protein content using the BCA assay and made up to 
xl disruption buffer. Equivalent protein amounts of WCE were separated through a 12%
SDS-PAGel, electroalotted and probed with the anti-Pk mAb and anti-LTAg mAb, followed 
O
by detection using ECL. Figure fjZ shows that cell-lines 9*2 (lanes 1 & 2) & 93 (lanes 3 & 4) 
may show a very small increase in P protein expression (46Kda band) after transient 
expression of the SV40 LTAg (~90Kda band), however, cell-line 9*1 (lanes 9 & 10) may be 
showing a small decrease in P protein expression. Therefore, overall, no substantially large 
increase in P protein expression was observed following transfection of P-expressing cell­
lines with the plasmid pSVori.
3.8/ Summary.
1) EBV-based vectors which possessed an SV40 ori were constructed, and shown to produce 
the SV5 P protein when expression was driven by an hCMV IE enhancer/promoter. This 
expression, in a transient expression analysis, was shown to be maximal when the orientation 
of the P gene transcription unit was similar to that of the EBNA-1 gene transcription unit.
2) Synchronisation of 293 cells prior to transfection did not result in a detectable increase in 
protein production.
3) An attempt at the construction of a plasmid which expressed the SV40 LTAg under control 
of an hCMV IE enhancer/promoter, resulted in the production of a nuclear-localised protein, 
but which primarily pottltted a mwt. of only ~33 Kda. A small amount of protein was 
detected at the expected mwt. of -90 Kda. The construction of a plasmid which inducibly 
expressed the SV40 LTAg was not carried out.
4) Transfection of 5 separate SV5 P producing cell-linlt (in which the P gene was encoded 
on an SV40 cri‘-tonraining EBV-based plasmid) with the LTAg expressing vector pSV ori, did 
not result in a detectable increase in P protein expression.
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I 10) pCEP8/P LNHE + LTAg.
Figure 60: Transient expression of the SV40 LTAg in cell-lines which constitutively 
express the SV5 P protein from an SV40ori -containing EBV-based episome.
Five 293 cell-lines which constitutively express the SV5 P protein (see text for details) 
were transfected with the plasmid pSVori (lanes 2, 4, 6, 8 & 10) or were mock 
transfected (lanes 1, 3, 5, 7 & 9). 72hrs post-transfection WCEs were prepared in 
immuneprecipitation buffer and their protein content was standardised using the BCA 
assay. Equivalent amounts of WCE were separated through a 10% SDS-PAGel under 
reducing conditions, electroblotted and probed with the anti-LTAg mAb and anti-Pk 
mAb followed, by detection using ECL.
DISCUSSION
1/ Pk-tag as an epitope-tag for the detection and purification of recom­
binant proteins.
1.1 Analysis of transiently expressed Pk-tagged HN & F.
The mammalian expression system chosen for the analysis of Pk-tagged HN & F 
processing was the vaccinia virus - T7 RDRP system. This system was chosen due to the ease 
of use, the high level of protein production which occurs, and the brief time that is required 
to obtain protein production. Vectors were constructed, termed pT7ntPk & pT7ctPk, which 
contained oligonucleotides coding for the Pk-tag which is subsequently positioned at the N 
or C-terminus, respectively, of an inserted gene. The SV5 HN & F genes or their truncated 
forms (A), were PCR-amplified from appropriate plasmids and inserted into the above 
vectors, to produce constructs which expressed the following proteins from the T701O 
promoter; HNntPk, HNctPk, FctPk, AHNntPk, AHNctPk & AFctPk.
1.1.1 / Analysis of full length Pk-tagged HN & F.
Western blot analysis of WCEs from transfected vTF7-3 infected 293 cells (figure 21) 
demonstrated that products of the expected mwt. were detected, using the anti-Pk mAh, and 
therefore, the addition of the Pk-tag did not prevent the expression of the Pk-tagged 
glycoproteins in mammalian cells. Whether the presence of the Pk-tag had significantly 
reduced the expression of Pk-tagged glycoproteins when compared to the native 
glycoproteins has not been extensively investigated due to the fragility of the vaccinia virus
118
infected 293 cells (whereby repeated addition/aspiration of medium resulted in the 
substantial disintegration of the cell monolayer), thereby rendering radio-labelling 
experiments redundant. However, a comparison between the intensity of the 
immunofluoresence, when incubated with anti-HN mAbs, observed between Pk-tagged HN 
(figures 24 & 26) and native HN (figure 23) would indicate that there is not a substantial 
reduction in expression of the Pk-tagged form of HN (a western blot analysis could not be 
performed due to the lack of a mAb which recognised Western blotted SV5 HN).
The Pk-tag epitope does not appear to be cleaved from the Pk-tagged proteins by 
cellular or vaccinia virus proteases as products could be detected when probed with the anti- 
Pk mAb (figure 21). Furthermore, immunofluoresence analyses shown in figures 24 & 26 
demonstrate a comparable level of detection of Pk-tagged HN using either the ant-HN or 
anti-Pk mAbs, which would tend to argue against there only being a small subset of proteins 
which possess an intact Pk-tag. However, a definitive analysis has not been carried out to 
determine whether or not a small proportion of the expressed proteins have lost the Pk-tag 
epitope.
The native SV5 F glycoprotein is a type I glycoprotein and possesses a cleavable 
signal sequence. The successful expression of the Pk-tagged form of F to produce a protein of 
the expected mwt., would infer that the presence of the Pk-tag at the C-terminus of the 
molecule did not prevent cleavage of the signal sequence by signal peptidase. Moreover, the 
addition of the Pk-tag to the C-terminus of F did not prevent the post-translational cleavage 
of the precursor protein Fo to the disulphide-linked Fi & F2 subunits.
Native HN & F undergo N-linked glycosylation which adds approximately 6-10 Kda 
to the apparent mwt. of the proteins. Pk-tagged HN and F were shown, using PNGase F 
digestion analysis (figure 22) or tunicamycin treatment, to be post-translationally modified 
by the addition of 6-10 Kda of N-linked oligosaccharides. Furthermore, native HN & F are 
expressed at the cell-surface of infected cells. Successful transport of Pk-tagged HN & F to the 
surface of transfected cells was demonstrated using immunofluoresence analysis (figures 24, 
26 & 27). However, experiments performed by Parks & Lamb (1990) on the SV5 HN protein 
demonstrated that the alteration/substitution of the N-terminal cytoplasmic tail may alter
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the transport of the mutant molecule through the exocytotic pathway resulting in a reduced 
transport rate or cessation of transport to the cell-surface. Although Pk-tagged HN & F were 
clearly transported to the cell-surface and were orientated in the expected manner, with 
HNctPk possessing the Pk-tag epitope on the exterior of the cell and HNntPk & FctPk 
possessing the Pk-tag on the interior of the cell, their rate of transport has not been 
determined. Since native HN is internalised from the cell-surface it may be prudent to 
investigate whether or not the Pk-tagged forms are also internalised. In terms of maximising 
recombinant protein production, a possible inhibition of SV5 HN internalisation, by the 
presence of the Pk-tag, may result in a greater yield of the protein due to retention at the cell- 
surface.
Native monomeric HN formed dimers which associated to produce a mixture of 
covalently and non-covalently linked tetramers. Preliminary evidence which suggested that 
Pk-tagged HN formed an oligomeric structure was demonstrated by employing non­
reducing SDS-PAGE (figure 28). This analysis demonstrated that the Pk-tagged forms of HN 
produced mwt. species which have a similar mwt. to dimeric (~ 140 Kda) and tetrameric 
(-289 Kda) forms of native HN (Ng et al., 1989). However, as above, the rate of oligomeric 
formation was not determined. Furthermore, perhaps sucrose density centrifugation 
analysis should be performed to further support the evidence for the oligomeric structure for 
Pk-tagged HN.
Using chemical cross-linking analysis, Russell et al. (1994) demonstrated that the SV5 
F protein probably formed non-covalently linked trimers. Using a similar method, it was 
demonstrated that, in the majority of the detected molecules, FctPk formed dimers and 
possibly trimers (figure 29). Smearing of the higher mwt. bands could not be alleviated by 
altering gel composition and electrophoresis times, and therefore may be a reflection that the 
proteins were not immuneprecipitated after chemical cross-linking, thereby possibly 
allowing the detection of promiscuously cross-linked species.
One of the most important features when the Pk-tag was added to the termini of HN 
& F, in terms of vaccine development & structural studies, was to determine if the presence 
of the Pk-tag altered the conformation of HN & F such that they could no longer be
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recognised by conformarionallylSlnsirive (cs) mAbs, which were raised against the native 
proteins. Immuneprecipitation analysis (figure 30) demonstrated that Pk-tagged HN was 
indeed recognised by all of the cs anti-HN mAbs employed in the experiment. Furthermore, 
mAb 4b has been shown (Ng et al., 1989) to bind only to the dimeric form of HN, thus 
supporting the evidence for an oligomeric structure for Pk-tagged HN. Immunofluoresence 
analysis (figure 27) demonstrated that the addition of the Pk-tag to the C-terminus of the F 
protein did not result in a loss of binding to the cs anti-F mAb.
1.1.2 I oftrrulcated Pk-taaied JHN & F.
Parks & Lamb (1990) have demonstrated that a truncated form of the SV5 HN protein 
(HN-F) could be secreted from CV-1 cells which were infected with an SV40 recombinant 
virus. The HN protein was converted into a secretaale form by replacing the N-rerminut 
signal/anchor domain with the fusion related ectodomain from the SV5 F protein. 
Approximately 40% of HN-F was secreted from the cells and found in a dimeric form (with a 
monomeric relative mwt. of ~66Kda), which retained antigenicity to cs anti-HN mAbs. The 
remainder of the HN-F was found to consist of dimers and monomers which were not 
recognised by cs anti-HN mAbs. The successful secretion, from mammalian cells, of 
truncated HN protein derived from PIV-3 has also been demonstrated by Lehman et al. 
(1993).
Therefore, it was determined whether or not Pk-tagged forms of truncated HN could 
also be secreted from mammalian cells. For this purpose, the vectors pT7AHNctPk & 
pT7AHNntPk were constructed which possessed the putative cleavable signal sequence from 
the EBV gp220/360 glycoprotein. Western blot analysis of WCEs from transfected vTF3-7 
infected 293 cells (figure 33) demonstrated that the majority of the detected AHNntPk & 
AHNctPk molecules were found as a doublet band of -60-62 Kda, which were not observed 
by Parks & Lamb (1990) during expression of the HN-F molecule. However, a minor band at 
-68Kda was detected from WCEs of cells transfected with the pT7AHNntPk vector which 
approximates to the expected mwt. for glycosylated monomeric AHNntPk. Indeed N-linked 
glycotylation of this minor -68 Kda species was confirmed by PNGase F digestion analysis
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(figure 36). However, no corresponding reduction in molecular weight was observed for the 
major doublet species. The minor -68 Kda species was also shown to bind to a pool of cs anti- 
HN mAbs as determined by an immuneprecipitation analysis, but was not detected in the 
medium (figure 34). Moreover, this minor species was absent from WCEs of cells transfected 
with the pT7AHNctPk vector, for reasons that are unclear, but could be related to the nature 
of the amino acids present immediately after the signal sequence, which differs between the 
two AHN molecules (see figure 62).
A lack of detectable secretion of AHNntPk & AHNctPk could be due to various 
factors, including; cleavage of the Pk-tag resulting in non-detection, lack of (or inefficient) 
cleavage of the putative signal sequence and, incomplete formation of transport competent 
molecules. Due to the inability to perform pulse-chase experiments on vTF7-3 infected 293 
cells (as mentioned earlier), it could not be determined whether non-secretion was due to a 
deficiency in detection when probed with the anti-Pk mAb.
A deficiency (or inefficiency) in cleavage of the EBV-derived signal sequence could 
lead to a lack of detectable secretion into the medium. Indeed, it has recently been elucidated 
that the putative signal sequence used in this experiment may not be efficiently cleaved and 
that a modified form has been produced which results in a more efficient cleavage (M. 
Mackett, personal communication). This modified form of the EBV gp220/360 signal 
sequence, or other cleavable signal sequences such as those derived from the influenza virus 
HA protein (Madison & Bird, 1992) or tissue plasminogen activator protein (Rhodes et al, 
1994), could be utilised in the construction of future vectors encoding secretory forms of Pk- 
tagged HN & F. However, if the hypothesis that the lack of secretion was due to non-existent 
or poor cleavage of the signal sequence, then full length Pk-tagged AHN molecules should 
be produced and would perhaps be expected to behave similarly to the Pk-tagged HN 
molecules described earlier. Clearly this was not observed.
Parks & Lamb (1990) demonstrated that the formation of the HN-F dimer was a 
prerequisite for transport to the medial golgi, but that the formation of complex 
oligosaccharide chains in the medial golgi is not a prerequisite for secretion. In their 
experiments, Parks & lamb used a different signal sequence for the secretion of the truncated
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A)
GAATTC ATG GAG GCA GCC TTG CTT GTG TGT CAG TAC ACC ATC CAG AGC CTG ATC CAT CTC
met glu ala ala leu leu val cys gin tyr thr lie gin ser leu He his leu
ACG GGG GTA CCC GGG ACC ATG GGA AAG CCG ATC CCA AAC CCT TTG CTC GGA
thr gly val pro gly thr met gly lys pro ile pro asn pro leu leu gly
TTG CAG TCC ACC TGG CGC GCC GAG AST
leu asp ser thr trp arg ala glu ser
B)
GAATTC ATG GAG GCA GCC TTG CTT ^£.1^ CAG TAC ..ACC ATC-CACACC■CT.G.. ATC.CAT CTC
met glu ala ala leu leu val cys gin tyr thr ile gin ser leu ile his leu
ACG 0^ GTA CCT GGG CGC GCC GAG AGT TTA ATA AGC CAA AAG CAA ATC
thr gly val pro gly arg ala glu ser leu lie thr gin lys gin lie
ATT AGC CAA GCA
met ser gin ala
Figure 61: Schematic depicting the DNA & amino acid sequence for the 5’ end 
of the genes encoding the Pk-tagged truncated forms of SV5 HN.
Panel A corresponds to the AHNntPk sequence. Panel B represents the AHNctPk 
sequence. Underlined sequences correspond to the putative DNA sequence 
encoding the EBV gp220/360 cleavable signal sequence. Amino acid sequences in 
outline text (panel A only) correspond to the 14 amino acid Pk-tag oligopeptide. 
Amino acids in shadow text correspond to the truncated HN sequence. The ATG 
codon shown in bold text (panel A) & the underlined ATG shown in shadow text 
(panel B), represent possible alternative sites for translation initiation.
HN construct. It was not known when the cleavage of the HN-F signal sequence occurred in 
relation to the completion of synthesis of the polypeptide chain. Therefore, it is not known if 
dimerisation, and therefore competent transport, is dependent upon attachment to the ER 
membrane. If it is the case that dimerisation occurs when the two monomers are still attached 
to the ER membrane, then a lack of secretion could partly be explained by an effic^^^t 
cleavage of the EBV signal sequence. This may result in a three dimensional diffusion of the 
monomers to find assembly partners compared with a two dimensional membrane-bound 
diffusion. This would lead to a slower dimerisation rate of the AHN Pk-tagged molecules and 
therefore inefficient secretion, resulting in the prominent detection of bands of a lower mwt. 
than expected, due to the lesser extent of post-translational modification. An analysis to 
determine whether Pk-tagged AHN molecules form oligomers has not yet been carried out, 
but an immune precipitation analysis using the anti-HN mAb 4b would be informative as to 
whether dimers are formed.
The reason for the presence of the prominent doublet band is unclear, but could be 
due to several reasons including; degradation of the protein, poor transport of the molecules 
through the exotytotic pathway (as described above) or, translation initiation from 
downstream ATGs. The latter explanation is of particular interest since, as described 
previously, the doublet band was not modified by the addition of N-linked oligosaccharides 
and therefore has probably not been targeted to the ER. This could be due to the initial ATG 
(GAATTCATG GAG) occurring in a poor context for translation initiation (particularly 
sequences 5' to the ATG) as determined by Kozak (1986 & 1989, and detailed in chapter 3 of 
the introduction). Furthermore, as figure 62 panel B shows, 3' to the putative gp220/360 
signal sequence, within the AHNctPk sequence, was an ATG codon which is perhaps in a 
context more suited for translation initiation. If translation initiation occurred at this codon, 
then the polypeptide would not be directed to the ER, would therefore not be N-linked 
glycosylated and would thus possess a lower relative mwt. than expected. Furthermore, as 
with the AHNctPk DNA sequence, the AHNntPk nucleotide sequence possessed a down­
stream ATG codon which was in a better context for translation initiation (figure 62 panel A).
An attempt to investigate whether initiation at a downstream ATG was the reason for
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the presence of the low mwt. doublet band could not be carried out. This was due to the 
inability to successfully introduce a more optimal translation initiation context 
(GCCGCCACC ATG ) by the insertion of a double stranded oligonucleotide 5' to the EBV- 
derived signal sequence (data not shown). However, using the constructs available, further 
studies involving trypsin digest & alkali fractionation of isolated microsomal membranes and 
in vitro transcription/translation (as detailed in Parks & Lamb, 1990), could be performed. 
These experiments should determine whether the protein is being targeted to the ER, if signal 
sequence cleavage is occurring, and if the polypeptide is being secreted into the ER lumen.
A truncated from of FctPk was constructed, in which the C-terminal cytoplasmic tail 
and membrane-anchor were deleted by an appropriate PCR amplification step, resulting in 
the vector pT7AFctPk. As with the truncated HN constructs. Western blot analysis (figure 35) 
showed the existence of a prominent doublet band at - 60-63 Kda which, in contrast to the 
AHN protein, approximates to the expected molecular weight for glycosylated truncated Pk- 
tagged F. Longer exposure of the film showed the detection of a further 2 bands at -58 & 
53Kda. Due to their relative molecular weights, the 4 bands appeared to have undergone 
post-translational modification (unmodified monomeric Pk-tagged truncated F should have a 
mwt. of - 48 Kda when electrophoresed under non-reducing conditions). Indeed, upon 
digestion with PNGase F, the 4 bands were reduced to a single mwt. species of - 48 Kda, 
thereby indicating that AFctPk had undergone N-linked glycosylation (figure 22). The 
presence of the 4 bands may therefore reflect differential glycosylation of individual 
polypeptides or, due to a slow transport rate, polypeptides from different compartments of 
the exocytotic pathway are being detected.
A comparison of the production of AFctPk to a truncated form of SV5 F which lacks 
the C-terminal cytoplasmic tail and transmembrane anchor (AF) was not be made since a AF- 
expressing plasmid was not constructed. However, a similarly truncated form of the 
influenza virus HA (also a type I glycoprotein) gene had been constructed by Paterson & 
Lamb (1987) and shown to produce only a single mwt. species when expressed in CV-1 cells 
by infection with a recombinant SV40 virus. Whether this reflects a difference in the
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properties of the proteins, differences in the detection system, or in the transient expression 
system utilised, remains to be determined.
Furthermore, as only the -48 Kda band could be detected when WCEs from SV5 
AFctPk expressing cells were treated with PNGase F and electrophoresed under reducing 
conditions, then this would imply that the expressed AFctPk molecule has not undergone 
post-translational cleavage from AF0 to AFi & F2. This phenomenon has also been observed 
for a C-terminal deletion mutant (but not including the membrane-anchor) of MeV F protein 
where proteolytic cleavage did not occur, and the mutant protein was inefficiently 
transported to the cell-surface (Sergei & Morrison, 1995). Furthermore, a chimaeric RSV F 
mutant produced by Anderson et al. (1992) which did not form oligomers and was not 
proteolytically activated was glycosylated - but not to complex, endo H resistant forms. 
Therefore, it would be interesting to determine whether SV5-derived AFctPk molecules are 
endoH resistant or sensitive, since this would give an indication of the position of the 
molecules in the exocytotic pathway.
Using chemical cross-linking analysis, Russell et al., (1994) demonstrated that the SV5 
F protein probably forms non-covalently linked trimers. Using a similar method, it was 
demonstrated that, in a small proportion of the expressed molecules, AFctPk forms dimers 
and possibly trimers. This result is in some agreement with Reitter et al. (1995) whereby the 
cytoplasmic tail and the transmembrane anchor of MeV F were deleted, but still resulted in 
the ability of the truncated F monomers to form trimers. However, in contrast to the results 
obtained for oligomerisation of SV5-derived AFctPk, the majority of the detected truncated 
MeV F molecules appeared to form oligomers. Whether this difference is due to the sucrose 
density centrifugation technique used by Reitter et al. as a means of oligomer analysis, 
compared to the chemical cross-linking analysis as used above, remains to be determined.
However, although the AFctPk monomer was glycosylated and did form an 
oligomeric structure in a minority of the expressed molecules, secretion of Pk-tagged AF into 
the medium could not be detected in a Western blot analysis, using the anti-Pk mAb, from 
samples of medium and concentrated medium (figure 35). This is in contrast to results 
obtained by Paterson & Lamb, (1987) where a truncated version of influenza virus HA was
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secreted into the medium, albeit in small amounts. Furthermore, Reitter et al. (1995) 
demonstrated successful secretion of a similarly truncated version of the MeV F protein into 
the medium. This lack of detectable secretion of AFctPk could be due to cleavage of the Pk- 
tag occurring, protein adsorbing to the Amicon membrane, protein adsorbing to the cell- 
surface, or a lack of secretion into the medium. An analysis to determine whether the Pk-tag 
has been cleaved from the protein could not be determined for reasons mentioned earlier 
regarding the fragility of the 293 cells/vaccinia virus expression system. An 
immuneprecipitation analysis performed on the medium to discount the second possibility 
should be carried out. As with the AHN constructs, tryptic digest & alkali fractionation of 
isolated microsomal membranes could be performed to determine whether AFctPk is found 
as a soluble protein in the lumen of the ER & golgi complex. Furthermore, an attempt was 
made at performing an immunofluoresence analysis on transfected cells to determine the 
cellular localisation of AFctPk but, due to technical difficulties, the result has not been 
resolved, and further experimentation is required.
2. I Isolation of cell-lines which produce Pk-tagged HN.
Given the encouraging results from section 1, which demonstrated that the addition 
of the Pk-tag epitope to the N or C-terminus of HN & C-terminus of F did not significantly 
alter the processing of the glycoproteins through the mammalian-cell exocytotic pathway, it 
would be beneficial to isolate cell-lines which expressed the Pk-tagged glycoproteins for 
protein production & purification, and for experiments to further characterise Pk-tagged 
glycoprotein processing.
2,11 Constitutive expression of Pk-tagged HN.
Initial studies to isolate cell-lines which constitutively expressed Pk-tagged HN 
employed EBV-based vectors. These vectors were chosen because they remain episomal in 
primate cell nuclei and therefore result in a greater frequency of drug-resistance cell isolation, 
combined with a moderately high gene copy and therefore gene expression (Yates et al., 
1985). Numerous EBV-based vectors were constructed which encoded the HNctPk protein.
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where transcription should be initiated at sequences derived from the hCMV major IE 
enhancer / promoter or the RSV LTR. However, no expression of HNctPk could be detected 
from transient expression analyses in 293 & 293/E (which conttitutively express the EBV 
EBNA-1 protein) cells, or from drug-resistant clll-linet which were isolated after transfection 
and selection by drug-resistance. The reason for the lack of expression was unknown and 
therefore it was decided to construct a set of non-EBV-batld vectors (the pcDNA series of 
vectors), including the gene encoding the HNntPk protein, in which the transcription of the 
inserted gene could be initiated from either the hCMV promoter, or the T701O promoter. As 
expression was observed previously when transcription was driven from the T7olO 
promoter, then this would act as a positive control. Indeed, expression could be observed, by 
Western blot analysis, from the pcDNA-bated vectors when transcription was initiated from 
the T7 promoter (figure 39). However, detectable expression was still not observed when 
transcription was initiated from the hCMV promoter (present in the same plasmid) upon 
transfection into 293 cells, or into Cos-7 cells where amplification of the transfected plasmid 
usually results in high levels of protein production (figure 40).
Possible reasons for a lack of detectable expression when transcription was initiated 
from the hCMV promoter include; poor or non-existent transcription initiation of the gene, 
inadequate or lack of post-transcriptional processing of the synthesised RNA or, mutations 
occurring within the gene preventing detection. The latter possibility is unlikely since 
HNctPk & HNntPk expression was detected when expression was driven from the T701O 
promoter, but this explanation cannot be ruled out for the Pk-tagged HN genes present in the 
EBV-based vectors. Poor or non-existent transcription of the HNctPk gene may be due to a 
faulty hCMV promoter. However, replacement of the HNctPk gene, within the pcDNA- 
based plasmid, with the bacterial f5-galactotidate gene, resulted in the expression of fi- 
galacrosidate from the hCMV promoter, thereby arguing against a faulty promoter being the 
source for the lack of detectable expression.
Therefore, perhaps the most likely reason for a lack of detectable expression was a 
failing at the level of RNA processing, perhaps due to the lack of an intron. Indeed, 
expression of SV5 HN in mammalian cells has, to date, only ever been initiated from an SV40
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promoter, as part of an SV40 recombinant virus or by transfection into Cos cells, or via the 
vaccinia virus/T7 system. Therefore, it is not known whether expression of SV5 HN from the 
hCMV promoter requires the presence of an appropriate intron for successful expression. A 
Northern blot analysis should be carried out to determine if transcription is occurring.
Furthermore, others have also extensively tried to isolate cell-lines which 
constitutively expressed the native SV5 HN protein but have been unsuccessful (R.A. Lamb, 
personal communication). This apparent inability to construct cell-lines which constitutively 
expressed SV5 HN may be unique to SV5, since cell-lines which constitutively expressed PIV- 
4A HN, MuV HN and MeV H have been isolated (Nishio et al., 1994; Hishiyama et al., 1996 
and Hirano & Wong, 1991). Therefore, in the assumption that expression of SV5 HN, and 
therefore Pk-tagged SV5 HN, may be uniquely toxic to the cells, an inducible expression 
system based upon the tetracycline transactivator protein was employed.
2.2 I Inducible expressic^o^
Non-EBV-based and EBV-based vectors were constructed in which the HNctPk & 
HNntPk genes were under the transcriptional control of the tetracycline transactivator 
protein. Western blot analysis (figures 43 & 51) and immunofluoresence analysis (figure 48) 
revealed that, in a transient expression analysis, HNntPk was successfully expressed from 
the various constructs. However, expression of HNctPk could not be detected in a transient 
expression analysis from any of the constructs. The successful expression of HNntPk from 
the tetracycline responsive promoter (TRP), would tend to argue against the explicit 
requirement of an intron for the successful expression of Pk-tagged HN proteins. 
Furthermore, it is difficult to perceive there exists an absolute requirement for an intron 
before HNctPk expression occurs whilst no such requirement exists for HNntPk protein 
production. Therefore, perhaps at least for the HNctPk vectors under control of the TRP, the 
most likely reason for a lack of expression is due to the presence of mutations which occurred 
during construction of the plasmid, thereby preventing successful expression of the HNctPk 
protein. Re-cloning of HNctPk may therefore, prove beneficial.
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Despite the disappointing lack of expression of the HNctPk protein, construction of 
cell-lines which inducible express HNntPk from EBV-based vectors were attempted, due to 
the successful expression of HNntPk from the tetracycline-responsive promoter in a transient 
assay. An initial attempt at selecting for drug-resistant 293 cells which had been co­
transfected with the constructs pEBV--Ta/neo & pTEP4HNntPk (->->) resulted in only one 
drug-resistant colony growing up from an initial 10^ transfected cells. Subsequent analysis of 
this clone proved negative for both HNntPk & tTa expression.
Since only one drug-resistant clone was produced, two approaches to try and increase 
this number were examined. The first approach utilised an EBNA-1 expressing 293-derived 
cell-line, in which the constitutive expression of EBNA-1 facilitates the retention & replication 
of EBV-based vectors upon transfection, resulting in a greater frequency of drug-resistant 
colonies. However, the EBNA-1 expressing 293-derivative also expresses neomycin 
aminoglycoside phosphotransferase. Therefore, the tTa/neo expressing constructs could not 
be utilised and similar vectors expressing tTa adjoined to the gene coding for hygromycin B 
phosphotransferase (hyg B PT) were constructed. As figure 46 demonstrates, functional tTa 
and hyg B PT were expressed from the tTa/2A/hyg B vectors, thereby indicating that the 
addition of an extra amino acid (proline, derived from the 2A sequence after cleavage) to the 
N-terminus of hygB PT did not inhibit its function. However, upon transfection and selection 
of 293/E cells with pEBV-tTa/hygB & pTEPSHNntPk (->->) (in the presence of tetracycline), 
again only 1 colony grew from an initial 106 cells transfected which tested negative for tTa & 
HNntPk expression by immunofluorescence (data not shown).
However, the second approach in which native 293 cells were transfected with the 
plasmid pEBV-tTa/neo and subsequently selected with Geneticin, resulted in the successful 
isolation of a cell-line (table 5) which expressed high-levels of the tTa protein. This cell-line 
was transfected with the EBV-based HNntPk expressing plasmids pTEP4HNntPk (->->) & 
pTEPSHNntPk (->->), and are currently undergoing selection for the isolation of drug- 
resistant cell-lines.
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2.3 / Influence of vector type on transient gene expression.
In an attempt to construct cell-lines which inducibly expressed Pk-tagged HN, 
various driver and responder vectors were constructed in which episomal or non-episomal 
sequences are present. In a transient expression analysis in EBNA-1 expressing 293 cells, it 
was observed that the presence of EBV-sequences on the responder and driver plasmids 
significantly increased the production of HNntPk (figures 51 & 52). The increase in protein 
production from the EBV-based plasmids is most likely due to their continued retention and 
replication in the cell nucleus. Furthermore, it must be noted that the observed increase in 
expression of HNntPk is probably conservative, as equivalent weights of EBV and non-EBV 
plasmids were transfected. Therefore, the actual number of EBV-based plasmid molecules 
transfected into the 293/E cells would have been approximately half as many compared to 
the non-EBV plasmids, due to the larger size of the EBV-based vectors.
3 / Amplification of EBV-based vectors.
High-level recombinant protein production from mammalian cells has routinely been 
achieved through the amplification of genome-integrated sequences, whereby copy numbers 
reaching 100 to 1000 are frequently obtained after amplification. However, this process of 
amplification usually takes place over a long period involving up to 3 months work due to 
the time required for drug-selection and clonal isolation. A perhaps more attractive approach 
to gene amplification is through the amplification of episomally maintained plasmids.
The amplification of episomes within mammalian cells is not a novel idea and has 
been successfully demonstrated by Dubridge et al. (1985) in which an SV40 orz-containing 
BPV-based vector, present at a stable copy number in a mouse cell line, was amplified (50-100 
fold, to a maximum copy number of -10,000 per cell) upon fusion with the SV40 LTAg- 
expressing cell-line Cos-7. Furthermore, Haase et al. (1989) and Heinzel et al.(1988) have 
demonstrated the amplification of EBV-based vectors in mammalian cells, whereby SV40 orz- 
containing EBV-based plasmids were amplified by the transient production of the SV40 
LTAg, to a maximum copy number of -1000 per cell.
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Furthermore, an important feature of the SV40 LTAg amplification system is that
there is not a significant increase in the frequency of point mutations which occur in the 
vector after amplification, although there was a small, but demonstrable, increase in the 
frequency of deletion mutations, especially if the plasmids contained inverted repeat regions 
(Heinzel et al., 1988).
Although, as detailed above, amplification of EBV-based vectors has already been 
established, it has not been investigated whether the increase in the EBV-based plasmid copy 
number results in a subsequent increase in gene expression & protein production of an 
encoded protein. Furthermore, the above amplification findings have been performed in cells 
which stabily maintain an episome and are amplified via transfection with plasmids 
encoding the SV40 LTAg, or are fused to cells expressing the LTAg. Neither of these two 
situations are satisfactory if even a small scale-up in protein production was required.
Therefore, a system was envisaged whereby a primate cell-line would be produced 
which could inducibly express the SV40 LTAg, using the tTa system. The tTa scheme was 
chosen as the inducible system primarily for three reasons; (1) the tTa system has been 
utilised in this laboratory and the components were immediately available, (2) basal levels of 
expression in the uninduced phenotype have been demonstrated to be negligible or very low, 
and (3) ease of induction, by the removal of tetracycline. Clones would be isolated which 
produced LTAg to high-levels upon induction, but which demonstrated negligible 
production in the non-induced phenotype. The cell-line (in an uninduced state) would then 
be transfected with an SV40 on-containing EBV-based plasmid which encodes the gene of 
interest under a constitutive promoter such as the hCMV IE enhancer/promoter. Cell-lines 
which produced the protein of interest to varying levels, would be isolated and the episome 
amplified by the induction of the SV40 LTAg and protein production, prior to and after 
induction of LTAg, would be determined. Therefore, the first stage of the project was to 
construct a suitable plasmid encoding the tTa protein. For this purpose the plasmid pGEM- 
tTa/hygB (which does not possess an SV40 ori) was successfully constructed and shown to 
express functional tTa and hygromycin B phosphotransferase (figures 45 & 46). The second
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part of the project was to construct a suitable amplifiable EBV-based plasmid which encoded
a non-toxic protein.
3.1 I IPoductionooft^e SV5 Pprottuiffom tonSV50 ori-containinnifcBV-batsd plaasnid.
Two EBV-based vectors which possessed an SV40 ori and which encode the non-toxic 
SV5 P protein downstream from the hCMV enhancer /promoter, were constructed and 
shown to express SV5 P by immunofluoresence and Western blot analysis (figures 54 and 55). 
The two plasmids differed in that the orientation of the P transcription unit was opposite to 
that of the EBNA-1 transcript in the vector designated pCEP8/P (-><-), whist the vector 
termed pCEP8/P (->->), had the P transcript in the same orientation to that of EBNA-1. The (- 
>->) vector was shown to produce more P protein in a transient expression assay when 
compared to the (-><-) vector (figure 56).
This result is in agreement with the findings of Young et al. (1988), where the similar 
orientation of transcripts resulted in more protein production than the opposite orientation. 
However, in contrast to the results obtained by Young et al. where the interferon-gamma 
gene positioned in the opposite orientation to that of EBNA-1 resulted in negligible 
production of the protein (compared to the high-level production observed when the 
transcripts were in the same orientation), there was only a moderate -3 fold difference in P 
protein production from the two plasmids (figure 56). This observed difference may be a 
reflection on the transcription activation elements used by Young et al. which consisted of 
either a; hCMV IE enhancer combined with an SV40 promoter, or a moloney sarcoma virus 
enhancer combined with a metallothionien promoter, whereas, in the experiment reported 
here, the P protein was driven by a hCMV IE enhancer/promoter element. A further factor 
in the observed difference may be due to the use, by Young et al, of monkey CV-1 cells 
compared to human 293 cells that were utilised in P protein production. However, this 
moderate difference in protein production between the two orientations was also observed 
for the HNntPk protein when expression was driven from the tetracycline responsive 
promoter (figures 51 & 52), which may suggest that the substantial difference in protein 
production observed by Young et al. is the exception rather than the norm.
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Furthermore, synchronisation of 293/E ciIIs at the G2/M phase of the cell-cycle 
prior to transfection, did not result in an increased production of the P protein when 
compared to untynchronisld cells (figure 57). This is in contrast to the findings of 
Teshigawara & Katsura (1992), who demonstrated a 10-fold increase in IL-2 receptor E-chain 
production after transfection of their EBV-based plasmid into G2/M synchronised cells. This 
increase in protein production was attributable to an increase in plasmid copy number as 
determined by a Southern blot analysis of a Hirt extract. However, the analysis of protein 
production carried out by Teshigawara & Katsura was performed on transiently transfected 
EBV-derived Blcellt (Raji) in which transfection efficiencies (determined by fluorescent 
activated cell sorting) was 24 % in the unsynchronised cell population (90% transfection 
efficiency in the synchronised cell population), whereas the P protein experiment was 
analysed on transiently transfected embryonic kidney cells (293), with a transfection 
efficiency (determined by E-gal. assay) of only -10%. However, another possible reason for 
the observed lack of increased protein production after synchronisation, is that perhaps the 
293 cells were not in fact synchronised since, other than the visual observation that the cells 
has slowed in their replication rate, a direct analysis was not performed to confirm 
synchrony of the population,.
Having successfully constructed appropriate EBV-based plasmids and demonstrated 
the successful production of a non-toxic protein (the SV5 P protein) encoded from these 
plasmids, the next part of the project was to construct the plasmid which would inducibly 
produce the SV40 LTAg.
3.2 / Production ofthe SV40LTAg protein.
Prior to constructing the plasmid which should inducibly express the LTAg, the PCR 
product obtained from the PCR-amplification of the cDNA of the LTAg gene (from the 
plasmid pSV on) was sua-olonld into the vector pcDNAl / amp (due to necessary restriction 
endonuclease sites being available) to produce the plasmid pCT7LTAg. Transient 
transfection of the plasmid into 293 cells resulted in the detection of a nuclear-localised 
protein (figure 59), as expected for the SV40 LTAg. However, further analysis by Western
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blot (figure 60, panel A) revealed the presence of a prominent band at - 33 Kda, with minor 
bands at - 40 Kda, 55 Kda and 90 Kda (the latter of which corresponds to full length 
modified SV40 LTAg).
It is not clear why the lower mwt. species were detected since similar sized products 
were not detected from the control Cos-7 cell extracts or from the pSVori transfected cell 
extracts. PCR-induced mutagenesis resulting in premature translation-termination might 
have explained the presence of the lower bands, if it was not for the detection of some full 
length product. Furthermore, 5 separate transformants demonstrated a similar detection 
pattern (figure 60, panel B). Perhaps expression of the LTAg gene from the T701O promoter in 
vTF7-3 infected cells might further elucidate why the lower mwt. bands are being detected, 
i.e. is the lack of an intron affecting the expression of the LTAg gene. Due to the unexpected 
truncated product, sub-cloning into the plasmid for inducible expression of LTAg was not 
undertaken. Therefore, a cell-line which inducibly expressed the LTAg was not produced. 
However, the feasibility of increasing protein production from constitutively expressing cell­
lines, using the SV40 LTAg to amplify SV40 orz-containing EBV-based. plasmids, was 
investigated.
3.3 / Anah/sii of rtie trensieet (^^pUbfc^tic^fi oeprer-^e^t.
For this purpose, 293-based cell-lines were constructed which constitutively produced 
the SV5 P protein encoded on an EBV-based plasmid. Five cell-lines were characterised and 
shown to have varying levels of P protein production. However, transient transfection of the 
SV40 LTAg plasmid, pSVorz, into the cell-lines did not result in any significant increase in 
expression of the P protein (figure 61). The lack of an increased level in protein production 
could be due to the following reasons;
1) Insufficient amounts of LTAg were produced, leading to insufficient plasmid 
amplification. Indeed experiments performed by Gerard & Gluzman (1985) demonstrated a 
direct correlation between high-level expression of SV40 LTAg and high-level replication of 
SV40 DNA. Furthermore, the expression of the LTAg gene from the pSVon' plasmid is driven 
by the SV40 early promoter which has been demonstrated to be down regulated by the
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adenovirus Ela protein (Veliech & Ziff, 1985) which is constitutively expressed in 293 cells 
(Graham et al., 1977). Indeed, as figure 60 panel A demonstrated, the amount of LTAg 
produced in the pSVori transfected 293 cells is considerably less than in Cos-7 cells which 
expressed high levels of LTAg.
2) It is possible, although unlikely, that the pCEP8/P (->->) plasmid might in fact not be 
maintained as an episome and has instead been integrated into the genome. Indeed, Stary & 
Sarasin (1992) have demonstrated the isolation of a cell clone in which an EBV-based vector 
had integrated into the Hela cell genome. A Hirt extract (Hirt, 1969) followed by a Southern 
blot analysis ( or PCR analysis) would determine whether this is the case or not.
3) The transfection efficiency of the pSVori plasmid into the P cell-lines (as determined by a fi- 
gal. assay) was only ~10 %. Therefore, perhaps there were insufficient cells expressing the 
LTAg, within the transfected population, to produce a significant increase in protein 
production.
4) It is also possible that sequences present within the EBV-based vectors are inhibitory to 
amplification by the SV40 LTAg. However, Heinzel et al. (1988) have demonstrated that 
EBNA-1 & ori P sequences, at least, are not inhibitory for replication by SV40 LTAg. 
Transfection of the pCEP8/P vectors into Cos-7 cells would resolve whether inhibitory 
sequences are present.
5) It is also possible that substantial plasmid amplification did occur, but that there was not a 
corresponding increase in protein production. An analysis by Hirt extraction followed by 
Southern blotting would clarify the matter.
4 / Future Developments.
4.1 / Pk-tag & anti-Pk mAb for use as an epitope-tagging system.
It has been demonstrated that the Pk-tag oligopeptide does not interfere with the
processing and antigenicity of the SV5 HN & F glycoproteins when attached to the termini of 
these proteins, and will therefore further the use of Pk-tag for the epitope-tagging of 
glycoproteins produced in mammalian cells. The above analysis was primarily directed
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towards the production of Pk-tagged glycoproteins for use in vaccine development, and 
therefore the functional characteristics of the Pk-tagged HN & F have not been determined. 
Therefore, an analysis to determine whether or not the presence Pk-tag at the termini of HN 
or F interferes with the haemagglutinin & neuraminidase function of HN, and the fusion 
function of F, should be carried out. Fiurthermore, the above analysis has only been 
performed on two model glycoproteins and further analysis with other Pk-tagged 
glycoproteins expressed in mammalian ciIIs will support the use of Pk-tag/anti-Pk mAb for 
use as a "universal" epitope-tagging system. Moreover, if problems were encountered when 
using the 14 amino acid Pk-tag, then the length of the tag can be reduced to 9 amino acids 
without loss of affinity to the anti-Pk mAb (Southern it al., 1991). Furthermore, preliminary 
data suggests that the epitope recognised by the anti-Pk mAb may even be as small as 5 
amino acids (R.E. Randall, personal communication).
However, a drawback in the Pk-tag/anti-Pk mAb system, in comparison to for 
example the BTag system, is that the current anti-Pk monoclonal antibody has such a high 
affinity for the Pk-tag epitope that, for the purpose of immuno-affinity purification, 
denaturing conditions have to be employed for successful antibody/antigen separation. 
However, this problem should be rectified by the isolation of lower binding-affinity Pk-tag 
specific monoclonal antibodies which are currently being produced and screened (C. Dunn, 
Ph.D project, University of St. Andrews).
4.2 / Novel oectens Ott rscombinant protein orofucttof int mammalionc tils.
It has been observed by Haase ct nl. (1989) that after amplification of SV40 cn■- 
containing plasmids by a transient production of LTAg, within only 12 days the plasmid 
copy number had significantly dropped. The aforementioned system of controlled inducible 
expression of LTAg would allow "boosting" of the copy number at regular intervals. 
Furthermore, an adaptation of this system is envisaged where selectable markers such as 
DHFR or MDR-1 could be added to the EBV-based plasmids, in addition to the current 
histidinol or hygromycin B resistance markers. Initial expressing cell-lines would be selected 
using hygB or hisD, and after amplification of the plasmid copy number by transient
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production of the LTAg (either inducibly expressed, or transfected into the cells via plasmid 
DNA) cells in which the copy number has been boosted to high-levels could be selected for 
by incubation in high concentrations of selectable drug (such as methotrexate, if DHFR, or 
colchicine, if MDR-1). Maintenance of the cells in the high concentration of drug may 
maintain a high episomal copy number. This system would also be useful for the 
amplification of plasmids encoding toxic proteins, as the protocol would allow the isolation 
of stable high copy number clones without the requirement for induction of protein 
production (if the protein was under control of tTa, then induction of LTAg production 
would also lead to induced production of the toxic protein).
Many experiments are performed in cell-lines derived from rodents, and 
subsequently the above systems would be redundant in those cells due to the need for 
primate-cell factors for the replication of plasmids by EBNA-1 and SV40 LTAg. However, a 
suitable alternative episomal amplification system for rodent cells could be conceptualised by 
employing the rodent-cell-replication-competent-EBV-based-plasmid (Krysan & Calos, 1993) 
with the addition of a polyomavirus ori, whereby expression of polyomavirus LTAg would 
lead to the amplification of the episomal plasmid in rodent cells.
An even more interesting and exotic development could be to produce a dual nuclear 
and cytoplasmic amplification system (NACA system, figure 63), whereby the nuclear 
amplification stage of a DNA virus is combined with the cytoplasmic amplification phase of 
an RNA virus. In one scenario, as previously detailed, a cell-line would be produced where 
the SV40 LTAg was under tTa control. An SV40 orz'-COntaining EBV-based plasmid would be 
constructed which contained the gene-of-interest adjoined to the replicase/transcriptase (rep) 
coding sequence from the alphavirus; semliki forest virus, in which expression of the 
transcript is under tTa control. Upon induction of the tetracycline responsive promoter, 
amplification of the episome in the nucleus occurs along with the concurrent expression of 
the rep/gene-of-interest transcript. The rep/gene-of-interest transcript is transported to the 
cytoplasm whereby translation of the mRNA results in the production of the rep genes and 
the subsequent high-level amplification of the rep / gene-of-interest transcript followed by a 
simultaneous high-level expression of the gene-of-interest. The firefly luciferase protein or
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the green fluorescent protein would be suitable reporter proteins for initial analysis of the 
feasibility of the system..
Furthermore, it has been observed by Haase et al. (1994) that high-level transcription 
can inhibit the replication of autonomously replicating plasmids. Therefore, if this was found 
to be a problem, the above system could be modified by, as previously described, adding 
selectable markers encoding DHFR or MDR-1 to the plasmid vector, and selecting for cells 
harbouring high copy number episomes after the transient introduction of the LTAg. 
Expression of the rep/gene-of-interest should not occur since the cells would be in the 
uninduced state, and therefore transcription should not interfere with the plasmid 
amplification phase of the system.
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Amp ColEl pA DHFR/MDR-1 pSV40
Episomally maintained, SV40orz-containing (for 
amplification by SV40 LTAg), EBV-based Plasmid with inducible 
gene-of-interest expression.
ori P pTK HisD/HygB
Rep/GOT
Promoter for rraneoriprion 
of the gene-of-interest by 
the Rep genes.
AAAAAp(mRNA), 5' CAP
Recognition sequences for 
the amplification of the 
mRNA within the cytoplasm 
by the Rep genes
Figure 62: Diagramatic representation of the components involved in the proposed 
scheme of a dual Nuclear And Cytoplasmic Amplification (NACA) system.
The depicted plasmid is transfected into primate cells which oonerirut-vely express high- 
levels of the tTa driver protein, and drug reeietant cells are isolated using b-etidinol or 
hygromycin B. The epieomal-conrain-ng cell-line is then transfected with a plasmid 
expressing the SV40 LTAg, and cells which have amplified the episomal copy number are 
selected with drugs selecting for high levels of DHFR or MDR-1. Induction of expression 
of the Rep/ GOI transcript leads to high level production of mRNA which is transported to 
the cytoplasm. Translation of the mRNA leads to synthesis of the Rep proteins which 
further amplify the mRNA in the cytoplasm and also rranecriaee & caps the mRNA for the 
gene-of-interest. Such a process should lead to the production of high-levels of epeo-fied 
protein.
APPENDIX A
Open reading frame of the SV5 HN-gene (W3a),
(1698bp, 565 amino acids, 62,164 Da unmodified).
ATG GTT GCA GAA GAT GCC CCT GTT AGG GCC ACT TGC CGA GTA TTA TTT
Met val ala glu asp ala pro va 1 arg ala thr cys arg val leu phe
CGA ACA ACA ACT TTA ATC TTT CTA TGC ACA CTA CTA GCA TTA AGC ATC
arg thr thr thr 1 eu ile phe 1 eu cys thr 1 eu leu ala leu ser ile
TCT ATC CTT TAT GAG AGT TTA ATA ACC CAA AAG CAA ATC ATG AGC CAA
ser ile 1 eu tyr glu ser leu ile thr gin lys gin ile met ser gin
GCA GGC TCA ACT GGA TCT AAT TCT GGA TTA GGA AGT ATC ACT GAT CTT
ala gly ser thr gly ser asn ser gly leu gly ser ile thr asp leu
CTT AAT AAT ATT CTC TCT GTC GCA AAT CAG ATT ATA TAT AAC TCT GCA
leu asn asn ile 1 eu ser val ala asn gin ile ile tyr asn ser ala
GTC GCT CTA CCT CTA CAA TTG GAC ACT CTT GAA TCA ACA CTC CTT ACA
va 1 ala leu pro leu gin leu asp thr leu glu ser thr leu leu thr
GCC ATT AAG TCT CTT CAA ACC AGT GAC AAG CTA GAA CAG AAC TGC TCG
ala ile lys ser 1 eu gin thr ser asp lys 1 eu glu gin asn cys ser
TGG AGT GCT GCA CTG ATT AAT GAT AAT AGA TAC ATT AAT GGC ATC AAT
trp ser ala ala 1 eu ile asn asp asn arg tyr ile asn gly ile asn
CAG TTC TAT TTT TCA ATT GCT GAG GGT CGC AAT CTG ACA CTT GGC CCA
gin phe tyr phe ser ile ala glu gly arg asn 1 eu thr 1 eu gly pro
CTT CTT AAT ATG CCT AGT TTC ATT CCA ACT GCC ACG ACA CCA GAG GGC
leu 1 eu asn me t pro ser phe ile pro thr ala thr thr pro glu gly
TGC ACC AGG ATC CCA TCA TTC TCG CTC ACT AAG ACA CAC TGG TGT TAT
cys thr arg ile pro ser phe ser leu thr lys thr his trp cys tyr
ACA CAC AAT GTT ATC CTG AAT GGA TGC CAG GAT CAT GTA TCC TCA AAT
thr his asn val ile leu asn gly cys gin asp his va 1 ser ser asn
CAA TTT GTT TCC ATG GGA ATC ATT GAA CCC ACT TCT GCC GGG TTT CCA
gin phe val ser met gly ile ile glu pro thr ser ala gly phe pro
TTC TTT CGA ACC CTA AAG ACT CTA TAT CTC AGC GAT GGG GTC AAT CGT
phe phe arg thr 1 eu lys thr 1 eu tyr leu ser asp gly val asn arg
AAG AGC TGC TCT ATC AGT ACA GTT CCG GGG GGT TGT ATG ATG TAC TGT
lys ser cys ser ile ser thr val pro gly gly cys me t met tyr cys
TTT GTT TCT ACT CAA CCA GAG AGG GAT GAC TAC TTT TCT GCC GCT CCT
phe va 1 ser thr gin pro glu arg asp asp tyr phe ser ala ala pro
CCA GAA CAA CGA ATT ATT ATA ATG TAC TAT AAT GAT ACA ATC GTG GAG
pro glu gin arg ile ile ile met tyr tyr asn asp thr ile val glu
CGC ATA ATT AAT CCA CCC GGG GTA CTA GAT GTA TGG GCA ACA TTG AAC
arg ile ile asn pro pro gly val leu asp val trp ala thr leu asn
CCA GGA ACA GGA AGC GGG GTA TAT TAT TTA GGT TGG GTG CTC TTT CCA
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pro giy thr giy ser giy val tyr tyr leu giy trp val 1 eu phe pro
ATA TAT GGG GGG GTG ATT AAA GGT AGG AGT TTA TGG AAT AAT GAA GGA
ile tyr giy g 1 y val ile lys giy thr ser l eu trp asn asn gin ala
AAT AAA TAG TTT ATG GGG GAG ATG GTT GGT GGT GTG TGG TGA GAA AAG
asn lys tyr phe ile pro gin met val ala ala leu cys ser g i n asn
CAG GGA AGT GAA GTC GAA AAT GGT AAG TGA TGA TAG TAT AGG AGG TGG
gin ala thr gin val gin asn ala lys ser ser tyr tyr ser ser trp
TTT GGG AAT GGA ATG ATT GAG TGT GGG ATG GTG GGA TGT GGT GTT GGA
phe giy asn arg met ile gin ser giy ile leu ala cys pro leu arg
CAG GAT GTA AGG AAT GAG TGT TTA GTT GTG GGG TTT TGT AAT GAT GAG
gin asp leu thr asn glu cys leu val leu pro phe ser asn asp gin
GTG GTT ATG GGT GGT GAA GGG AGA TTA TAG ATG TAT GGT GAG TGG GTG
val 1 eu met giy ala glu giy arg leu tyr met tyr giy asp ser val
TAT TAG TAT GAA AGA AGG AAT AGT TGG TGG GGT ATG AGG ATG GTG TAT
tyr tyr tyr gin arg ser asn ser trp trp pro met thr met leu tyr
AAG GTA AGG ATA AGA TTG AGT AAT GGT GAG GGA TGT GGT ATA TGA GGT
lys va 1 thr ile thr phe thr asn giy gin pro ser ala ile ser ala
CAG AAT GTG GGG AGA GAG GAG GTG GGT AGA ^T GGG AGA GGA GAG TGG
gin asn val pro thr gin gin va i pro arg pro giy thr giy asp cys
TCT GGA AGG AAT AGA TGT ^G GGT TTT TGG TTG AGA GGA GTG TAT GGG
ser ala thr asn arg cys pro giy phe cys leu thr giy val tyr ala
GAT GGG TGG TTA GTG AGG AAG GGT TGG TCT A^ AGT AGA TTT GGA TGA
asp ala trp leu 1 eu thr asn pro ser ser thr ser thr phe giy ser
GAA GGA AGG TTG AGT GGT TGT TAT GTG AAG AGA GGA AGT CAG GGT ATG
glu ala thr phe thr giy ser tyr leu asn thr ala thr gin arg ile
AAT GGG AGG ATG TAT ATG GGG AAG AAG AGA GAG ATG ATA AGG TGA GAG
asn pro thr me t tyr ile ala asn asn thr gin ile ile ser ser gin
CAA TTT GGA TGA AGG GGT GAA GAA GGA GGA TAT GGG GAG AGA AGG TGT
gin phe giy ser ser giy gin glu ala ala tyr giy his thr thr cys
TTT AGG GAG AGA GGG TGT GTT ATG GTA TAG TGT ATG TAT ATT ATT GAA
phe arg asp thr giy ser va l met val tyr cys ile tyr ile ile glu
TTG TGG TGA TGT GTG TTA GGA GAA TTT GAG ATT GTC GGA TTT ATG GGT
leu ser ser ser leu l e u giy g i n phe g i n ile va l pro phe ile arg
GAG GTG AGA GTA TGG
g i n val thr leu ser
140
APPENDIX B
Open reading frame of the SV5 F-gene (W3a).
(1587bp, 529 amino acids 56,560 Da unmodified).
ATG GGT ACT ATA ATT GAA TTT CTG GTG GTG TGG TGT GTA TTG GGA GGA
Met giy thr ile ile gin phe leu va l val ser cys leu l e u ala giy
GCA GGG AGG GTT GAT GGA GGA G^ GTG ATG GAA ATG GGT GTG ATT GGA
ala giy ser leu asp pro ala ala l eu met gin ile giy val ile pro
ACA AAT GTG GGG GAA GTT ATG TAT TAT AGT GAG TGA TGA GGA TTG
thr asn val arg gin leu met tyr tyr thr g l u ala ser ser ala phe
ATT GTT GTG AAG TTA ATG AGA ATT GAG TGG ATT AGT GGA TGT
ile val val lys leu met pro thr ile asp s er pro i l e ser giy cys
AAT ATA AGA TGA ATT TGA AGG TAT AAT GGA AGA GTG AGA AAA GTG GTA
asn ile thr ser ile ser ser tyr asn ala thr val thr lys l eu leu
CAG ATG GGT GAG AAT TTG GAG AGG ATT AGG AAG GAG TTG ATT GGA
gin pro ile giy glu asn leu glu thr ile arg asn gin l eu ile pro
ACT GGG AGG AGA GGG GGG TTT GGA GGG GTG GTG ATT GGA TTA GGT GGA
thr arg arg arg arg arg phe ala giy val val ile giy leu ala ala
TTA GGA GTA GGT AGT GGA GAG GTG AGT GGA GTG GGA GTA GTA
leu giy val ala thr ala ala gin val thr ala ala val ala leu va l
AAG GGA AAT GAA AAT GGT GGG GGT ATA GTG AAT GTG AAA AAT GGA ATG
lys ala asn glu asn ala ala a l a ile leu asn leu lys asn ala ile
CAA AAA AGA AAT GGA GGA GTT GGA GAT GTG GTG GAG GGG AGA GAA TGA
gin lys thr asn ala ala va 1 ala asp val val gin ala thr gin ser
CTA GGA AGG GGA GTT GAA GGA GTT GAA GAT GAG ATA AAG AGT GTG GTA
1eu giy thr ala va l gin ala val gin asp hi s ile asn s er val va 1
AGT ^A GGA ATT AGA GGA G^ AAT TGT AAG GAA GAT GGT ATG ATT
ser pro ala i l e thr ala ala asn cys lys ala gin asp ala ile ile
GGG TGA ATG GTG AAT GTG TAT TTG A^ GAG TTG AGA AGG ATG TTG GAG
giy ser ile leu asn leu tyr 1 eu thr glu 1 eu thr thr ile phe hi s
AAT GAA ATT AGA AAG GGT GGA TTG AGT ATT AGA ATT GAA GGT TTA
asn gin i l e thr asn pro ala 1 eu ser pro ile thr ile gin ala leu
AGG ATG GTA GTG GGG AGT AGG TTG AGT GTG GTG GAA AAA TGT TTG
arg ile leu leu giy ser thr 1 eu pro thr val val glu lys ser phe
AAT A^ GAG ATA AGT GGA GGT GAG GTT GTG TGA TGA GGG TTA TTG AGA
asn thr g i n ile ser ala ala glu leu leu ser ser giy l eu leu thr
GGG GAG ATT GTG GGA TTA GAT TTG A^ TAT ATG GAG ATG GTG ATA AAA
giy gin ile val giy leu asp leu thr tyr met gin me t val ile lys
ATT GAG GTG GGA AGT TTA AGT GTA GAA GGT GGA AGG GAG ATG ATA GAT
ile glu leu pro thr leu thr val gin pro ala thr gin ile ile asp
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CTG GCC AGG ATT TGT GCA Ttg ATT AAG AAT GAA GAA GTG ATG GGG GAA
leu ala thr ile ser ala phe ile asn asn gin glu val me t ala gin
TTA CCA AGA GGT GTT ATG GTG AGT GGG AGG TTG ATG GAA GGG TAT GGG
leu pro thr arg val me t val thr gly ser l eu ile gin ala tyr pro
GCA TCG GAA TGG AGG ATT AGA G^ AAG AGT GTG TAG TGT AGG TAT AAT
ala ser gin cys thr ile thr pro asn t h r val tyr cys a r g tyr a s n
GAT GCC GAA GTA GTG TGA GAT GAT AGT ATG GGT TGG GAA GGT AAG
asp ala gin val 1 eu ser asp asp thr met ala cys leu gin gly asn
TTG ACA AGA TGG AGG TTG TGT GGA GTG GTT GGG AGG TTT GTG ACT GGA
leu thr arg cys thr phe ser pro val val gly ser phe l eu thr arg
TTC GTG GTG TTG GAT GGA ATA GTT TAT GGA AAT TGG AGG TGG ATG TTG
phe val leu phe asp gly ile val tyr ala asn cys arg ser met l e u
TGC AAG TGG ATG GAA GGT GGT GGT GTG ATG GTA GAG GGG AGT TGA TGG
cys lys cys me t gin pro ala ala val ile l eu g i n pro ser ser ser
COT GTA AGT GTG ATT GAG ATG TAG AAA TGT GTG AGT GTG GAG GTT GAG
pro val thr va l ile asp me t tyr lys cys val ser leu gin leu asp
AAT CTC AGA TTG AGG ATG AGT GAA TTG GGG AAT GTA AGG TAG AAT AGG
asn l eu arg phe thr ile thr gin leu ala asn val thr tyr asn ser
ACC ATG AAG CTT GAA TGA TGG GAG ATG TTG TGT ATT GAT GGG TTG GAT
thr ile lys leu glu ser ser gin ile leu ser ile asp pro leu asp
ATA TGG GAA AAT GTA GGT GGG GTG AAT AAG AGT GTA AGT GAT GGA GTA
ile ser gin asn leu ala a l a val asn lys ser leu ser asp ala leu
CAA GAG TTA GGA CAA AGT GAG AGA TAT GTT TGT GGA ATG AGA TGA GGT
gin his 1 eu ala gin ser asp thr tyr leu ser ala ile thr ser ala
ACG AGT AGA AGT GTA TTA TGG ATA ATA GGA ATG TGT GTT GGA TGG TTA
thr thr t h r ser val leu ser ile ile ala ile cys leu gly ser leu
GGT TTA ATA TTA ATA ATG TTG GTG AGT GTA GTT GTG TGG AAG TTA TTG
gly 1 eu ile leu ile ile leu l eu ser va l val val trp lys l e u leu
ACC ATT GTG GTT GGT AAT GGA AAT AGA ATG GAG AAT TTT GTT TAT GAT
thr ile val va l ala asn arg asn arg me t glu asn phe val tyr his
AAA TAA
lys OGH
142
REFERENCES
ABDUL JABBAR, M. and NAYAK, D.P. (1987). Signal processing, glycosylation and secretion of 
mutant haemagglutinins of a human influenza virus by S. cerevisiae. MOL. AND CELL. BIOL. 
7(4):,1476-1485.
AKUSJARVI, G., SVENSSON, C. and NYGARO, O. (1987). A mechanism by which adenovirus 
virus-associated RNAi controls translation in a transient expression assay. MOL. AND CELL. 
BIOL. 7(1):,549-551.
ANDERSON, K., STOTT, E.J. and WERTZ, G.W. (1992). Intracellular processing ofthe human 
respiratory syncytial virus fusion glycoprotein: amino acid substitutions affecting folding, transport 
and cleavage. J. GEN. VIROL. 73:,1177-1188.
ANTON, M. and GRAHAM, F.L. (1995). Site-specific recombination mediated by an adenovirus 
vector expressing the Cre recombinase protein: a molecular switch for control of gene expression. J. 
VIROL. 69(8) *.,4600-4606.
BAGAI, S. and LAMB, R.A. (1995). Quantitative measurement of paramyxovirus fusion: 
differences in requirements of glycoproteins between simian virus 5 and human parainfluenza virus 3 
or newcastle disease virus. J. VIROL. 69(11):,6712-6719.
BAGAI, S. and LAMB, R.A. (1995). Individual roles of N-linked oligosaccharide chains in 
intracellular transport ofthe paramyxovirus SV5 fusion protein. VIROLOGY 209(1):,250-256.
BERGERON, J.J.M., BRENNER, M.B., THOMAS, D.Y. and WILLIAMS, D.B. (1994). Calnexin: 
a membrane-bound chaperone ofthe endoplasmic reticulum. TIBS 19:,124-128.
BERGLUND, P., TUBULEKAS, I. and LILJESTROM, P. (1996). Alphaviruses as vectors for gene 
delivery. TIBTECH 14:,130-134.
BERNS, K.I. Parvoviridae: The viruses and their replication. In: Fields Virology, edited by 
Fields, B.N., Knipe, D.M. and Howley, P.M. Philadelphia: Lippincott-Raven, 1996, p. 2173- 
2197.
BERTHOLET, C., DRILLIEN, R. and WITTER, R. (1985). One hundred base pairs of 5' flanking 
sequence of a vaccinia virus late gene are sufficient to temporally regulate late transcription. PROC. 
NATL. ACAD. SCI. USA 82:,2096-2100.
BLOBEL, G. and Sabatini, D.D. Biomembranes, Plenum Publishing, 1971. pp. 193-195.
BLUMBERG, B.M., GIORGI, C. and KOLAKOFSKY, D. (1983). N-protein of vesticular 
stomatitis virus selectively encapsidates leader RNA in vitro. CELL 32:,559-567.
BOECK, R. and KOLAKOFSKY, D. (1994). Positions +5 and +6 can be major determinants ofthe 
efficieny ofnon-AUG codons for protein synthesis. EMBO J 13(15):,3608-3617.
BOHN, W., RUTTER, G., HOHENBERG, H., MANNWEILER, K., et al. (1986). Involvement of 
actin filaments in budding of measles virus: studies on cytoskeletons of infected cells. VIROLOGY 
149:,91-106.
143
BOMSEL, M. and MOSTOV, K. (1991). Ststing tf plasma mcmbsanc psttcins in epithelial tells. 
CURR. OPEN. CELL BIOL. 3 :,647-653.
BONIFACINO, J.S. and LIPPINCOTT-SCHWARTZ, J. (1991). DcgsaUatitn tf psttcins within 
thc cnUtplasmit sctitclcm. CURR. OPEN. CELL BIOL. 3:,592-600.
BOUSSE, T., TAKIMOTO, T. and PORTNER, A. (1995). A singlc amint atiU thangc cnhantcs thc 
fusitn pstmttitn attivity tf human pasainflucnza vises typc 1. VIROLOGY 209:,654-657.
BRICKELL, P.M. and PATEL, M.S. (1995). Epstcin-Bass vises scplitatitn stuUics anU thcis 
applitatitn tt vcttts Ucsign. MOL. BIOTECH. 3:/'l(^(9-205.
BRINSTER, R.L., ALLEN, J.M., BEHRINGER, R.R., GELINA, R.E., et al. (1988). Intrnns 
intscasc tsanscsiptifnnl eftitiency in tsansgcnit mitc. PROC. NATL. ACAD. SCI. USA 85(3):,836- 
840.
BUCHHOLZ, C.J., SPEHNER, D., DRILLIEN, R., NEUBERT, W.J., et al. (1993). Thc ttnscsvcU 
N-tcsminal scgitn tf ScnUai visus nutlcttapsiU psttcin, NP, is scquiscUfts nutlctcapsiU asscmbiy. J. 
VIROL. 67:,5803-5812.
BUCHMAN, A.R. and BERG, P. (1988). Ctmpasistn tf intstn-UcpcnUcnt anU intstn-inUcp^^Uc^t 
gcnc cxpscssitn. MOL. AND CELL. BIOL. 8(10) :,4395l4405.
CARAVOKYRI, C. and LEPPARD, K.N. (1995). Ctnstitutivc cpistmal cxpscssitn tf ptlypcptiUc 
IX (pIX) in a 293-bascU tcll linc ttmplcmcnts thc Ucfiticnty tf pIX mutant aUentvisus typc 5. J. 
VIROL. 69(11):,6627-6633.
CHAKRABARTI, S., BRECHLING, K. and MOSS, B. (1985). Vattinia visus cxpscssitn vcttts: 
Ct-cxpscssitn tf b-galatttsiUasc gcnc pstviUcs visual scsccning tf sctombinant visal plaqucs. MOL. 
AND CELL. BIOL. 5:,3403-3409.
CHARTIER, C., DEGRYSE, E., GANTZER, M., DIETERLE, A., et al. (1996). Effiticnt 
gcncsatitn tf scttmbinant aUcntvisus vctttss by htmfltgtcs scttmbinatitn in Esthcsitia ttli. J. 
VIROL. 70(7):,4805-4810.
CHEN, X., LI, Y., XIONG, K. and WAGNER, T.E. (1994). A sclf-initiating cukasyttit tsansicnt 
gcnc cxpscssitn systcm bascU tn tt-tsansfcctitn tf battcsitphagc T7 RNA ptSymcsasc anU DNA 
vctttss trnntaining a T7 auttgcnc. NAR 22(11):,2114-2120.
CHIDGEY, M.A.J. (1993). Psttcin tasgcting tt Ucnsc ttsc sctscttsy gsanulcs. BIOESSAYS 
15(5):,317-321.
CHOPPIN, P.W. AND COMPANS, R.W. Reproduction of Paramyxoviruses. In: 
Ctmpschcnsivc Vist^y Vtlume 4, edited by Fraenkel-Conrat, H. and Wagner, R.R. New York: 
Plenum Publishing Corporation, 1975, p. 95-178.
COLLEY, KJ.., LEE, E.U.., ADLER, B.., BROWNE, J.K.., et al. (1989). Ctnvcssitn tf a Gtlgi 
appasatus sialyltsansfcsasc tt a sctscttsy psttcin by scplatcmcnt tf thc NH2-tcsminal signal anthts 
with a signal pcptiUc. J. BIOL. CHEM. 264(30) :,17619l17622/
COLLINS, P.L. The molecular biology of human respiratory syncytial virus (RSV) of the 
genus Pneumovirus. In: Thc Paramyxtvisuscs, edited by Kingsbury, .. New York: Plenum 
Publishing Corporation, 1991, p. 103-162.
COLLINS, P.L. and MOTTET, G. (1991). Ptsttsanslatitnal pstGcssing anU tligtmcsisatitn tf thc 
fusitn glyctpsttein tf human scspisattsy syntytial visus.]. GEN. VIROL. 72:,3095-3101.
144
COLMAN, P.M., VARGHESE, J.N. and LAVER, W.G. (1983). Structure o/ the catalytic and 
antigenic sites in influenza-virus neuraminidase. NATURE 303:,41-44.
COLMAN, P.M., HOYNE, P.A. and LAWRENCE, M.C. (1993). Sequence and structure 
alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. J. 
VIROL. 67:,2972-2980.
COSSON, P. and LETOURNEUR, F. (1994). Coatomer interaction with di-lysine endoplasmic 
reticulum retention motifs. SCIENCE 263(5153:,1629-1631.
COTTEN, M., WAGNER, E., ZATLOUKAI, K. and BIRNSTIEL, M.L. (1993). Chicken 
adenovirus (CELO virus) particles augment receptor-mediated DNA delivery to mammalian cells 
and yield exceptional levels ofstable transformants.]. VIROL. 67(7) :,3777-3785.
CREGG, J.M. (1993). Recent advances in the expression of foreign genes in Pichia pastoris. 
BIOTECH 11:,905-910.
CROWLEY, K.S., REINHART, G.D. and JOHNSON, A.E. (1993). The signal sequence moves 
through a ribosomal tunnel into a noncytoplasmic aqueous environment at the ER membrane early in 
translocation. CELL 73:,1101-1115.
CURRAN, J., HOMANN, H., BUCHHOLZ, C., ROCHAT, S., et al. (1993). The hypervariable c- 
terminal tail of the sendai paramyxovirus nucleocapsid protein is required for template function but 
not for RNA encapsidation. J. VIROL. 67:,4358-4364.
CURRAN, J., MARQ, J. and KOLAKOFSKY, D. (1992). The Sendai virus nonstructural C 
proteins specifically inhibit mRNA synthesis. VIROLOGY 189:,647-656.
CURRAN, J., PELET, T. and KOLAKOFSKY, D. (1994). An acidic activation like domain of the 
Sendai virus P protein is required for RNA synthesis and encapsidation. VIROLOGY 202:,875-884.
CZARNOTA, G.J., ANDREWS, D.W., FARROW, N.A. and OTTENSMEYER, F.P. (1994). A 
structure for the signal sequence binding-protein SRP54 - 3D reconstruction from stem images of 
single molecules. J. STRUCT. BIOL. 113(l):,35-46.
DAHLER, A., WADE, R.P., MUSCAT, G.E.O. and WATERS, M.J. (1994). Expression vectors 
encoding human growth hormone (hgh) controlled by human muscle-specific promoters: prospects for 
regulated production ofhgh by myoblast transfer or intravenous injection. GENE 145:,305-310.
DANKO, I. and WOLFF, J.A. (1994). Direct gene transfer into muscle. VACCINE 12(16):,1499- 
1502.
DAVIS, H.L., MICHEL, M-L., MANCINI, M, SCHLEEF, M., et al. (1994). Direct gene transfer 
in skeletal muscle: plasmid DNA-based immunization against the hepatitis B virus surface antigen. 
VACCINE 12(16):,1503-1509.
DAVIS, H.L., SCHRIMBECK, R., REIMANN, J. and WHALEN, R.G. (1995). DNA-mediated 
immunization in mice induces a potent MHC class I-restricted cytotoxic T-lymphocyte response to 
the hepatitis-B envelope protein. HUMAN GENE THERAPY 6(11) :,1447-1456.
DENG, R., WANG, Z., MIRZA, A.M. and IORIO, R.M. (1995). Localization of a domain on the 
paramyxovirus attachment protein required for the promotion of cellular fusion by its homologous 
fusion protein spike. VIROLOGY 209:,457-469.
DEUSCHLE, U., MEYER, W.K.H. and THIESEN, H-J. (1995). Tetracycline-reversible silencing 
ofeukaryotic promoters. mOl. AND CELL. BIOL. 15(4) :,1907-1914.
DIDCOCK, L.J. Honours project thesis, University ofSt. Andrews, 1996.
145
DOMS, R.W., KELLER, D.S., HELENIUS, A.H. and BALCH, W.E. (1987). Role for ATP in 
regulating the assembly and transport of vesicular stomatitis virus G protein trimers, J. CELL. 
BIOL. 105:,1957-1969.
DU, R-P., GAIL, E.D., WYDE, P.R., YAN, W-Y., et al. (1994). A prototype recombinant vaccine 
against respiratory syncytial virus and parainfluenza virus type 3. BIOTECH 12:,813-818.
DUBENSKY, T.W., DRIVER, D.A., POLO, J.M., BELLI, B.A., et al. (1996). Sindbis virus DNA- 
based expression vectors: Utility for in vitro and in vivo gene transfer. J. VIROL. 70(1) :,508-519.
DUBRIDGE, R.B., LUSKY, M., BOTCHAN, M.R. and CALOS, M.P. (1985). Amplification of a 
bovine papillomavirus-simian virus 40 chimera. J. VIROL. 56:,625-627.
ECTOR, K.J., NG, D.T.W. and LAMB, R.A. (1992). Specific residues flanking the transmembrane 
domain of a viral glycoprotein are involved in internalization and lysosomal transport. MOL. BIOL. 
CELL 3(5):,60.
EDWARDS, C.P. and ARUFFO, A. (1993). Current applications of Cos cell based transient 
expression systems. CURR. OPIN. IN BIOTECH. 4:,558-563.
ELROY-STEIN, O., FUERST, T.R. and MOSS, B. (1989). Cap-independent translation of mRNA 
conferred by encephalomyocarditis virus 5" sequence improves the performance of the vaccinia 
virus/bacteriophage T7hybrid expression system. PROC. NATL. ACAD. SCI. USA 86:,6126-6130.
FIEDLER, K. and SIMONS, K. (1995). The role of N-glycans in the secretory pathway. CELL 
81:,309-312.
FINK, D.J., DELUCA, N.A., GOINS, W.F. and GLORIOSO, J.C. (1996). Gene transfer to 
neurons using herpes simplex virus-based vectors. ANNUAL REVIEWS IN NEUROSCIENCE 
19:,265-287.
FUERST, T.R., EARL, P.L. and MOSS, B. (1987). Use of a hybrid vaccinia virus-T7 RNA 
polymerase system for expression of target genes. MOL. AND CELL. BIOL. 7 :,2538-2544.
FUERST, T.R., NILES, E.G., STUDIER, F.W. and MOSS, B. (1986). Eukaryotic transient 
expression system based upon recombinant vaccinia virus that synthesises bacteriophage T7 RNA 
polymerase. PROC. NATL. ACAD. SCI. USA 83:,8122-8126.
FULLER, D.H. and HAYNES, J.R. (1994). A qualitative progression in HIV type-1 glycoprotein- 
120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based 
glycoprotein-120 vaccine. AIDS RESEARCH AND HUMAN RETROVIRUSES 10(11):,1433- 
1441.
FUKUSHIGE, S. and SAUER, B. (1992). Genomic targetting with a positive-selection lox 
integration vector allows highly reproducible gene expression in mammalain cells. PROC. NATL. 
ACAD. SCI. USA 89:,7905-7909.
FYNAN, E.F., WEBSTER, R.G., FULLER, D.H., HAYNES, J.R., et al. (1993). DNA vaccines: 
Protective immunizations by parental, mucosal, and gene-gun inoculations. PROC. NATL. ACAD. 
SCI. USA 90:,11478-11482.
GALINSKI, M.S. (1991). Paramyxoviridae-transcription and replication. ADVANCES IN VIRUS 
RESEARCH 39:,129-162.
GAUT, J.R. and HENDERSHOT, L.M. (1993). The modification and assembly of proteins in the 
endoplasmic reticulum. CURR. OpIn. CeLl BIOL. 5:,589-595.
146
GEISOW, MJ. (1992). Glyttpsttcin gSytans-stlcs anU ctntstls. TIBTECH 10:,333-335.
GELLISSEN, G. (1992). Pstgscss in Ucvcltping mcthylttstphit ycasts as expsessitn systcms. 
TIBTECH 10:,413-417.
GERARD, R.D. and GLUZMAN, Y. (1985). Ncw htst ccll systcm fts scgulatcU simian visus 40 
DNA scplitatitn. MOL. AND CELL. BIOL. 5(11) :,3231-3240.
GETHING, M.J., MCCANNON, K. and SAMBROOK, J. (1986). Expscssitn tf wilU-typc anU 
mutant ftsms tf influcnza visus hcmagglutinin: thc stle tf ftlUing mtsa-tchulas tsansptst. CELL 
46:,938-952.
GETHING, M-J. (1991). MtSctuSas thapcstncs: inUiviUualists ts gstupics. CURR. OPIN. CELL 
BIOL. 3:,610-614.
GETHING, M-J. and SAMBROOK, J. (1992). PsttcinftlUing in thc tcll. NATURE 355:,33-44.
GHOSH, G., VANDUYNE, G., GHOSH, S. and SIGLER, P.B. (1995). Sfsuttusc tfNF-kB p50 
htmtUimcs btunU tt a kB sitc. NATURE 373 ::303-310.
GIANNI, M., GALLINA, A., BARB ANTI-BROD ANO, G. and MILANESI, G. (1988). 
Cfnstitutivc anU inUutiblc expscssitn tf tltncU human intcsfcstn-bS gcnc in hcla tclls thmugh an 
cpistmal eukaryttic vcctts. BBRC 157(3):,1175-1181.
GILBOA, E. and SMITH, C. (1994). Gcnc thcsapy fts infcttitus Uiscascs: thc AIDS mtUcl. TIG 
10(4):,139-144.
GILMORE, R. (1991). Thc psttcin tsanslfcatitn appasatus tf thc stugh cnUtplasmic sctitulum, its 
asstciatcU psttcins, anU thc imthanism tf tsansltcatitn. CURR. OPIN. CELL BIOL. 3:,580-584.
GLORIOSO, J.C., DELUCA, N.A. and FINK, D.J. (1995). Dcvcltpmcnt anU applitatitn tf hcspcs 
simplcx visus vctttss fts human gcnc thcsapy. aNnULA REVIEWS IN MICROBIOLOGY 
49:,675-710.
GLUZMAN, Y. (1981). SV40-tsansftsmcU simian tclls supptst thc scplitatitn tf c^^ly SV40 
mutants. CeLl 23:,175.
GOEDDEL, D.V. (1990). Gcnc cxpsessitn tcthntltgy. METHODS IN ENZYMOLOGY 185:,1­
471.
GOEDDEL, D.V. (1990). Systcms fts hetcstltgtus gcnc cxpscssitn. METHODS IN 
ENZYMOLOGY 185:,3-7.
GOLDSTEIN, S., FORDIS, C.M. and HOWARD, B.H. (1989). EnhantcU tsansfcttitn cfficicnty 
anU impsavcU celTscsvival aftcs cScttstptsatitn tf G2/M synchstniscU cclls anU tscatmcnt with 
stUium butysatc. NAR 17(10):,3959-397L
GOODBOURN, S. Eukasyttit gcnc tsanscsiptitn, OxforddRL PRESS, 1996.
GOSSEN, M. and BUJARD, H. (1992). Tight ttntstl tf gcnc expscssitn in mammalian cclls by 
tctsatytlinc-scsptnsive pstmttcss. PROC. NATL. ACAD. SCI. USA 89:,5547-5551.
GOSSEN, M., BONIN, A.L., FREUNDLIEB, S. and BUJARD, H. (1994). InUctible gmc 
cxpscssifn systcms fts highcs cukasyttit cclls. CURR. OPIN. BIOTECH. 5:,516-520.
GOSSEN, M., FREUNDLIEB, S., BENDER, G., MULLER, G., et al. (1995). Tsanscsiptitnal 
attivatitn by tctsacytlincs in mammalian tclls. SCIENCE 268:,,766-1769.
147
GRAHAM, F.L. AND PREVEC, L. Adenovirus based expression vectors and recombinant 
vaccines. In: Vaccines: New approaches to immunological problems, edited by Ellis, R.W. 
Butterworth, 1992, p. 363-390.
GRAHAM, F.L., SMILEY, J., RUSSELL, W.C. and NAIRU, R. (1977). Characteristics of a human 
cell-line transformed by DNA from human adenovirus type 5. J. gEn. VIROL. 36:,59-72.
GRUBER, C. and LEVINE, S. (1983). Respiratory syncytial virus polypeptides.3. The envelope- 
associated proteins. J. GEN. VIROL. 64:,825-832.
GRUBER, C. and LEVINE, S. (1985). Respiratory syncytial virus polypeptides.4. The 
oligosaccharides of the glycoproteins. J. GEN. VIROL. 66:,417-432.
GRUNERT, S. and JACKSON, R.J. (1994). The immediate downstream codon strongly influences 
the efficiency of utilisation of eukaryotic translation initiation codons. EMBO J 13(15) :,3618-3630.
GUPTA, R.K., RELYVELD, E.H., LINDBLAD, E.B., BIZZINI, B., et al. (1993). Adjuvants-a 
balance between toxicity and adjuvanticity. VACCINE H:,293-306.
HAASE, S.B., HEINZEL, S.S. and CALOS, M.P. (1994). Transcription inhibits the replication of 
autonomously replicating plasmids in human cells. MOL. AND CELL. BIOL. 14(4) :,2516-2524.
HAASE, S.B., HEINZEL, S.S., KRYSAN, P.J. and CALOS, M.P. (1989). Improved EBV shuttle 
vectors. MUTATION RESEARCH 220:,125-132.
HAMAGUCHI, M., YOSHIDA, T., NISHIKAWA, K., NARUSE, H., et al. (1983). Transcriptive 
complex of Newcastle disease virus I. Both L and P proteins are required to constitute an active 
complex. VIROLOGY 128:,105-117.
HAMMOND, C., BRAAKMAN, I. and HELENIUS, A. (1994). Role of N-linked oligosaccharide 
recognition, glucose trimming, and calnexin in glycoprotein folding and quality-control. PROC. 
NATL. ACAD. SCI. USA 91(3) :,913-917.
HAMMOND, C. and HELENIUS, A. (1995). Folding of VSV G-protein - sequential interaction 
with Bip and calnexin. SCIENCE 266(5184) :,456-458.
HANKE, T. and RANDALL, R.E. (1994). Processing of viral proteins for presentation by 
molecules of the major histocompatibility complex. REV. MED. VIROL. 4:,47-61.
HANKE, T., SZAWLOWSKI, P. and RANDALL, R.E. (1992). Construction of solid matrix- 
antibody-antigen complexes containing simian immunodeficiency virus p27 using tag-specific 
monoclonal antibody and tag-linked antigen. J. GEN. VIROL. 73:,653-660.
HANKE, T., YOUNG, D.F., DOYLE, C., JONES, I., et al. (1995). Attachment ofan oligopeptide 
epitope to the C-terminus of recombinant SlV gpl60 facilitates the construction ofSMAA complexes 
while preserving CD4 binding. J VIROL METHODS 53:,149-156.
HARRISON, T.M., HUDSON, K., MUNSON, S.E., UFF, S., et al. (1995). Derivation and partial 
analysis of two highly active myeloma cell transfeccante. BIOCHIMICA eT BIOPHYSICA ACTA 
1260:,147-156.
HASS, J., PARK, E.C. and SEED, B. (1996). Codon useage limitation in the expression of HIV-1 
envelope glycoprotein. CURRENT BlOLOGY 6(3):,315-324.
HEINZEL, S.S., KRYSAN, P.J., CALOS, M.P. and DUBRIDGE, R.B. (1988). Use of simian virus 
40 replication to amplify Epstein-Barr virus shuttle vectors in human cells. J. VIROL. 62(10):,3738- 
3746.
148
HERRLER, G. and COMPANS, R.W. (1983). Posttranslational modification and intracellular 
transport of mumps virus glycoproteins. J. VIROL. 47:,354-362.
HIEBERT, S.W., PATERSON, R.G. and LAMB, R.A. (1985). Haemagglutinin-neuraminidase 
protein of the paramyxovirus simian virus 5: nucleotide sequence of the mRNA predicts an N- 
terminal anchor. J. VIROL. 54:,l-6.
HIEBERT, S.W., PATERSON, R.G. and LAMB, R.A. (1988). Cell surface expression and 
orientation in membranes of the 44 amino acid SH protein of simian virus 5. J. VIROL. 62:,2347­
2357.
HIGH, S. (1995). Protein translocation at the membrane of the endoplasmic reticulum. PROG 
BIOPHYS MOLEC BIOL 63:,233-250.
HIRANO, A. and WONG, T.C. (1991). Generation of mammalian-cells expressing stably measles- 
virus proteins via bicistronic RNA. J VIROL METHODS 33:,135-147.
HIRT, B. (1967). Selective extraction of polyoma DNA from infected mouse cell cultures. J. MOL. 
BIOL. 26:,365-369.
HISHIYAMA, M., TANABAYASHI, K., TAKEUCHI, K. and YAMADA, A. (1996). 
Establishment of cell-lines stably expresing mumps-virus giycoproteins. JAPANESE JOURNAL OF 
MEDICAL SCIENCE & BIOLOGY 49(1) ,29-38.
HITT, M., BETT, A.J., ADDISON, C., PREVEC, L., et al. (1995). Techniques for human 
adenovirus vector construction and characterisation. METHODS IN MOLECULAR GENETICS 
7:,13-30.
HOHFELD, J. and HARTL, F.U. (1994). Post-translational protein import and folding. CURR. 
OPIN. IN BIOTECH. 6:,499-509.
HORIKAMI, S.M., CURRAN, J. and KOLAKOFSKY, D. (1992). Complexes of sendai virus NP-P 
and P-L proteins are required for defective interfering particle genome replication in vivo. J. VIROL. 
66:,4901-4908.
HORVATH, C.M. and LAMB, R.A. (1992). Studies on the fuion peptide of a paramyxovirus fusion 
glycoprotein: roles of conserved residues in cell fusion. J. VIROL. 66(4):,2443-2455.
HU, A.H., CATTANEO, R. and SCHWARTZ, S. (1994). Role of N-linked oligosaccharide chains 
in the processing and antigenicity of measles virus haemagglutinin protein. J. GEN. VIROL. 
75:,1043-1052.
HU, A.H. and NORRBY, E. (1994). Role of individual cysteine residues in the processing and 
antigenicity of the measles virus haemagglutinin protein. J. GEN. VIROL. 75:,2173-2181.
IMLER, J-L. (1996). Adenovirus vectors as recombinant viral vaccines. VACCINE 13(13):,1143- 
1151.
IWATA, S., SCHMIDT, A., TITANI, K., SUZUKI, M., et al. (1994). Assignment of disulfide 
bridges in the fusion glycoprotein of sendai virus. J. VIROL. 68:,3200-3206.
JALANKO, A., KALLIO, A., SALMINEN, M. and ULMANEN, I. (1989). Efficient synthesis of 
influenza virus haemagglutinin in mammalian cells with an extrachromosomal Epstein-BArr virus 
vector
. GENE 78:,287-296.
JANKNECHT, R. and NORDHEIM, A. (1992). Affinity purification of histidine-tagged proteins 
transiently produced in Hela cells. GeNe 121:,321-324.
149
JIN, H., SUBBARAO, K., BAGAI, S., LESER, G.P., et al. (1996). PalmitySntiom tf thc influcnza 
visus hcmagglutinin (H3) is ntt csscntial fts visus asscmbly os infcttivity. J. VIROL. 70(3) :,1406- 
1414.
JUNGNICKEL, B. and RAPOPORT, T.A. (1995). A ptsttasgcting signal scqucntc scttgnititn 
cvcnt in thc cmUoplasmit-reticulum mcmbsanc. CELL 82:l261l270.
KANE, S.E. and GOTTESMAN, M.M. (1993). Usc o/ multiUsug scsistantc gcnc in mammalian 
expscssifn vcctrnrs. METHODS IN ENZYMOLOGY 217:,34-47.
KAUFMAN, R.J. and MURTHA, P. (1987). Tsanslatitnal ttntstl mcUiatcU by cukasyttic 
initiatitn fattts-2 is scstsictcU tt spccific mRNAs in tsansfcttcU tclls. MOL. AND CELL. BIOL. 
7(4):,1568-1571.
KAWAHARA, N., YANG, X.Z., SAKAGUCHI, T., KIYOTANI, K., et al. (1992). Distributt 
anU substsatc spctifitity tf mtsaccllulas psttctlytit psttcssing cnzymc(s) fos pasamyxoviscs fusitn 
glyttpsttcins. J. gEn. VIROL. 73::583-590.
KAWAMOTO, T., MAKINO, K., NIW, H., SUGIYAMA, H., et al. (1988). IUcntifitatitn tf thc 
human bcta-actin cnhantcs anU its binUing-fattts. MOL. AND CELL. BIOL. S:,267-272.
KEMBALL-COOK, G., GARNER, I., IMANAKA, Y., NISHIMURA, T., et al. (1994). Hig-h-lcvc.l 
psoUcttion tf human bl^U ttagulatitn fatttss VII anU XI using a ncw mammalian cxpscssitn 
vcttts. GENE 139 :,275-279.
KOHARA, A. and ET AL., (1992). Cfnftsmatitn anU lcngth tf thc signal scqucncc affctt 
prfccssmg tf setsctory psotein. FEBS 311(3):,226-230.
KOZAK, M. (1989). Thc scanning mtUcl fos tsamslation-an upUatc. J. CELL. BIOL. 108(2):,229- 
241.
KRIEGLER, M. (1990). Asscmbly tf cnhantcss, pstmttcss anU splitc signals tt ttntstl cxpscssitn tf 
tsansfcsscU gcms. METHODS IN ENZYMOLOGY 185 :,512-527.
KRONMAN, C., VELAN, B., GOZES, Y., LEITNER, M., et al. (1992). PsfUuction anU sctsctitn 
tf high lcvcls cf sct^^mbi^nant human atctylthtlincstcsasc in tultuscU tcll lincs: micsohctcsogenicty tf 
thc catalytic subunit. GENE 121 :,2995304.
KRYSAN, P.J. and CALOS, M.P. (1993). Epstcin-Bass visus-bascU vctttss that scplicatc in mUrnt 
tclls. GENE 136:,137443.
KUCHLER, K. (1993). Unusual mutcs tf psoteim sctsctitn: thc casy way tut. TRENDS IN CELL 
BIOLOGY 3::421-425.
LAMB, R.A. and CHOPPIN, P.W. (1977). Thc synthcsis tf ScnUai visus ptlypcptiUcs in infcttcU 
tclls. III. Phtsphtsylatitn ()fpolypcptiUes. VIROLOGY 81:,382-397.
LAMB, R.A. and KOLAKOFSKY, D. PasamyxtvisiUac: The viruses and their replication. In: 
FiclUs Vistltgy, edited by Fields, B.N., Knipe, D.M. and Howley, P.M. Philadelphia: 
Lippincott-Raven, 1996, p. 1177-1204.
LAMB, R.A., MAHY, B.W.J. and CHOPPIN, P.W. (1976). Thc synthcsis tf ScnUai visus 
ptlypcptiUcs in infcctcU cclls. VIROLOGY 69:l116-l31/
LAURING, B., KREIBICH, G. and WIEDMANN, M. (1995). Thc mtsinsit ability tf sibtstmcs tt 
binU tt enUoplasmic scticclum mcmbsancs is segulatcU by signal scttgnititn pastitlc anU nastcnt 
ptlypcptiUc asstciatcU ctmplcx. PROC. NATL. ACAD. sCi. USA 92(21):z9435-9439.
150
LAURING, B., SAKAI, H., KREIBICH, G. and WIEDMANN, M. (1995). Nascent polypeptide- 
associated complex protein prevents mistargeting of nascent chains to the endoplasmic reticulum. 
PROC. NATL. ACAD. SCI. USA 92(12) :,5411-5415.
LEBKOWSKI, J.S., MCNALLY, M.M., OKARMA, T.B. and LERCH, L.B. (1988). Adeno- 
associated virus: a vector system for efficient introduction and integration of DNA into a variety of 
mammalian cell types. MOL. AND CELL. BIOL. 8:,3988-3996.
LECHNER, J. (1989). Structure and biosynthesis of prokaryotic glycoproteins. ANNU. REV. 
BIOCHEM. 58:,173-194.
LEHMAN, D.J., ROOF, L.L., BRIDEAU, R.J., AEED, P.A., et al. (1993). Comparison ofsoluble 
and secreted forms of human parainfluenza virus type-3 glycoproteins expressed from mammalian 
and insect cells as subunit vaccines. J. GEN. VIROL. 74(3):,459-469.
LEIB, D.A. and OLIVO, P.D. (1993). Gene delivery to neurons: Is herpes simplex virus the right 
tool for the job. BIOESSAYS 15(8) :,547-554.
LESER, G.P., ECTOR, K.J. and LAMB, R.A. (1996). The paramyxovirus simian virus 5 
hemagglutinin-neuraminidase glycoprotein, but not the fusion glycoprotein, is internalized via coated 
pits and enters the endocytic pathway. MOL. BIOL. CELL 7:,155-172.
LETOURNEUR, F., GAYNER, E.C., HENNECKE, S., DEMOLLIERE, C., et al. (1994). 
Coatomer is essential for retrieval of dilysine-tagged proteins to the endoplasmic reticulum. CELL 
79:,1199-1207.
LEVINSON, A.D. (1990). Expression of heterologous genes in mammalian cells. METHODS IN 
ENZYMOLOGY 185 :,485-496.
LEVITSKAYA, J., CORAM, M., LEVITSKY, V., IMREH, S., et al. (1995). Inhibition of antigen 
processing by the internal repeat region of the Epstein-Barr virus nuclear antigen -1. NATURE 
375:,685-688.
LEVY, J.P., MULDOON, R.R., ZOLOTUKHIN, S. and LINK, C.J. (1996). Retrovital transfer 
and expression of a humanised, red-shifted green fluorescent protein gene into human tumor cells. 
NATURE BIOTECHNOLOGY 14(5) :,610-614.
LEWIS, M.J. and PELHAM, H.R.B. (1992). Ligand-induced redistribution of a human KDEL 
receptor from the Golgi complex to the endoplasmic reticulum. CELL 68:,353-364.
LIEBER, A., SANDIG, V., SOMMER, W., BAHRING, S., et al. (1993). Stable high-level gene 
expression in mammalian cells by T7 phage RNA polymerase. METHODS IN ENZYMOLOGY 
217:,47-66.
LILJESTROM, P. (1994). Alphavirus expression systems. CURR. OPIN. BIOTECH. 5:,485-500.
LILJESTROM, P. and GAROFF, H. (1991). A new generation of animal cell expression vectors 
based on the Semliki forest virus replicon. BIOTECH 9:,1356-1361.
LINGAPPA, V.R., CHAIDEZ, J., YOST, C.S. and HEDGPETH, J. (1984). Determinants for 
protein localisation-beta-lactamase signal sequence directs globin across microsomal membranes. 
PROC. NATL. ACAD. SCI. USA 81(12):,456-460.
LUPTON, S. and LEVINE, A.J. (1985). Mapping genetic elements of Epstein-Barr virus that 
fucilitate extrachromosomal persistence of Epstein-barr-virus derived plasmids in human cells. MOL. 
AND CELL. BIOL. 5:,2533-2542.
151
LUZIO, J.P. and BANTING, G. (1993). Eukaryotic membrane traffic: retrieval and retention 
mechanisms to achieve organelle residence. TIBS 18:,395-398.
LYKO, P., MARTOGLIO, B., JUNGNICKEL, B., RAPOPORT, T.A., et al. (1995). Signal 
sequence processing in rough microsomes. J. BIOL. CHEM. 270(34) :,19873-19878.
MACHAMER, C.E. (1993). Targeting and retention of Golgi membrane proteins. CURR. OPIN. 
CELL BIOL. 5;,606-612.
MACKETT, M., SMITH, G.L. and MOSS, B. (1982). Vaccinia virus: A selectable eukaryotic 
cloning and expression vector. PROC. NATL. AcAd. sCi. USA 79:,7415-7419.
MACKETT, M., SMITH, G.L. and MOSS, B. (1984). General method for the production and 
selection of infectious vaccinia virus recombinants expressing foreign genes. J. VIROL. 49:,857-864.
MADISON, E.L. and BIRD, P. (1992). A vector pSHT for the expression and secretion of protein 
domains in mammalian cells. GENE 121:,179-180.
MALLABIABARRENA, A., JIMENEZ, M., RICO, M. and ALARCON, B. (1995). A tyrosine- 
containing motif mediates ER retention of CD3-epsilon and adopts a helix-turn structure. EMBO J 
14(10):,2257-2268.
MANCINI, M., DAVIS, H., TIOLLAIS, P. and MICHEL, M.L. (1996). DNA-based 
immunization against the envelope proteins of the hepatitis-B virus. JOURNAL OF 
BIOTECHNOLOGY 44(1-3) :,47-57.
MARGOLSKEE, R.F., KAVATHAS, P. and BERG, P. (1988). Epstein-Barr virus shuttle vector 
for stable episomal replication of cDNA expression libraries in human cells. MOL. AND CELL. 
BIOL. 8(7):,2837-2847.
MARKWELL, M.A.K. and FOX, C.F. (1980). Protein-protein interactions within Paramyxoviruses 
identified by native disulphide bonding or reversible chemical cross linking. J. VIROL. 33:,152-166.
MATTHEWS, R.E.F. (1982). Classification and nomenclature of viruses. INTERVIROLOGY 17:,1­
18.
MELLITS, K.H. and MATHEWS, M.B. (1988). Effects of mutations in stem and loop regions on 
the structure and junction of adenovirus VA RNAi . EmBO J 7(9):,2849-2859.
MIGLIACCIO, G., NICCHITTA, C.V. and BLOBEL, G. (1992). The signal sequence receptor, 
unlike the signal recognition particle receptor, is not essential for protein translocation. J. CELL. 
BIOL. 117:,15-25.
MIGNATTI, P., MORIMOTO, T. and RIFKIN, D.B. (1992). Basic fibroblast growth-factor, a 
protein devoid of secretory signal sequence, is released by cells via a pathway independent of the 
endoplasmic-reticulum Golgi-complex. JOURNAL OF CELLULAR PHYSIOLOGY 151(1) :,81-93.
MILSTEIN, C., BROWNLEE, G., HARRISON, T. and MATHEWS, M.B. (1971). A possible 
precursor of immunoglobulin light chains. NATURE NEW BIOLOGY 239:,117-120.
MINER, J.N. and HRUBY, D.E. (1990). Vaccinia virus: a versatile tool for molecular biologists. 
TIBTECH 8 ;,20-25.
MIZUSHIMA, S. and NAGATA, S. (1990). pEF-BOS, a powerful mammalian expression vector. 
NAR 18(17):,5322.
MORGAN, E.M., RE, G.G. and KINGSBURY, D.W. (1984). Complete sequence of the Sendai 
virus NP gene from a cloned insert. VIROLOGY 135-,279-287.
152
MORRISON, T.G. (1988). Structure, function and intracellular processing of paramyxovirus 
membrane-proteins. VIRUS RESEARCH 10:,113-135.
MORRISON, T.G. and PORTNER, A. Structure, function and intracellular processing of the 
glycoproteins of Paramyxoviridae. In: The Paramyxoviruses, edited by Kingsbury, .. New 
York: Plenum Publishing Corporation, 1991, p. 347-382.
MORRISON, T.G., MCQUAIN, C., OCONNELL, K.F. and MCGINNES, L.W. (1990). Mature 
cell associated HN protein of NDV exists in two forms differentiated by posttranslational 
modification. VIRUS RESEARCH 5:,113-134.
MORRISON, T.G. AND SIMPSON, D. Conformation and activity of the Newcastle disease 
virus HN protein in the absence of glycosylation. In: The replication of negative strand viruses, 
edited by Bishop, D.H.L. and Compans, R.H. Amsterdam: Elsevier/North Holland, 1981, p. 
471-477.
MULLER, R. (1995). Transcriptional regulation during the mammalian cell cycle. TIG 11(5):,173- 
178.
NAKAMURA, K., HOMMA, M. and COMPANS, R. (1982). Effect of tunicamycin on the 
replication ofSendai virus. VIROLOGY 119:,447-487.
NANICHE, D., VARIOR-KRISHNAN, G., CERVONI, F., WILD, F., et al. (1993). Human 
membrane cofactor protein (CD46) acts as a receptor for measles virus. J. VIROL. 67:,6025-6032.
NEUBERGER, M.S. and WILLIAMS, G.T. (1988). The intron requirement for immunoglobulin 
gene expression is dependent upon the promoter. NAR 16(14):,6713-6724.
NG, D.T.W., HIEBERT, S.W. and LAMB, R.A. (1990). Different roles of individual N-linked 
oligosaccharide chains in folding, assembly and transport of the simian virus 5 haemagglutinin- 
neuraminidase. MOL. AND CELL. BIOL. 10(5) :,1989-2001.
NG, D.T.W., RANDALL, R.E. and LAMB, R.A. (1989). Intracellular maturation and transport of 
the SV5 type II glycoprotein hemagglutinin-neuraminidase: specific and transient association with 
GRP78-BiP in the endoplasmic reticulum and extensive internalisation from the cell surface. J. 
CELL. BIOL. 109(6 pt2),3273-3289.
NG, D.T.W. and WALTER, P. (1994). Protein translocation across the endoplasmic reticulum. 
CURR. OPIN. IN BIOTECH. 6:,510-516.
NILSSON, T. and WARREN, G. (1994). Retention and retrieval in the endoplasmic reticulum and 
Golgi apparatus. CURR. OPIN. IN BIOTECH. 6:,517-521.
NISHIO, M., TSURUDOME, M., KOMADA, H., KAWANO, M., et al. (1994). Fusion 
properties of cells constitutively expressing human parainfluenza virus type 4A hemagglutinin- 
neuraminidase and fusion glycoproteins. J. GEN. VIROL. 75(12):,3517-3523.
NOVICK, S.L. and HOEKSTRA, D. (1988). Membrane penetration of sendai virus glycoproteins 
during the early stage offusion with liposomes as determined by hydrophobic affinity labelling. 
PROC. NATL. ACAD. SCI. USA 85:,7433-7437.
OGONAH, O.W., FREEDMAN, R.B., JENKINS, N., PATEL, K., et al. (1996). Isolation and 
characterisation of an insect cell line able to perform complex N-linked glycosylation on recombinant 
proteins. BIOTECHNOLOGY 14:,197-202.
153
PANICALI, D. and PAOLETTI, E. (1981). Construction of poxviruses as cloning vectors: Insertion 
of the thymidine kinase gene from herpes simplex into the dNa of infectious vaccinia virus. PROC. 
NATL. ACAD. SCI. USA 79:,4927-4931.
PARKS, G. and LAMB, R.A. (1990). Defective assembly and transport of mutant paramyxovirus 
haemagglutinin-neuraminidase proteins containing altered cytoplasmic domains. J. VIROL. 
64(8):,3605-3616.
PARKS, G. and LAMB, R.A. (1990). Folding and oligomerisation properties of a soluble and 
secreted form of the paramyxovirus haemagglutinin-neuraminidase glycoprotein. VIROLOGY 
178:,498-508.
PARKS, G. and LAMB, R.A. (1991). Topology of eukaryotic type II membrane proteins-importance 
of N-terminal positively charged residues flanking the hydrophobic domain . CELL 64:,777-787.
PARKS, G.D. (1994). Mapping of a region of the paramyxovirus L protein required for the formation 
of a stable complex with the viral phosphoprotein P. J. VIROL. 68:,4862-4872.
PATERSON, R.G., HARRIS, T.J.R. and LAMB, R.A. (1984). Fusion protein of the paramyxovirus 
simian virus 5: nucleotide sequence predicts a highly hydrophobic glycoprotein 
. PROC. NATL. ACAD. SCI. USA 81:,6706-6710.
PATERSON, R.G., HIEBERT, S.W. and LAMB, R.A. (1985). Expression at the cell surface of 
biologically active fusion and Haemagglutinin-neuraminidase proteins of the paramyxovirus simian 
virus 5 from cloned cDNA. PROC. NATL. ACAD. SCI. USA 82:,7520-7524.
PATERSON, R.G. and LAMB, L.A. (1990). Conversion of a class II integral membrane protein into 
a soluble and efficiently secreted protein: multiple intracellular and extracellular oligomeric and 
conformationalforms.J. CELL. BlOL. 110:,999-1011.
PATERSON, R.G. and LAMB, R.A. (1987). Ability of the hydrophobic fusion-related external 
domain of a paramyxovirus F protein to act as a mebrane anchor. CelL 48:,441-452.
PATERSON, R.G., LAMB, R.A., MOSS, B. and MURPHY, B.R. (1987). Comparison of the 
relative roles of the F and HN surfacce glycoproteins of the paramyxovirus simian virus 5 in inducing 
protective immunity. J. VIROL. 61(6):,1972-1977.
PELHAM, H. (1992). The Florey lecture 1992, the secretion of proteins by cells. PROC. R. SOC. 
LOND. 250:,1-10.
PELHAM, H. (1994). About turn for COPS. CELL 79:,1125-1127.
PELHAM, H.R.B. (1990). The retention signal for soluble proteins of the endoplasmic reticulum. 
TIBS 15:,483-486.
PELHAM, H.R.B. (1991). Recycling of proteins between the endoplasmic reticulum and Golgi 
complex. CURR. OPIN. CELL BIOL. 3:,585-591.
PETITCLERC, D., ATTAL, J., THERON, M.C., BEARZOTTI, M., et al. (1995). The effect of 
various introns and transcription terminators on the efficiency of expression vectors in various 
cultured-cell lines and in the mammary-gland of transgenic mice. JOURNAL OF 
BIOTECHNOLOGY 40(3) :,169-178.
POCH, O., BLUMBERG, B.M., BOUGUELERET, L. and TORDO, N. (1990). Sequence 
comparison of five polymerases (L proteins) of unsegmented negative strand RNA viruses: theoretical 
assigment of functional d<^r^m^i-ii^. J. GEN. VIROL. 71:,1153-1162.
154
PORTNER, A., SCROGGS, R.A. and METZGER, D.W. (1987). Distinct functitns of antigcnit 
sitcs tf thc HN glyctpsttcm of scnUai visus. VIROLOGY 198:,61-68.
PRECIOUS, B., YOUNG, D.F., BERMINGHAM, A., FEARNS, R., et al. (1995). ImUutible 
cxpscssitn tf thc P, V anU NP gcncs of thc pasamyxtvisus simian visus 5 in tcll lincs anU an 
cxamination of NP-P anU NP-V intcsattitns. J. VIROL. 69:,8001l8010.
RANDALL, R.E., YOUNG, D.F., GOSWAMI, K.K.A. and RUSSELL, W.C. (1987). Istlatitn anU 
chasactcsisatifn tf momoclonal antibtUics tt simian visus 5 anU thcis usc in scvcalin.g antigcnit 
Uiffcscntcs bctwccn human, taninc anU simian istlatcs. J. GEN. VIROL. 68:,2769-2780/
RANDALL, R.E. and YOUNG, D.F. (1988). Humtsal anU cytotoxic T ccll immunc scspomscs tt 
in.tcsn.al anU cxtcrnal stscctcral psttcins tf simian visus 5 inUuccU by immunisatitn with soliU 
matsix-nnti.boUy-an.tigen■ ttmplexcs. J. GEN. VIROL. 69:,2505-2516.
RANDALL, R.E., YOUNG, D.F. and SOUTHERN, J.A. (1988). Immunisatitn. with stliU matsix- 
antibtUy-antigcn ctmplcxcs containing susfacc ts rntcsnal visus stsuttusal psftcims psttctts mitc 
from infcttion with thc pasamyxtvirus, simian visus 5. J. GEN. VIROL. 69:l2517-2526.
RANDALL, R.E. (1989). StliU matsix-amtibtUy-an.tigcn (SMAA) ctmplexcs fts tontsutting 
multivalcnt submit vaccines. IMMUNOLOGY TODAY 10:,336-339.
RANDALL, R.E. and YOUNG, D.F. (1991). StliU matsix-antibtUy-antigcn ctmplcxcs inUutc 
antigcn spctifit CD8+ cclls that clcas a pcssist^^t pasamyxtvisus imfcttifn. J. VIROL. 65(2):,719- 
726.
RANDALL, R.E., HANKE, T., YOUNG, D.F. and SOUTHERN, J.A. (1993). Twt-tag 
pusificatitn tf sccombinant psttcins fos thc tmtstsuttitn tf stliU matsix-amtiboUy-antigcn (SMAA) 
ttmplcxcs as vattincs. VACCINE 11(12):l1247-1952.
RANDALL, R.E. and SOUBERBIELLE, B.E. Presentation of virus anrigent for the induction 
of protective immunity. In:, 1994,
RANDALL, R.E., YOUNG, D.F., HANKE, T., SZAWLOWSKI, P., et al. (1994). Pusifitation tf 
antibtUy-antigcn ttmplcxcs containing sctfmbinant SIV psotcms: tompasistn. tf antigcn anU 
antibtUy-antigcn ctmplcxcs fts immunc psiming. VACCINE 12(4) :,351-358.
RAPIEJKO, P.J. and GILMORE, R. (1994). Signal scqucntc sccognititn anU tasgcting tf sibtsfmcs 
tt thc cnUtpSasmic-sctitulum■ by thc signal sctfgnititn pasticlc Ut ntt scquisc GTP. MOL. BIOL. 
CELL 5(8):,887-897.
REFF, M. (1993). High-lcvcl pstUuction. tf sctombinant immunoglobulins in mammalian tclls. 
CURR. OPIN. IN BIOTECH. 4:,573-576.
REHEMTULLA, A. and KAUFMAN, R.J. (1992). Psttcin. pstccssing within thc setscttsy 
pathway. CURR. OPIN. BIOTECH. 3:,560-565.
RHODES, A.D., SPITALI, M., HUTCHINSON, G., RUD, E.W., et al. (1994). Expscssiom, 
chasattcsisation. anU pusificatitn ts simian immcnoUefiticncy visus solublc, tligtmcsiscU gp 160 frtm 
mammalian tclls. J. GEN. VIROL. 75:,207-213.
RICHARDSON, J.H. and MARASCO, W.A. (1995). Intsaccllulas antiboUics: Uevcltpmcnt anU 
thcsapeutit potential. TIBTECH 13:,306-310.
ROBERTSON, J.S. (1994). Safety tonsiUcsations fos nutlcit atiU vaccinec. VACCINE 12(16) :/1596- 
1528.
155
ROSENBLUM, J.S., GILULA, N.B. and LERNER, R.A. (1996). On signal sequence 
polymorphisms and diseases ofdistribution. PROC. NATL. ACAD. SCI. USA 93(9) :,4471-4473.
ROTONDARO, L., MELE, A. and ROVERA, G. (1996). Efficiency of different viral promoters in 
directing gene expression in mammalian cells: effect of 3' - untranslated sequences. GENE 168:,195­
198.
ROUX, L., BEEFY, P. and PORTNER, A. (1985). Three variations in the cell surface expression of 
the haemagglutinin-neuraminidase glycoprotein of sendai virus. J. GEN. VIROL. 66:,987-1000.
RUDERT, F., VISSER, E., GRADL, G., GRANDISON, P., et al. (1996). pLEF, a novel vector for 
expression of glutathione S-transferase fusion proteins in mammalian cells. GENE 169:,281-282.
RUSSELL, R., PATERSON, R.G. and LAMB, R.A. (1994). Studies with cross-linking reagents on 
the oligomeric form of the paramyxovirus fusion protein. VIROLOGY 199:,160-168.
RYAN, K.W. and PORTNER, A. (1990). Separate domains of Sendai virus P protein are required 
for binding to viral nucleocapsids. VIROLOGY 174:,515-521.
SABBIONI, S., NEGRINI, M., RIMESSI, R., MANSERVIGI, R., et al. (1995). A BK virus 
episomal vector for constitutive high expression of exogenous cDNAs in human cells. ARCH. 
VIROL. 140:,335-339.
SAMBROOK, J., FRITSCH, E.F. AND MANIATIS, T. Expression of cloned genes in cultures 
mammalian cells. In: Molecular Cloning: A laboratory manual, edited by Ford, N., Nolan, C. 
and Ferguson, M. New York: Cold Spring Harbor Laboratory Press, 1989, p. 16.3-16.29.
SANDERSON, C.M., MCQUEEN, N.L. and NAYAK, D.P. (1993). Sendai virus assembly-m- 
protein binds to viral glycoproteins in transit through the secretory pathway. J. VIROL. 67:,651-663.
SANDERSON, C.M., AVALOS, R., KUNDU, A. and NAYAK, D.P. (1995). Interaction of 
Sendai viral F, HN and M proteins with host cytoskeletal and lipid components in Sendai virus- 
infected cells. Virology 209:,701-707.
SAUER, B. (1994). Site-specific recombination: developments and applications. CURR. OPIN. 
BIOTECH. 5:,521-527.
SCHEID, A. and CHOPPIN, P.W. (1974). Identification of biological activities of paramyxovirus 
glycoproteins. Activation of cell fusion, hemolysis and infectivity by proteolytic cleavage of an 
inactive precursor protein of Sendai virus. VIROLOGY 57:,470-490.
SERGEL, T. and MORRISON, T.G. (1995). Mutations in the cytoplasmic domain of the fusion 
glycoprotein of Newcastle disease virus depress syncytia formation. VIROLOGY 210:,264-272.
SERGEL-GERMANO, T. (1994). Mutations in the fusion peptide and heptad repeat regions of the 
Newcastle disease virus fusion protein block fusion. J. VIROL. 68(11) :,7654-7658.
SHAW, A.S., ROTTIER, P.J.M. and ROSE, J.K. (1988). Evidence for the loop model of signal- 
sequence insertion into the endoplasmic-reticulum. PROC. NATL. ACAD. SCI. USA 8 5 
(20):,7592-7596.
SHEN, E.S., COOKE, G.M. and HORLICK, R.A. (1995). Improved expression cloning using 
reporter genes and Epstein-Barr virus ori-containing vectors. GENE 156:,235-239.
SHENK, T. Adenoviridae: The viruses and their replication. In: Fields Virology, edited by 
Fields, B.N., Knipe, D.M. and Howley, P.M. Philadelphia: Lippincott-Raven, 1996, p. 2111­
2148.
156
SIMON, S. (1993). Translocation of proteins across the endoplasmic reticulum. CURR. OPIN. 
CELL BIOL. 5:,581-588.
SIMPSON, D.A. and LAMB, R.A. (1992). Alterations to influenza virus haemagglutinin 
cytoplasmic tail modulate virus infectivity. J. VIROL. 66(2) :,790-803.
STARY, A. and SARASIN, A. (1992). Simian virus 40 (SV40) large T antigen-dependent 
amplification of an Epstein-Barr virus-SV40 hybrid shuttle vector integrated into the human Hela 
cell genome. J. GEN. VIROL. 73:,1679-1685.
SUGDEN, B., MARSH, K. and YATES, J.L. (1985). A vector that replicates as aplasmid and can be 
efficiently selected in B lymphocytes transformed by Epstein-Barr virus. MOL. AND CELL. BIOL. 
5:,410-413.
TANIGAWA, T., HIKIDA, M., TAKAI, T. and OHMORI, H. (1993). Enhancement of expression 
of introduced b-galactosidase gene by 2-aminopurine in mammalian cell lines. JOURNAL OF 
FERMENTATION AND BIOENGINEERING 76(2) :,145-147.
TESHIGAWARA, T. and KATSURA, Y. (1992). A simple and efficient mammalian gene 
expression system using an EBV-based vector transfected by electroporation in G2/M phase. NAR 
20(10):,2607,
TIWARI, R.K. and ET AL, (1988). GENE INDUCTION BY INTERFERONS AND DOUBLE­
STRANDED RNA: SELECTIVE INHIBITION BY 2-AMINOPURINE. MOL. AND CELL. 
BIOL. 8(10):,4289-4294.
TRATSCHIN, J-D., MILLER, I.L., SMITH, M.G. and CARTER, B.J. (1985). Adeno-associated 
virus vector for high-frequency integration, expression, and rescue of genes in mammalian cells. 
MOL. AND CELL. BIOL. 5(11) :,3251-3260.
TRIMBLE, R.B. and VEROSTEK, M.F. (1995). Glycoprotein oligosaccharide synthesis and 
processing in yeast. TRENDS IN GLYCOSCIENCE AND GLYCOTECHNOLOGY 7(33) :,l-3.
ULMER, J.B., DECK, R.R., DEWITT, C.M., FRIEDMAN, A., et al. (1994). Protective immunity 
by intramuscular injection of low doses of influenza virus DNA vaccines. VACCINE 12(16):,1541- 
1544.
VALENZUELA, P.A., MEDINA, A., RUTTER, W.J., AMMERER, G., et al. (1982). Synthesis 
and assembly of hepatitis B virus surface antigen particles in yeast. NATURE 298;,347-350.
VARGHESE, J.N., WEBSTER, R.G., LAVER, W.G. and COLMAN, P.M. (1983). Structure of 
the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution. NATURE 303 :,35-40.
VIELICH, A. and ZIFF, E. (1985). Adenovirus Ela proteins repress transcription from the SV40 
early promoter. CELL 40:,705-716.
VEIT, M., SCHMIDT, M.F.G. and ROTT, R. (1989). Different palmitoylation of paramyxovirus 
glycoproteins. VIROLOGY 168:,173-176.
WALTER, P. and BLOBEL, G. (1981). Translocation of proteins across the endoplasmic reticulum. 
III. Signal recognition particle (SRP) causes signal sequence-dependent and site specific arrest of 
chain elongation that is released by microsomal membranes. J. CELL. BIOL. 91:,557-561.
WALTERS, M.C., FIERING, S., EIDEMILLER, J., MAGIS, W., et al. (1995). Enhancers increase 
the probability but not the level of gene expression. PROC. NaTl. ACAD. SCI. USA 92:,7125­
7129.
157
WANG, L-F., YU, M., WHITE, J.R. and EATON, B.T. (1996). BTag: a novcl six-scsiUuc cpittpc 
tag fos susvcillantc anU pusifitatitn tf sccombinant psotcins. GENE 169:,53-58.
WARD, G.A., STOVER, C.K., MOSS, B. and FUERST, T.R. (1995). Stsingcnt thcmital anU 
thcsmal scguSatitm of scttmbinant gcnc expscssifn by vaccinia visus vettoss in mammalian tclls. 
PROC. NATL. ACAD. SCI. USA 92:l6773l6777.
WARREN, C.E. (1993). Glyctsy/lation. CURR. OPIN. IN BIOTECH. 4:l596l602.
WAXHAM, M.N. and WOLINSKY, J.S. (1986). A fusing mumps visus vasiant seScctcU fstm a 
non-fusing pascnt with thc ncusaminiUasc inhibitos 2-Uctxy-2,3-UihyUst-N-atetylncusamimic atiU. 
VIROLOGY 151:,286-295.
WERTZ, G.W., COLLINS, P.L., YUNG, H.A., GRUBER, C., et al. (1985). NutlcotiUc-scqucntc tf 
thc G-psotein gcnc tf human scspisattry syntytial visus scvcals an unusual typc of visal mcmbsanc- 
psotcm. PROC. NATL. ACAD. SCI. USA 82:,4075-4079.
WHITE, J.M., KIELIAN, M. and HELENIUS, A. (1983). Mcmbsame fusion psotcins of cnvclopeU 
animal visuscs. QUARTERLY REVIEW OF BIOPHYSICS 16:l151l195.
WIEDMANN, B., SAKAI, H., DAVIS, T.A. and WIEDMANN, M. (1994). A psotcin complcx 
scquiscU fts signaTscqucncc-spccifit sorting anU tsanslotation. NATURE 370:,434-440.
WILD, TR, FAYOLLE, J., BEAUVERGER, P. and BUCKLAND, R. (1994). Mcaslcs visus 
fusion: solc of thc cystcine-sich scgion of thc fusion glytopsotem.J. VIROL. 68(ll):,7546-7548.
WILKINSON, G.W.G. and AKRIGG, A. (1991). Thc cytfmegalovisus majos immcUiate casly 
psomotcs anU its usc in cukasyotic expscssitn systcms. ADV. GENE TECH. 2:,287l310.
WILSON, C., GILMORE, R. and MORRISON, T.G. (1987). Tsanslatitn anU mcmbsanc imsestion 
tf thc hacmagglutimm-nccoaminiUasc glyttpsotcin. tf Ncwcastlc Uiscasc visus. MOL. AND CELL. 
BIOL. 7(4)::1386-1392/
WILSON, LA., SKEHEL, J.J. and WILEY, D.C. (1981). Stsuctusc of thc hacmagglutmin 
membsamc glyctpsttcin of influcnza visus at 3 A scstlution. NATURE 289:,366-373.
WOLFE, S.L. MtlcccSas anU tcHulas bitltgy, Be!mont:Wadsworth Publishing Company, 1993.
WYATT, L.S., MOSS, B. and ROZENBLATT, S. (1995). Rcplicatitn-Ucfiticnt vaccinia visus 
cnttUing battcsiophagc T7 RNA ptlymcsasc fos tsansicnt gcnc cxpscssifn in mammalian tclls. 
VIROLOGY 210:,202l205/
XIANG, Z.Q., SPITALNIK, S.L., CHENG, ERIKSON, J., et al. (1995). Immunc scsponscs tt 
nutlcit atiU vattincs to sabics visus. VIROLOGY 209 :,569-579.
XU, Z.Z., KROUGLIAK, V., PREVEC, L., GRAHAM, F.L., et al. (1995). Invcstigatitn tf 
psomotcs firnittion in human anU animal tclls infcttcU with human sctombinant aUcmfviscscs 
cxpscssing sotavisus antigcn VP7st. J. GEN. VIROL. 76:,1971-1980.
YOUNG, D.F. M.Sc. thcsis, Univcssity tf St. AnUscws, 1991.
YOUNG, J.M., CHEADLE, C., FOULKE, J.S., DROHAN, W.N., et al. (1988). Utilisation tf an 
Epsteim-Bass visus scplictn as a cukasyotit vcttts. GENE 62:471-185.
YATES, J.L., WARREN, N., REISMAN, D. and SUGDEN, B. (1984). A cis-acting clcmcntfstm 
thc Epstcin-Bass visal gcnomc that pcsmits stablc scplitatOfn tf sctombinant plasmiUs in latcntly 
infcttcU cclls. PROC. NATL. ACAD. SCI. USA 81,3806-3810.
158
YATES, J.L., WARREN, N. and SUGDEN, B. (1985). Stable replication of plasmids derived from 
Epstein-Barr virus in various mammalian cells. NATURE 313 :,812-815.
ZENTGRAF, H., FREY, M., SCHWINN, S., TESSMER, C., et al. (1995). Detection of histidine- 
tagged fusion proteins by using a high-specific mouse monoclonal anti-histidine tag antibody. NAR 
23(16):,3347-3348.
ZHANG, W.W., CHARE'S!', H. and MATLASHEWSKI, G. (1995). The expression of biologically 
active human p53 in Leishmania cells: a novel eukaryotic system to produce recombinant proteins. 
NAR 23(20):,4073-4080.
ZOLOTUKHIN, S., POTTER, M., HAUSWIRTH, W.W., GUY, J., et al. (1996). A humanised 
green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J. VIROL. 
70(7):,4646-4654.
ZWART, D.E., BREWER, C.B., LAZAROVITS, J., HENIS, Y.I., et al. (1996). Degradation of 
mutant influenza-virus hemagglutinins is influenced by cytoplasmic sequences independent of 
internalization signals. J. BIOL. CHEM. 271(2):,907-917.
159
